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Abstract
Plasmodium falciparum is a protozoan parasite responsible for the most severe form of human 
malaria, with infection often resulting in death. Efforts to control malaria have been hindered by 
an increased spread of parasite resistance to previously effective antimalarial drugs, leading to 
an intensified  search for  novel  antimalarial  drug targets.  A group of  proteins suggested as 
potentially effective targets are the integral membrane transport proteins, since they play key 
roles in  Plasmodium parasite growth and replication.  One such membrane protein recently 
characterised  was  the  P.  falciparum  copper  efflux  transporter.  Treatment  of  cultured  P. 
falciparum parasites  with  the  intracellular  copper  chelator  neocuproine inhibited  parasite 
growth, suggesting that additional mechanisms for malaria parasite copper homoeostasis are 
likely to be present.  Copper is an essential  trace element involved in enzymatic processes 
requiring  redox-chemistry.  In  higher  eukaryotes  copper  is  transported  across  the  plasma 
membrane  via  the  copper  transport  protein,  Ctr1,  and  distributed  intracellularly  by  copper 
metallochaperones. The mechanisms for copper acquisition and distribution in the Plasmodium 
parasite are, however, yet to be characterised.
An in silico Basic Local Alignment Search Tool for protein (BLASTp) screen of the Plasmodium 
database  (www.plasmodb.org)  identified  sequences  corresponding  to  a  putative  copper 
transporter,  and associated copper metallochaperones,  in  eight  species of  the  Plasmodium 
parasite. Each of the  Plasmodium copper transport protein sequences was found to contain 
features  common  to  the  well  characterised  copper  transporters.  These  features  included 
predicted copper-binding motifs  in  the protein's  amino terminus,  three membrane spanning 
domains  and the characteristic  MxxxM and GxxxG motifs  located  in  the  second and  third 
transmembrane  domains,  respectively.  Affinity  purified  anti-peptide  antibodies,  generated 
against an immunogenic peptide (CSDKQSGDDECKPILD) in the amino terminus of a putative 
malaria parasite copper transporter (PY00413), detected the target protein in murine malaria 
parasites in association with a parasite membrane. The open reading frames corresponding to 
the amino terminal domains of one P. berghei [PBANKA_130290 (447 bp)] and two P. falciparum 
[PF14_0211 (132 bp) and PF14_0369 (282 bp)]  putative  copper transport proteins were PCR 
amplified,  ligated  into  pGEM®-T  and  then  expressed  as  recombinant  fusion  proteins  with 
maltose binding protein (MBP). The resulting sizes for the recombinant proteins were 61kDa for 
MBP-PbCtrNt,  48kDa  for  MBP-PfCtr211NtTD  and 55kDa  for  MBP-PfCtr369NtTD,  with  each 
protein  being  recognised  by  a  corresponding  anti-peptide  antibody.  All  three  recombinant 
proteins  bound copper  in  vitro and  in  vivo, with  each having a  binding preference for  the 
reduced  cuprous  ion.  This  preference  has been  similarly  established  for  the  characterised 
copper transporters. Although the results supported the expression and copper binding ability of 
v
a  Plasmodium parasite copper transport  protein,  the directional transport  of copper, by this 
protein, requires experimental confirmation as does its specific location.
The identification of a P. falciparum copper transporter, and other copper dependent proteins, 
implies  a parasite  metabolic  requirement  for  copper.  Mammalian and yeast  cells  require  a 
Cox17  metallochaperone  for  copper  delivery  to  cytochrome-c  oxidase.  Identification  of  P. 
falciparum orthologs for Cox17 (PF10_0252) and a number of cytochrome-c oxidase subunits 
(PF13_0327;  PF14_0288;  mal_mito_1;  mal_mito_2;  PFI1365w;  PFI1375w),  suggests  the 
existence  of  similar  parasite  mechanisms for  copper  delivery.  Analysis  of  the  Plasmodium 
Cox17-like  sequences identified  essential  amino  acids  conserved in  the  well  characterised 
yeast and mammalian Cox17. This included the identification of six cysteine residues essential 
for  Cox17  function.  A homology model  of  P.  falciparum Cox17,  with  human Cox17 as  the 
template [PDB ID: 2RN9 (apoCox17); 2RN8 (Cu+-Cox17)], suggested that Plasmodium Cox17 
orthologs would adopt a similar structural conformation. The open reading frames for full-length 
P. yoelii [PY03823 (192 bp)] and P. falciparum [PF10_0252 (195 bp)] Cox17 were PCR amplified, 
ligated into pGEM®-T and then expressed as recombinant fusion proteins with either a His6-tag 
or glutathione S-transferase (GST)-tag, respectively. The resulting sizes for the recombinant 
proteins  were 11.6kDa for  His6-PyCox17 and 33.5kDa for  GST-PfCox17,  with  each protein 
being recognised by a corresponding anti-peptide antibody. Both recombinant Cox17 proteins 
bound  the  cuprous  ion in  vitro  and in  vivo,  similar  to  mammalian  and  yeast  Cox17.  This 
supported the likely existence of a mitochondrial copper metallochaperone pathway within the 
malaria parasite; however, this requires further experimental confirmation. Identification of a 
parasite  copper  transport  protein,  and  associated  metallochaperones,  could  provide  novel 
targets for drug-based inhibition of parasite growth. Alternatively, the copper transporter may 
provide a novel mechanism for drug delivery into the Plasmodium parasite. The potential of 
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1.1 Overview of malaria
Malaria  is  a  serious,  acute  and  chronic  relapsing  infection.  Over  three  billion  people, 
representing approximately 40 percent of the world's population, live at risk of contracting the 
disease  (Tuteja, 2007). Around 250 million malaria cases are reported annually,  resulting in 
approximately a million deaths. More than 90 percent of these deaths are recorded in the sub-
Saharan regions of Africa, with the majority being children under the age of five years (Breman 
et al., 2004). Malaria is caused by a protozoan parasite, belonging to the Plasmodium genus, 
and is transmitted by the bite of the female  Anopheles mosquito. More than 100 species of 
Plasmodium parasites infect multiple animal species including birds, reptiles and a number of 
mammals.  However,  only four  species  infect  humans,  namely  Plasmodium falciparum, 
Plasmodium vivax,  Plasmodium ovalae and  Plasmodium malariae,  although it  was recently 
established that the primate-infecting  Plasmodium knowlesi parasite can also infect humans 
with  a  potentially  fatal  outcome  (Cox-Singh et  al.,  2010;  Galinski  and  Barnwell,  2009).  In 
Southeast  Asia,  malaria caused by  P. knowlesi is  primarily  a zoonosis with wild  macaques 
acting as the reservoir hosts (Lee et al., 2011). Symptoms of malaria can develop as soon as 
six to eight days following a mosquito bite or as late as several months following departure from 
a malarious area (Tuteja, 2007). Malaria is generally characterised by fever, headache, painful 
joints,  respiratory distress,  watery diarrhoea,  vomiting and convulsions  (Miller et  al.,  2002). 
Human mortality, as a result of malaria infection, is predominantly caused by P. falciparum. This 
form of malaria is complex with several pathogenic processes such as jaundice, kidney failure 
and severe anaemia combining to cause an often fatal outcome (Miller et al., 2002). In malaria 
endemic countries the severity of malaria is reflected by economic hardship. It is estimated that, 
on average,  malaria  causes a 1.3% loss to annual  economic  growth in  endemic countries 
owing to a reduction in productivity (Sachs and Malaney, 2002). Efforts to prevent and control 
the  disease  have,  more  recently,  been  hindered  by  an  increased  parasite  resistance  to 
currently available antimalarial drugs  (Crompton et al., 2010; Ekland and Fidock, 2008). This 
problem underlines  the requirement  for  novel  antimalarial  drug  development  (Gamo et  al., 
2010; Le Roch et al., 2003; Rosenthal, 2003; Staines et al., 2010).
1.1.1 Geographical distribution of malaria
In  2007  the  global  area  at  risk  of  P.  falciparum malaria  infection  was  29.73  million  km2, 
predominantly  distributed  between  the  Americas,  Africa  and  Central  and  South  East  Asia 
(Figure 1.1) (Hay et al., 2009). This affected area is largely distributed between the tropics and 
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subtropics, with many areas of the tropics highly endemic for the disease. The countries of sub-
Saharan  Africa  account  for  the  majority  of  all  recorded  malaria  cases  with  the  remainder 
accounted for in India, Brazil, Afghanistan, Sri Lanka, Thailand, Indonesia, Vietnam, Cambodia 
and China (Tuteja, 2007). In Africa, malaria is highly endemic in western and central countries, 
particularly  around  the  Congo  basin.  Disease  transmission  is  largely  seasonal  with  peak 
infection rates occurring during the rainy season as a result of increased mosquito reproduction 
(Hay et al., 2009). In more temperate regions, such as Western Europe and the USA, malaria 
has  been  successfully  eradicated  as  a  result  of  public  health  measures  and  economic 
development (Tuteja, 2007).
Figure 1.1 Global distribution of malaria
Countries at risk of malaria transmission are highlighted. The severity of disease transmission in Africa is clearly 
evident. Data is according to the World Health Organisation (WHO). 
Malaria transmission in the Southern African countries of Botswana, Namibia, South Africa and 
Zimbabwe is highly seasonal with a generally lower transmission intensity than the rest of sub-
Saharan Africa (World Health Organisation, 2010). In South Africa the main malaria areas are 
the low-lying parts of the Limpopo province, Mpumalanga province and the north-eastern parts 
of  Kwazulu-Natal.  Approximately 10 percent  of  the South African population lives at  risk of 
malaria and although this disease continues to be a problem, the effects of malaria were much 
more severe in the early 20th century (Tren and Bate, 2004). Malarial areas during this period 
extended as far southwards as Port St Johns (Eastern Cape) and as far inland as Pretoria 
(Gauteng).  This  area  was  significantly  reduced  with  the  introduction  of  dichloro-diphenyl-
trichloroethane  (DDT)  (Maharaj et  al.,  2005).  Indoor  residual  spraying  and  the  use  of 
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artemisinin-based combination therapy, from 2001, has since helped maintain low numbers of 
malaria cases in South Africa (World Health Organisation, 2010).
1.1.2 A brief history of malaria
Malaria, as a disease, is one of the most ancient infections known to man. However, it was not 
until the end of the nineteenth century (1880) that Alphonse Laveran, a French army physician, 
discovered that malaria was not the result of air emanating from swamps, but rather the result 
of an infection by a parasite belonging to the  Plasmodium genus  (Lavaran, 1881; Tren and 
Bate, 2004). Thereafter, in 1898, Sir Ronald Ross, a British army surgeon, identified that it was 
the Anopheles mosquito that acted as the parasite vector, transmitting the parasite from one 
host to the next  (Ross, 1899). To this day, malaria remains an economic and social  health 
burden  to  many  developing  countries.  An  effective  vaccine  is  yet  to  be  developed  and 
controlling the disease is made increasingly difficult by the parasite's resistance to an array of 
previously effective chemotherapeutics  (Crompton et al.,  2010; Olliaro and Yuthavong, 1999; 
Rosenthal, 2003).
Early in the 20th century malaria was a severe problem in South Africa, dramatically affecting 
farming and economic activies  (Tren and Bate, 2004). The manifestation of this disease was 
largely due to the infiltration of labourers carrying the disease, combined with heavy rain fall 
around the same time. Together these factors created ideal conditions for the breeding of the 
Anopheles vector and thus the spread of malaria (Tren and Bate, 2004). In an effort to control 
the spread of the disease, testing of insecticides began in KwaZulu-Natal in 1931 and by 1932 
a widespread residual house-spraying programme, using pyrethrum, was established. This was 
soon replaced, in 1946, by the more effective insecticide DDT (Mabaso et al., 2004). Due to 
environmental safety issues surrounding the use of DDT, this insecticide was replaced by the 
pyrethroid deltamethrin in 1996. Unfortunately this policy shift resulted in the re-emergence of 
the  Anopheles  funestus  vector,  owing  to  its  pyrethroid-resistance,  subsequently  causing  a 
significant increase in the number of reported malaria cases and deaths (Figure 1.2).  As a 
result, DDT was reintroduced in 2000 causing a significant reduction in the number of malaria 
cases and deaths reported (Figure 1.2).
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Figure 1.2 Annual number of reported malaria cases and deaths in South Africa
The number of malaria cases (A.) and deaths (B.) reported in South Africa between 1971 and 2003 are plotted. Data 
was  according  to  the  South  African  Department  of  Health.  DDT spraying  was  stopped  in  1996  (↓)  but  then 
reintroduced in 2000 (↓) (Mabaso et al., 2004).
The use of  insecticides,  such as DDT,  controls  the spread of  malaria  by limiting mosquito 
survival.  Although insecticide treatment  reduces the number  of  reported malaria  cases and 
deaths, it has no direct effect on the Plasmodium parasite. The malaria parasite still manages 
to lead a very destructive path amongst humans, especially amongst children who are at the 
most risk of infection (Rosenthal, 2003). This point is highlighted by the fact that, in South Africa 
alone, the  Plasmodium parasite has developed resistance to both  chloroquine (by 1985) and 
sulfadoxine pyrimethamine (by 2000), reaching levels at which these drugs can no longer be 
used in monotherapy (Guidelines for the prevention of malaria in South Africa, 2003). This, in 
turn, has lead to changes in chemoprophylaxis and treatment policies in South Africa where 
artemisinin-based  combination  therapy  is  now  the  preferred  method  of  disease  treatment 
(World Health Organisation, 2010). The requirement for new treatment policies, in South Africa 
alone, further highlights the necessity for novel drug design and new target identification.
1.1.3 The Plasmodium parasite life cycle
The life cycle of  the  Plasmodium parasite is  extremely complex with one stage of  asexual 
development  in  the  vertebrate  host  and  a  second  stage of  sexual  development  within  the 
invertebrate  mosquito  vector  (Figure  1.3).  Parasite  survival  relies  on  the  expression  of 
specialised proteins  for  the  invasion of  a  variety  of  cell  types and for  the  evasion of  host 
immune responses (Tuteja, 2007). With a single mosquito bite infective sporozoites are injected 
into the human host blood stream, where they are slowly released from the site of injection and 
migrate  to  the  liver  (Yamauchi et  al.,  2007).  Once  the  liver  cells  have  been  invaded,  P. 
falciparum and P. malariae trigger immediate schizogony. On the other hand,  P. vivax and P. 
ovale can either  trigger  immediate schizogony or  delay this  process and pass through the 














































hypnozoite stage, which are dormant parasites found in the liver (Tuteja, 2007). This stage of 
asexual replication, known as exo-eryhtrocytic schizogony, gives rise to tens of thousands of 
merozoites  inside  the  hepatocytes.  Each  merozoite  that  is  released  from the  liver  is  then 
capable of  infecting a new red blood cell.  The time taken to complete this  tissue stage of 
development varies between species and is known as the prepatent period. Only after this 
period, and during the erythrocytic stage of parasite development, do the clinical symptoms and 
pathology of malaria become evident (White, 1992; van den Ende and van Gompel, 1997).
Figure 1.3 Life cycle of the Plasmodium parasite
The life cycle of the malaria parasite is complex. One stage of asexual development occurs within the vertebrate 
host (left  side of cycle), whilst the second stage of sexual  development occurs within the invertebrate mosquito 
vector (right side of cycle). Adapted from Winzeler (2008).
Following merozoite release from hepatocytes, the merozoites enter erythrocytes by a complex 
invasion process that is divided into four distinct phases  (Miller et al., 2002). The entry and 
exposure of merozoites in the blood stream, coupled with the highly specific series of molecular 
interactions for erythrocyte invasion, has implicated this stage as an attractive target for the 
development  of  anti-malarial  strategies  (Crompton et  al.,  2010;  Frevert et  al.,  1993).  Once 
inside  the  erythrocyte  the  merozoite  begins  asexual  division,  with  the  parasite  developing 
through a number of different stages. These stages progress from the early trophozoite, or ring 
stage,  to the trophozoite and finally the schizont  stages of development (Figure 1.3).  Each 
mature schizont contains merozoites that are released following red blood cell lysis and these 
invade new, uninfected red blood cells. This repetitive cycle of invasion-multiplication-release-
invasion continues, taking around 48 h for P. falciparum, P. ovale and P. vivax infections whilst a 
P. malariae infection cycle takes around 72 h  (Tuteja, 2007). Following a variable number of 
cycles of asexual schizogony, a small proportion of the merozoites do not enter this repetitive 
cycle of  development  but  rather  differentiate  into micro-  and macrogametocytes  (male  and 
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female, respectively). Gametocytes are ingested by the mosquito in a blood meal and these 
undergo sexual development within the mosquito midgut. The resulting ookinete penetrates the 
midgut  cell  wall,  transforms into an oocyst  and undergoes sporogony,  producing numerous 
sporozoites (Figure 1.3). Sporozoites are then released by rupture and migrate to the salivary 
glands for onward transmission of the disease (Tuteja, 2007).
1.1.4 Treatment of malaria
Malaria  is  a  curable  disease if  correctly  diagnosed and promptly  treated.  Appropriate  drug 
treatment of malaria and prophylactic drug treatment of  newcomers to malarious areas are 
integral parts of malaria control (World Health Organisation, 2009). However, antimalarial drug 
resistance is  hindering these efforts. Resistance to chloroquine, a previously effective and safe 
antimalarial  administered as the first  line of  treatment for  P. falciparum infections,  was first 
documented five decades ago  (Moore and Lanier, 1961). Other commonly used and cheap 
antimalarials  against  which  the  parasite  has  proven  resistant  are  mefloquine,  quinine  and 
sulfadoxine-pyrimethamine (Hakim et al., 1996; Koenderink et al., 2010; Smithius et al., 1997). 
To overcome the problem of  resistance and increase the effective lifespan of antimalarials, 
combination therapy has been employed in many malaria endemic countries. However, even 
when used in combination new drugs are not impervious to resistance. Therefore the efficacy of 
currently used antimalarials is intensely monitored (World Health Organisation, 2009).
The effective action of chloroquine resulted in its global employment for malaria treatment until 
the emergence of resistance (Muregi and Ishih, 2010; Travassos and Laufer, 2009). Although it 
is no longer used for the treatment of  P. falciparum infections, chloroquine is still the drug of 
choice to treat less severe but recurrent P. ovale and P. vivax malaria infections (Travassos and 
Laufer,  2009).  P.  falciparum resistance  to  chloroquine  is  mediated  by  the  Chloroquine 
Resistance  Transporter  (PfCRT)  and is  associated with  a  marked  reduction  in  chloroquine 
accumulation in the parasite food vacuole (Martin et al., 2009b). Chloroquine acts by inhibiting 
the  parasite  mechanism  of  haematin  detoxification  in  the  food  vacuole,  however,  the 
replacement of PfCRT lysine 76 with a threonine results in chloroquine export from the parasite 
food vacuole rendering the drug ineffective. This export  mechanism is a direct result  of  the 
mutation since wild-type PfCRT does not possess a chloroquine transport mechanism (Martin 
et  al.,  2009b).  Due  to  widespread  chloroquine  resistance,  sulfadoxine-pyrimethamine  was 
introduced  as  the  replacement  drug  for  malaria  treatment.  Sulfadoxine-pyrimethamine  is 
composed of two drugs that act on sequential enzymes in the pathway for folate synthesis 
(Travassos  and  Laufer,  2009).  However,  the  spread  of  parasite  resistance  to  sulfadoxine-
pyrimethamine  was  even  more  rapid  than  it  was  for  chloroquine  (Sibley et  al.,  2001). 
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Consequently,  the World Health Organisation (WHO) recommended the use of combination 
therapy that includes an artemisinin derivative for first-line treatment. By the end of 2009, 77 of 
the 86 P. falciparum-endemic countries and territories had adopted this recommendation (World 
Health Organisation, 2010).
Artemisinins are derived from the Chinese sweet wormwood plant, Artemisia annua, and have 
been used by Chinese herbalists for more than 2000 years (Maude et al., 2010). Artemisinin 
and its derivatives, artesunate and artemether, are potent antimalarials that act rapidly by killing 
Plasmodium parasites  throughout  its  erythrocytic  life  cycle  (Pukrittayakamee et  al.,  2004; 
White, 2008). Although the mechanism of action of artemisinin has not been fully elucidated, it 
is  thought  to  inhibit  a  Plasmodium parasite sarco/endoplasmic reticulum ATPase  (Eckstein-
Ludwig et al., 2003). Artemisinin is also thought to reduce malaria transmission since it acts on 
gametocytes as well (Pukrittayakamee et al., 2004). If used in monotherapy, it is necessary to 
administer  artemisinin  over  a  five  to  seven  day  course  to  avoid  the  risk  of  recrudescent 
infection. Although the recurrent parasites are not resistant to artemisinin, they are capable of 
evading the short duration of activity exhibited by artemisinin  (Ittarat et al.,  2003), therefore 
artemisinins are rather combined with a longer acting partner drug. Currently there are five 
recommended  artemisinin-based  combination  therapies;  artemether  plus  lumefantrine, 
artesunate  plus  amodiaquine,  artesunate  plus  mefloquine,  artesunate  plus  sulfadoxine-
pyrimethamine and dihydroartemisinin plus piperaquine (World Health Organisation, 2010). 
1.1.5 Plasmodium genomics and antimalarial drug discovery 
Recent reports of P. falciparum resistance to artemisinin treatment (Dondorp et al., 2009; Noedl 
et al., 2008) highlights the urgent requirement for more selective and effective antimalarials. 
Identifying effective antimalarials and/or target proteins has been assisted by the sequencing of 
multiple  Plasmodium parasite  genomes,  most  recently  including  P.  vivax and  P.  knowlesi  
(Carlton et  al.,  2002;  Carlton et  al.,  2008;  Gardner et  al.,  2002;  Pain et  al.,  2008).  The 
availability of these genome sequences has the potential to reveal a large number of novel 
genes and proteins important for parasite biology and pathogenesis. The genomics revolution 
has, however, yet to result in the development of new antimalarial drugs with target-based lead 
discovery producing disappointing results  thus far.  In fact,  no new antimalarials  have been 
introduced into clinical practice since 1996 (Gamo et al., 2010). The functional genomics-based 
approach for target identification has, however, recently gained impetus through the release of 
a  chemical  library  of  P.  falciparum intraerythrocytic  cycle  inhibitors  from  GlaxoSmithKline 
(Gamo et al., 2010). Access to the chemical structures and associated data of a number of lead 
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compounds is hoped to help accelerate the pace of drug development for malaria.
An important feature of a candidate drug is that it demonstrates effective inhibition of a target 
essential to the life cycle of the parasite, resulting in parasite death. Furthermore it is important 
that the targeted protein does not show significant similarities to any host orthologs (Rosenthal, 
2003).  Although  the  availability  of  a  drug  repository  assists  with  the  identification  of  new 
antimalarials (Gamo et al., 2010), novel drug design can follow several strategies, ranging from 
minor modifications of existing drugs to the design of novel agents  (Olliaro and Yuthavong, 
1999; Rosenthal, 2003). A group of proteins playing key roles in the growth and replication of 
the  Plasmodium parasite are the integral membrane transport proteins  (Krishna et al., 2001; 
Martin et al., 2005; Martin et al., 2009a). Surprisingly though, these parasite proteins remain 
poorly  understood  and  their  potential  as  antimalarial  drug  targets  remains  largely 
underexploited (Kirk, 2004; Staines et al., 2010). To date, more than 100 known and putative 
transporter sequences have been identified in the P. falciparum genome, with a large number 
considered to have therapeutic potential (Martin et al., 2005; Martin et al., 2009a; Staines et al., 
2010). However, only a few of these proteins have been sufficiently characterised to allow for 
potential  targeting  by  antimalarials.  One  well  characterised  membrane  protein  is  the  P. 
falciparum copper efflux protein, PfCuP-ATPase (Rasoloson et al., 2004).
The identification of a novel P. falciparum copper efflux protein suggested the likely existence of 
more  elaborate  mechanisms for  parasite  copper  homoeostasis,  similar  to  those  previously 
characterised in both yeast and mammalian systems (Kaplan and Lutsenko, 2009; Kim et al., 
2008;  Lutsenko,  2010).  Copper  and  its  associated  transport  mechanisms  have  been 
established as essential to cell metabolism, suggesting copper would be similarly important to 
the parasite. Targeting parasite proteins required for copper homoeostasis could therefore be of 
possible  therapeutic  value.  Supporting  this  idea  was  the  finding  that  the  copper  chelators 
diethyldithiocarbamate (DDC) and neocuproine inhibited the growth of  P. falciparum parasites 
in vitro (Meshnick et al., 1990; Rasoloson et al., 2004). Interestingly, the complexation of the 
antimalarials  buparvaquone,  pyridine-2-carboxamidrazone  and  3-arylazo-4-hydroxy-1,2-
napthoquinone to copper(II) significantly enhanced their antimalarial properties (Gokhale et al., 
2001; Gokhale et al., 2003; Gokhale et al., 2006).  Although exact reasons for this enhanced 
activity were not determined, it was suggested to pertain to the positive reduction potentials of 
the copper compounds as well as their four-coordinate planar geometry. These properties were 
proposed to enhance the internalization and efficacy of these compounds (Gokhale et al., 2001; 
Gokhale et al., 2003). Alternatively, the enhanced activity was thought to be a result of site 
specific action, of the copper complex, on a component of the electron transport chain (Gokhale 
et  al.,  2006).  Taken  together,  these  findings  support  further  investigation  of  putative 
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Plasmodium spp. copper transport and distribution pathways for potential antimalarial targets.
1.2 Biological and physiological importance of copper
Copper is essential to life because of the catalytic and structural roles it plays in numerous 
proteins. The ability of copper to cycle between the stable oxidized Cu(II) and unstable reduced 
Cu(I)  redox  states  is  the  property  harnessed  by  cuproenzymes  involved  in  various  redox 
reactions.  However,  if  not  correctly  managed,  it  is  this  same property  that  makes  copper 
potentially toxic to cells  (Camakaris et al., 1999; Dameron and Harrison, 1998). As a result, 
cellular  systems  have  evolved  elaborate  mechanisms  to  regulate  intracellular  copper 
concentrations and ensure targeted copper  delivery to the necessary intracellular  enzymes 
(Figure 1.4). Enzymes requiring copper as a cofactor are generally involved in fundamental 
biological processes necessary for cellular growth and development. These processes include 
iron  transport,  oxidative  stress  protection,  peptide  hormone  production,  skin  pigmentation, 
blood clotting as well as connective tissue formation  (Bertinato and L'Abbe, 2004; Lutsenko, 
2010; Nose et al., 2006; Puig and Thiele, 2002; Sharp, 2003). The average daily copper intake 
of an adult human ranges from 0.6 to 1.6 mg, with the main sources being grains, nuts, beans, 
shellfish and liver  (Linder and Hazegh-Azam, 1996; Tapiero et  al.,  2003). In normal human 
blood plasma, non-toxic concentrations of free copper ions are estimated to be in the order of 
10-18 to 10-13 M (Linder and Hazegh-Azam, 1996), whilst a normal erythrocyte has about 20 µM 
copper, 70% of which is contained in Cu/Zn superoxide dismutase (Cu/Zn SOD) (Hatano et al., 
1982;  Rasoloson et  al.,  2004;  Shields et  al.,  1961).  In  excess  of  these  normal  cellular 
concentrations copper can, however, prove to be cytotoxic.
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Figure 1.4 Copper acquisition and distribution in a generalised mammalian cell
Mechanisms  of  copper  homoeostasis  within  a  mammalian  cell  are  both  sophisticated  and  diverse.  Following 
extracellular  copper  acquisition,  by  CTR1 or  CTR2,  entering  copper  is  retrieved by  copper  chaperones  having 
multiple functions: CCS distributes copper to SOD1 in the cytosol and mitochondria, Atox1 transfers copper to the 
secretory pathway and nucleus whilst an ensemble of proteins appear to deliver copper to cytochrome-c oxidase in 
mitochondria. CTR2 is predominantly localised intracellularly (for mobilisation of copper stores) but is also found 
associated with the plasma membrane. STEAP3/4 are presumed to act as intracellular reductases that facilitate 
copper transport across lysosomal membranes. ATP7A and ATP7B transport copper to the secretory pathway for 
incorporation into metalloenzymes and mediate copper excretion by sequestering excess copper in vesicles. Stars 
(  ) represent phosphorylation of the Cu-ATPases, which is essential for protein trafficking between locations. CTR2 
Adapted from Lutsenko (2010).
Copper, similar to iron, can undergo Fenton chemistry resulting in the production of the highly 
damaging hydroxyl radical (Cu+ + H2O2 → Cu2+ + •OH + OH-). Hydroxyl radicals can cause 
membrane lipid peroxidation, direct oxidation of proteins and cleavage of both DNA and RNA 
(Halliwell and Gutteridge, 1984). Furthermore, excess free copper ions have been shown to 
exert  a  toxic  effect  by  displacing  other  essential  metal  co-factors,  such  as  zinc,  from 
metalloenzymes  thereby  rendering  these  enzymes  inactive  (Predki  and  Sarkar,  1992). 
However, cellular systems avoid these negative effects through the evolution of sophisticated 
homoeostatic  mechanisms (Figure 1.4).  These mechanisms involve  the influx  and efflux of 
copper as well as processes whereby copper is delivered to various subcellular locations via 
specific copper metallochaperones (Kaplan and Lutsenko, 2009; Kim et al., 2008; Leary et al., 
2009; Lutsenko, 2010; Rosenzweig, 2002). The importance of these mechanisms is perhaps 
best  highlighted by  Menkes and Wilson's  diseases,  which are  human diseases caused by 
mutations to the ATP7A and ATP7B genes, respectively (Mercer, 2001; Shim and Harris, 2003). 
Both diseases are generally characterised by severe neurological disorders caused by copper 
imbalances and associated toxicity (Shim and Harris, 2003). Although not causally associated, 
imbalances in cellular copper concentrations have also been linked with Alzheimer's diseases 
(Kim et al., 2008; Tapiero et al., 2003).
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Cu-ATPase-mediated excretion of  excess copper has been proposed to be the main factor 
controlling  cellular  copper  homoeostasis  (Tapiero et  al.,  2003).  Equally  important  is  the 
mechanism of  copper acquisition and uptake, which is mediated by the integral  membrane 
copper transport protein, Ctr1, in yeast and mammalian cells  (Dancis et al., 1994; Lee et al., 
2002;  Zhou  and  Gitschier,  1997).  The  importance  of  Ctr1  to  mammalian  growth  and 
development has been demonstrated in two independent gene-targeting studies in mice. The 
production  of  a  Ctr1-/- phenotype,  through  gene  knock-out  experiments,  resulted  in  the 
termination  of  embryonic  development  midway  through  gestation  thereby  supporting  an 
essential role for this protein  (Kuo et al., 2001; Lee et al., 2001). A similar observation was 
made  following  gene  knock-out  of  the  Drosophila  melanogaster Ctr1B gene,  which  also 
resulted in developmental defects and arrest (Zhou et al., 2003). Once transported into the cell, 
copper is distributed to specific destinations via dedicated copper metallochaperone proteins. 
These proteins include CCS, which distributes copper to Cu,Zn superoxide dismutase in the 
cytosol and mitochondria, Atox1, which transfers copper to the secretory pathway and nucleus, 
whilst an ensemble of proteins delivers copper to cytochrome-c oxidase in mitochondria (Kim et  
al.,  2008;  Lutsenko,  2010;  Rosenzweig,  2002).  With  regards  to  the  Plasmodium parasite, 
currently there is limited research focussed on identifying mechanisms of copper homoeostasis. 
To date, a mechanism for copper efflux, by the  PfCuP-ATPase protein, has been proposed 
(Rasoloson et al., 2004); however, mechanisms of copper acquisition and distribution remain 
uncharacterised.
1.2.1 Acquisition of copper and the copper transport protein
In  eukaryotic  cells  the  copper  transport  protein,  Ctr1,  plays  a  key  role  in  copper  uptake. 
Depending on cell type, this integral membrane protein can be found associated with either the 
plasma membrane or  intracellular  vesicles  (Figure 1.4).  This  has been hypothesised to be 
reflective  of  a  protective  post-translational  control  mechanism  against  the  accumulation  of 
excessive intracellular copper concentrations  (Klomp et al., 2002; Ooi et al., 1996). A single 
Ctr1 polypeptide is characterised by three transmembrane domains, a methionine-rich amino 
terminus and an essential  MxxxM motif  in the second transmembrane domain  (Puig et  al., 
2002a) (Figure 1.5).  This conserved and essential  methionine motif  has been implicated in 
modulating the protein's affinity for copper and the rate of its transport by Ctr1  (Eisses and 
Kaplan,  2005;  Puig et  al.,  2002a).  Genetic,  biochemical  as well  as recent  two-  and three-
dimensional  crystallographic  studies  indicate  that  Ctr1  is  present  in  the  membrane  as  a 
homotrimer (Aller et al., 2004; Aller and Unger, 2006; De Feo et al., 2009; Lee et al., 2002) with 
the translocation pore or pathway formed at its centre  (Aller and Unger, 2006; De Feo et al., 
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2009).  Protein  oligomerisation  is  essential  to  Ctr1  function,  with  stable  oligomer  formation 
dependent on a GxxxG motif (Figure 1.5) in the third transmembrane domain (Aller et al., 2004; 
Eisses and Kaplan, 2002) as well as a cysteine residue in the carboxy terminus (Eisses and 
Kaplan, 2005; Lee et al., 2007).
Figure 1.5 Schematic representation of the features characteristic of the copper transport proteins
Copper transport proteins are characterised by three transmembrane domains (1 – 3) resulting in a topology that  
places the amino terminus (Nt) extracellularly and the carboxy terminus (Ct) intracellularly. Methionine motifs (▬) 
are found in the Nt for initial copper acquisition. The two most important motifs for function and oligomeric structure 
are MxxxM and GxxxG, located in the second and third transmembrane domains, respectively. 
The mechanism by which Ctr1 transports copper is likely to be passive since Ctr1 function is 
unaffected by metabolic inhibitors (Lee et al., 2002). Additionally, Ctr1 protein sequences lack 
an identifiable ATP-binding domain. In yeast, copper uptake via Ctr1 is dependent upon the 
Cu2+/Fe3+ metalloreductases  Fre1  and  Fre2  for  maximal  activity  (Georgatsou et  al.,  1997; 
Hassett and Kosman, 1995; Rees and Thiele, 2007), with Cu+ presumed to be the transported 
species. In agreement with this, was the finding that in human cells divalent metal ions do not 
inhibit  copper  uptake  whereas  isoelectric  and  similar  sized  Ag+ ions  block  hCtr1-mediated 
copper uptake  (Bertinato et al., 2010; Lee et al., 2002). Furthermore, the reductant ascorbic 
acid has been shown to enhance 64Cu uptake in both yeast and human cell lines (Puig et al., 
2002a).  In  addition,  it  has  been  established  that  the  Cu+ ion  is  the  preferred  species  for 
intracellular distribution. This was supported by a study demonstrating the efficient and rapid 
transfer of Cu+ ions from a recombinant yeast copper transport protein carboxy terminus to the 
Atx1  metallochaperone  (Xiao  and  Wedd,  2002).  Transfection  studies  and  copper  uptake 
assays, with yeast and mammalian cells, have established that Ctr1 has a Michaelis-Menten KM 
for copper in the low micromolar range (1-5 μM) (Dancis et al., 1994; Lee et al., 2002).
A second copper transport protein, identified in both yeast and human cells, is Ctr2 (Rees et al., 










intracellular  in  human  cells  (van  den  Berghe et  al.,  2007) and  is  predicted  to  function  in 
releasing copper from vacuole compartments in yeast cells (Rees et al., 2004). A small fraction 
of  overexpressed human Ctr2 does,  however,  appear  to localise at  the plasma membrane 
where it  can mediate copper uptake  (Bertinato et  al.,  2008).  Reasons for  this  location are 
unknown,  however,  it  is  thought  to  perhaps  help  facilitate  copper  import  when  Ctr1  is 
downregulated (Lutsenko, 2010). Similar to Ctr1, Ctr2 functions in tandem with a reductase to 
convert Cu2+ to Cu+  for translocation across the membrane of the lysosome (Rees and Thiele, 
2007).  Since  lysosomes  are  predicted  to  have  an  oxidising  environment  compared  to  the 
cytosol,  the  action  of  a  reductase  is  required  to  maintain  copper  in  the  reduced  form for 
successful translocation (Lutsenko, 2010). Due to structural similarities it is also presumed that 
Ctr2 would possess a similar biochemical mechanism to Ctr1 for the transport of copper across 
a  membrane.  However,  further  investigations  into  the  role  and  mechanism  of  Ctr2,  in 
mammalian cells, are still required.
1.2.2 Structural requirements for copper uptake
In  general,  membrane-bound transport  proteins are of  two possible  orientations.  The more 
commonly  observed  orientation  is  one  where  the  protein  has  a  sufficiently  large  enough 
monomeric  structure capable of  forming an independent  translocation pore across the lipid 
bilayer  (Aller  and Unger,  2006). The alternative orientation is referred to as having a “half-
transporter”  architecture  where  a  substrate  is  transported  between  the  interface  of  two 
subunits.  An  example  of  such  a  protein  is  the  Escherichia  coli multidrug  resistance  efflux 
transporter EmrE (Ma and Chang, 2004). These transport proteins are thought of as being a 
hybrid between the classical transporter structure and the channel proteins, for example the 
potassium channels (Figure 1.6). Another class of proteins displaying a similar hybrid structure, 
is  the  Ctr1  family  of  proteins.  The  transporter  function  of  Ctr1  is  dependent  on  trimeric 
oligomerisation (Aller et al., 2004) with its overall architecture lying somewhere between that of 
a traditional monomeric transporter and that of a channel (Figure 1.6).
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Figure 1.6 General structural orientation of transport and channel proteins
The majority of “typical” transport proteins contain a permeation pathway within a single monomer displaying pseudo 
twofold symmetry (A.). Half-transporter type proteins are generally composed of two subunits (B.). Each subunit 
contains 6-10 transmembrane domains that dimerise to form a pore through which substrates can be transported. In 
contrast, hCtr1 monomers are too small to form a pore, thus making oligomerisation essential for function (C.) This 
structure appears to be a hybrid of typical transporter and channel proteins. Adapted from Aller and Unger (2006).
The three-dimensional structure of Ctr1 was recently determined and yielded the first insights 
into the general organisation and operating principles of this family of proteins (Aller and Unger, 
2006;  De Feo  et  al.,  2009).  Despite their  importance to cell  physiology,  the Ctr1 family  of 
proteins vary greatly in primary sequence and length. Thus, it appears to be the overall design 
and architecture of the proteins rather than sequence identity that is key to their mechanism of 
transport. Indeed, it has been proposed that the first transmembrane domain of Ctr1 serves as 
an adaptor allowing evolutionarily distant copper transport proteins to adopt a similar, but not 
identical, overall structure (De Feo et al., 2010). Further supporting the conservation of protein 
structure for function, was the finding that human Ctr1 is functional in Drosophila cells (Hua et  
al.,  2010). From the solved structure, it  was proposed that copper uptake occurs along the 
central  threefold  axis  of  the  copper  transporter  trimer  where  the  second  transmembrane 
domain, with contributions from the first and third domains, creates a copper-permeable pore 
through the membrane  (De Feo  et al.,  2009). This orientation was strongly supported by a 
tryptophan scan of human Ctr1 and yeast Ctr3  (De Feo  et al., 2010). However, the precise 
mechanism by which copper is moved across the membrane, by Ctr1, remains only partially 
defined. 
An improved model mechanism for copper translocation across the membrane was recently 
proposed (Aller and Unger, 2006; De Feo et al., 2009; De Feo et al., 2010). Due to its channel-
like architecture, it was presumed that for Ctr1 to function correctly it would require a gating 
mechanism to control the influx of Cu+ ions. This was proposed to be achieved extracellularly 
through the amino terminus or intracellularly through interactions with residues of the second 
transmembrane domain  (Eisses and Kaplan, 2005). Numerous lines of biochemical evidence 
have,  in fact,  largely implicated the MxxxM motif  in controlling the gating and selectivity  of 
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copper.  In  addition  to  this,  it  was  suggested  that  the  transport  mechanism  involves  a 
conformational change of the protein during transport  (De Feo et al.,  2009). This idea was 
supported by an carbon-alpha trace model  study of hCtr1, which suggested that copper ions 
are transported one at a time through the pore with the transmembrane subunits of the trimer 
alternating  between  four  confirmations  (Figure  1.7)  (Schushan  et  al.,  2010).  Currently  the 
favoured model for the Ctr1 transport mechanism is one in which copper is acquired by the 
extracellular amino terminus, transferred to the MxxxM motif thereby causing a conformational 
change  allowing  the  copper  ion  to  be  transferred  through  the  pore  via  a  chain  of  copper 
exchange reactions between defined Cu+-binding sites (De Feo et al., 2009; Schushan et al., 
2010). The proposed kinetic control of copper movement through Ctr1 would also explain the 
protein's independence from an ATP-hydrolysis mechanism for transport (De Feo et al., 2009). 
To  what  extent  the  cytoplasmic  carboxy  terminus  is  involved  is  not  yet  fully  understood, 
however, it  is believed to regulate the entry of copper into the cytoplasm for transfer to the 
intracellular copper metallochaperones (Xiao and Wedd, 2002).
Figure 1.7 Proposed mechanism of transport for the human copper transport protein
The three Ctr1 subunits are shown in red, blue and grey with residues of interest depicted in dark grey and the 
copper ion in yellow. Step 1: In its basal state no copper is bound to the transmembrane domains, with the Met154 
triad serving as an external gate. Unprotonated His139 remains separate from Glu84. Step 2: Activation, resulting 
from a  pH  shift  or  ion  binding,  causes  a  conformational  change  at  the  cytoplasmic  end along  with  rotational 
movement at the extracellular end. Protonated His139 and Glu84 interact to stabilise the conformation. Step 3: With 
a second conformational shift at the extracellular end the copper ion is passed from the Met154 triad to the Met150 
triad. Met154 triad returns to blocking the pore entrance. Step 4: The copper ion is then passed through the polar 
pore, although how the ion is passed to the carboxy tail remains to be determined. Adapted from Schushan et al. 
(2010).
1.3 Intracellular copper trafficking
Once copper enters the cell, soluble Cu+-binding metallochaperones bind the ion and deliver it 
to target proteins through protein-protein interactions  (Rosenzweig, 2002). Although it is not 
clear how these chaperones are loaded with Cu+, it is thought to perhaps be through a direct 
interaction with the Ctr1 transporter (Xiao et al., 2004). Well characterised pathways of copper 
delivery include those for CCS (Copper Chaperone for Superoxide dismutase), which delivers 
1. 2. 4.3.
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copper to Cu,Zn superoxide dismutase (SOD), as well as for Atox1, which transfers copper to 
the membrane-bound, copper transporting P-type ATPases in the secretory pathway (Figure 
1.4)  (Kim  et  al.,  2008;  Leary  et al.,  2009;  Lutsenko,  2010).  Copper  is  also required in  the 
mitochondrion for the maturation and activity of cytochrome-c oxidase and Cu,Zn superoxide 
dismutase.  In  this  regard,  the  copper  metallochaperones Cox11,  Cox17,  Cox19,  Sco1 and 
Sco2 are essential for the formation of a functional cytochrome-c oxidase complex (Cobine et 
al.,  2006a;  Leary  et  al.,  2009).  The  mechanism  by  which  copper  is  delivered  to  the 
mitochondrion does,  however,  require further elucidation  (Kim  et al.,  2008;  Lutsenko, 2010; 
Rees and Thiele, 2004). 
1.3.1 Copper trafficking to the mitochondrion
Based on the localisation of Cox17 to the cytosol and mitochondrial intermembrane space, it  
was originally believed that this small, cysteine-rich protein was responsible for the delivery of 
copper to the mitochondrion  (Beers  et al., 1997; Glerum  et al., 1996). The simple prediction 
was that Cox17 would shuttle Cu+ ions into the intermembrane space for use in the assembly of 
cytochrome-c oxidase. This idea was supported by the finding that purified Cox17 could bind 
copper  (Heaton  et  al.,  2001;  Palumaa  et  al.,  2004;  Srivastava  et  al.,  1997).  However,  by 
tethering Cox17 to the mitochondrial inner membrane only it was established that the cox17Δ 
cells  displayed  normal  cytochrome-c  oxidase  activity,  thereby  reversing  the  expected 
respiratory defect. This therefore suggested that perhaps the function of Cox17 was spatially 
restricted to the intermembrane space (Maxfield  et al., 2004). Consequently, it was proposed 
that Cox17 was still required for the delivery of copper to cytochrome-c oxidase, but it may not 
be metallated until reaching the intermembrane space. This was supported by the finding that a 
deletion of COX17 did not decrease the total mitochondria-associated copper levels (Carr and 
Winge, 2003). It was found that the bulk of mitochondrial copper was localised within the matrix 
in a soluble, low molecular weight complex (Figure 1.8). This complex contains Cu+, is resistant 
to proteinase K or trypsin digestion, is anionic and is eluted in a monodisperse fraction on 
reverse phase HPLC (Cobine et al., 2004). Furthermore, it was found that the complex could be 
depleted of Cu+ by two heterologously expressed copper binding proteins, human SOD1 or 
yeast Crs5 metallothionein, suggesting it  could be involved in a copper delivery mechanism 
(Cobine et al., 2006b).
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Figure 1.8 Metallochaperone-mediated loading of copper into mitochondrial cytochrome-c oxidase
Copper is shuttled from the cytoplasm to the mitochondrion by an as yet incompletely characterised mechanism. It is 
thought that a small ligand (denoted L) binds cytosolic copper and delivers it to the mitochondrial intermembrane 
space (IMS). The Cu+ ions are then bound by Cox17 for transfer to Sco1, which transfers copper to the Cox2 
subunit, or to Cox11, which delivers copper to the Cox1 subunit of cytochrome-c oxidase (CCO). The novel copper 
ligand is thought to perhaps be involved in mitochondrial copper storage as well. Adapted from Kim et al. (2008).
Although the precise mechanism of copper delivery to the mitochondrion remains to be fully 
elucidated, the importance of copper to cytochrome-c oxidase assembly and function remains 
well documented (Cobine et al., 2006a; Kim et al., 2008; Leary et al., 2009). Copper is one of 
the catalytic cofactors in cytochrome-c oxidase, therefore copper insertion into this enzyme is 
essential for its function (Tsukihara et al., 1996). A number of accessory factors are important 
for the copper metallation of cytochrome-c oxidase. These include Cox11, Cox17, Sco1 and 
Sco2 (Figure 1.8), although Sco2 is not required in yeast cells  (Cobine  et al., 2006a). Three 
copper ions are inserted into two sites of cytochrome-c oxidase; a single ion into the CuB site 
and  two  ions  into  the  CuA site.  These  sites  are  located  in  the  Cox1  and  Cox2  subunits 
respectively, which form part of the core cytochrome-c oxidase enzyme. The insertion of copper 
into the CuA and CuB sites is likely to occur in the intermembrane space with Sco1 and Cox11 
implicated as the respective donor molecules (Carr et al., 2002; Hiser et al., 2000; Lode et al., 
2000).  These  two  co-metallochaperones  obtain  copper  ions  from  Cox17  through  transient 
interactions mediated by distinct structural interfaces (Horng et al., 2004). Copper transfer from 
Cox17 to Sco1 was also found to be coupled with a transfer of electrons, which was thought to 
perhaps assist with selective copper delivery (Banci  et al., 2008a). The essential requirement 
for Cox17-mediated copper delivery is perhaps best highlighted by embryonic lethality in Cox17 
null  mice  (Takahashi  et  al.,  2002).  Additionally  yeast  cells  lacking  Cox17  are  respiratory 
deficient due to a lack of cytochrome-c oxidase activity, however, this mutant phenotype can be 
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suppressed by the addition of high copper salt concentrations to the growth medium (Glerum et 
al., 1996).
1.3.2 Structural features of Cox17
The Cox17 metallochaperone can readily adopt multiple oligomeric states and is thus capable 
of forming a number of distinct Cu+ conformers  (Arnesano  et al., 2005; Heaton  et al., 2001; 
Voronova  et  al.,  2007a).  However,  in  the  intermembrane space the bioactive  conformer  of 
Cox17 appears to consist of a single Cu+ ion coordinated to a monomeric protein stabilised by 
two disulfide bonds (Abajian et al., 2004; Banci et al., 2008b; Voronova et al., 2007b). This was 
supported  by  the  finding  that,  in  vitro, the  partially  oxidised   state  of  Cox17  (Cox172S-S), 
containing a single copper ion, and not the fully oxidised form, containing four copper ions, 
transfers  Cu+ to  apoWT-hSco1  (Banci  et  al.,  2007).  In  this  active  state,  human Cox17  is 
structurally  organised  in  a  coiled-coil-helix-coiled-coil-helix  (CHCH)  structural  motif  with  a 
flexible amino terminal tail. The single copper ion bound to this conformer is coordinated by two 
consecutive cysteine residues at positions C22 and C23 (Banci  et al., 2008b). The additional 
Cox17 cysteine residues are organised in a twin CX9C motif, located at the amino and carboxy-
terminal ends of  each helix of  the CHCH motif,  which form two interhelical  disulfide bonds 
(Banci et al., 2008b). It has, however, been suggested for yeast Cox17 that only three of the six 
conserved cysteine residues are essential for in vivo function (Heaton et al., 2000; Punter and 
Glerum, 2003). These three essential cysteine residues are present in a C23CxC26 motif and are 
involved in copper coordination (Abajian et al., 2004; Heaton et al., 2000).
The  import  of  Cox17,  into  the  mitochondrial  intermembrane  space,  is  dependent  on  an 
oxidative  folding mechanism.  This  is  achieved by the TOM complex through a  Mia40/Erv1 
disulfide-relay  process  (Mesecke  et  al.,  2005).  Mia40  and  Erv1  are  located  within  the 
intermembrane space and mediate the import of small, cysteine-rich Tim proteins in addition to 
Cox17 (Rissler  et al., 2005). Erv1 catalyses the formation of disulfides in Mia40 allowing it to 
transiently  capture  imported  proteins,  containing  reduced  thiolates,  by  forming  interchain 
disulfide bonds.  The bound polypeptides are then released by disulfide exchange reactions 
resulting in disulfide bond formation within the imported protein (Mesecke et al., 2005). Due to 
the highly  reducing conditions  of  the  cell  cytosol,  it  is  presumed that  Cox17 exists  in  this 
environment in its fully reduced molten globule state, since this is necessary for its import into 
the intermembrane space (Mesecke et al., 2005). The two CX9C motifs present in Cox17 are 
also present in Mia40 (Chacinska et al., 2004), thus it is presumed that the similar folds found 
in these proteins could be involved in the protein-protein recognition process that occurs during 
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Cox17  entrapment  in  the  intermembrane  space  (Banci  et  al.,  2008b).  Once  in  the 
intermembrane  space  Cox17  is  predominantly  matured  into  the  Cox172S-S.  This  state  is 
presumed  to  predominate  as  a  result  of  the  more  oxidative  redox  environment  of  the 
intermembrane  space  compared  to  the  cytosol  (Voronova  et  al.,  2007b).  This  redox 
environment would allow for the reduction of the easily reducible disulfide bond, between the 
cysteine residues involved in copper binding, whilst the two disulfides in the CHCH motif are 
highly stable toward reduction and therefore unaffected (Banci et al., 2008b). Cox172S-S would 
subsequently be loaded with copper in the intermembrane space for transfer to the two co-
metallochaperones Sco1 and Cox11. These proteins then load copper into the CuA and CuB 
sites of cytochrome-c oxidase.
1.4 Outline of study
The ever increasing development of  Plasmodium parasite resistance to previously  effective 
antimalarial drugs, coupled to recent reports of reduced susceptibility to artemisinins in western 
Cambodia (Dondorp et al., 2009; Noedl et al., 2008), highlights the urgent need for new drugs. 
The advent of the genomics era was hoped to stimulate target-based lead discovery, however, 
to date this has yielded disappointing results  (Gamo  et al.,  2010). In an effort to overcome 
these shortcomings, a web-based system was recently developed where researchers can mine 
information on malaria proteins, predict ligands, as well as perform comparisons to human and 
mosquito host protein characteristics. The resulting system, termed Discovery, has aimed at 
allowing  the  identification  of  putative  protein  targets  as  well  as  potential  lead  compounds 
(Joubert  et  al.,  2009).  Although  the  Discovery  system offers  a  good  starting  platform,  the 
development  of  new  antimalarial  drugs  can  still  follow  alternate  strategies  ranging  from 
modifications of existing drugs to the design of novel agents against new targets (Rosenthal, 
2003). In terms of new target identification, a largely under-exploited group of parasite proteins 
are the integral membrane proteins (Staines et al., 2010).
An attractive property of parasite membrane transporters, as drug targets, is the fact that the 
structure of these proteins, as well as their transport mechanisms, appear to be significantly 
different  to  host  membrane  proteins  thus  providing  the  potential  for  selective 
chemotherapeutics  (Martin  et  al.,  2009a;  Rosenthal,  2003;  Staines  et  al.,  2010).  The 
characterisation of a parasite membrane bound transporter, involved in copper ion efflux and 
localised to the parasite and erythrocyte membranes (Rasoloson et al., 2004), suggested the 
exploration of parasite copper metabolic pathways for novel targets. Targeting proteins involved 
in  parasite  copper  homoeostasis  is  supported  by  the  finding  that  the  copper  chelators 
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diethyldithiocarbamate and neocuproine inhibit  P. falciparum growth  in vitro (Meshnick  et al., 
1990;  Rasoloson  et  al.,  2004).  Apart  from the identification  of  the  parasite  P-type ATPase 
copper efflux protein (Rasoloson et al., 2004), limited data exists on parasite copper acquisition 
and  distribution.  The  aim  of  the  current  study  was  to  identify  and  characterise  a  novel 
membrane-bound copper transporter as well as an associated intracellular copper chaperone 
within the Plasmodium genus. Using both computational and biochemical methodology, each 
protein was assessed for its ability to potentially bind copper. The expression and localisation of 
each  native  protein  was  to  be  determined  using  anti-peptide  antibodies.  An  expanded 
understanding of the Plasmodium parasite’s copper metabolic pathways could help lead to the 
identification of novel antimalarial drug targets.
A BLASTp search of PlasmoDB lead to the identification of several copper-requiring protein 
orthologs, thus supporting the likely parasite requirement for cellular copper (Chapter 3). One of 
these protein orthologs identified corresponded with the intracellular copper metallochaperone 
Cox17.  The  identification  of  this  and  the  other  copper  dependent  proteins  suggested  the 
potential  for a dedicated mechanism for parasite copper acquisition. A subsequent BLASTp 
search of the  Plasmodium database was therefore employed and identified sequences for a 
copper transporter in eight species of the parasite (Chapter 3). A thorough in silico analysis of 
the putative  P. falciparum copper transporter and Cox17 sequences was used to support the 
predicted  function  of  each  protein.  In  an  effort  to  confirm  native  protein  expression,  the 
Predict7TM computer  algorithm  (Cármenes  et  al.,  1989) was  used  to  identify  immunogenic 
regions in each protein from both the murine and human malaria parasites (Chapter 3).
To  establish  the  copper  binding  abilities  of  the  parasite  copper  transporter  and 
metallochaperone, significant amounts of purified protein was required. To this end, the coding 
domain for the predicted amino terminus of the copper transporter was PCR amplified and 
cloned (Chapter 4), whilst the full-length Cox17 metallochaperone was similarly amplified and 
cloned (Chapter 5). In both instances the coding domains were amplified from a rodent malaria 
parasite source as well as P. falciparum. Sequencing of the inserted products confirmed identity 
and supported the presence of a native parasite coding domain for each respective protein. 
Each  protein  was  expressed  in  Escherichia  coli and  the  recombinant  proteins  purified  for 
functional studies. The ability of each recombinant protein to bind copper was tested both  in 
vitro and  in  vivo.  Copper  was detected using the copper  specific  bicinchoninic  acid  assay 
(Brenner and Harris, 1995). Additionally, the  in vitro  copper binding ability of each respective 
recombinant protein was tested using the ascorbic acid oxidation assay (Chapter 4 and 5). To 
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establish native parasite protein expression and location, anti-peptide antibodies were raised in 






This  chapter  describes  the  biochemical,  immunochemical,  parasitological  and  molecular 
biology techniques used in this study. 
2.2 Materials
The following reagents and antibodies were purchased from Sigma-Aldrich-Fluka (Steinheim, 
Germany): 2-mercaptoethanol,  4-chloro-1-naphthol, acrylamide,  ampicillin, avidin, Biomax® X-
ray film, bisacrylamide, bromophenol blue, Coomassie Brilliant Blue G-250, Coomassie Brilliant 
Blue R-250, Ellman’s Reagent,  formamide,  Freund’s complete adjuvant, Freund’s incomplete 
adjuvant,  Giemsa  stain,  glycine,  isopropyl  β-D-1-thiogalactopyranoside (IPTG),  L-cysteine, 
kanamycin, maleimidobenzoyl-N-hydroxysuccinimide  ester  (MBS), N-laurylsarcosine, 
ovalbumin,  p-iodophenol,  polyvinypyrrolidine,  Ponceau  S,  rabbit  serum  albumin,  saponin, 
Sephadex G-25, Sephadex G-10, N,N,N’,N’-tetramethyethylenediamine (TEMED), Triton X-100, 
tryptone, Tween-20, urea and yeast extract. Bovine serum albumin was purchased from Roche 
(Mannheim,  Germany).  Equipment  purchased  from  BioRad  (California,  USA):  Poly  Prep® 
affinity column, low range protein molecular weight marker, Mini Protean II™ vertical PAGE unit 
and the VersaDoc™ imaging system. The following were purchased from Fermentas (Vilinius, 
Lithuania): agarose,  10× T4 DNA ligase buffer, T4 DNA ligase, DNA MassRuler™, dNTP mix, 
EcoRI, molecular biology grade DTT, NotI, Buffer O™, shrimp alkaline phosphatase (SAP) and 
an unstained protein molecular weight marker. The pMal expression system and broad range 
protein molecular weight marker were purchased from New England BioLabs (Massachusetts, 
USA). Molecular biology reagents were purchased from Solis Biodyne (Tartu, Estonia), which 
included the  10× PCR buffer (MgCl2 and detergent-free), PCR MgCl2 stock solution (25 mM) 
and Taq polymerase. The Escherichia coli host cells, plasmids and antibodies purchased from 
Novagen  (Damstadt,  Germany)  were  BL21  (glycerol  stock),  BL21  (DE3)  (glycerol  stock), 
JM109  (glycerol  stock)  and  JM103  (glycerol  stock)  cells;  pET-23a  and  pET-28a  plasmids; 
mouse monoclonal anti-His-Tag IgG, rabbit polyclonal anti-glutathione S-transferase IgG and 
peroxidase-conjugated  sheep  monoclonal  anti-mouse  IgG.  Polyethylene  glycol  6000  was 
purchased  from  Merck  Biosciences  (Damstadt,  Germany).  di-Ammonium  2,2’-azino-bis(3-
ethybenzothiazoline-sulfonate) (ABTS) was purchased from Boehringer (Mannheim, Germany). 
An orbital shaking incubator was purchased from New Brunswick Scientific (New Jersey, USA). 
SulfoLink™ Coupling Gel  and Snake skin™ dialysis  membrane were purchased from Pierce 
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Perbio  Science  (Erembodegem,  Belgium).  pGEX-4T-1,  Hybond-C™  Extra  nitrocellulose 
membrane and the Ultraspec 2100pro UV/visible spectrophotometer were purchased from GE 
Healthcare  (Buckinghamshire,  England).  Peroxidase-conjugated  rabbit  anti-IgY,  peroxidase-
conjugated rabbit anti-mouse IgG and peroxidase-conjugated goat anti-rabbit IgG antibodies 
were from Jackson Immunochemicals (Pennsylvania, USA).  Ni-NTA® metal affinity resin was 
purchased from Qiagen (Duesseldorf,  Germany).  Improm II® Reverse Transcription  System 
was  purchased  from  Promega  (Wisconsin  USA).  Oligonucleotide  primers  for  the  P.  yoelii 
copper  transport  protein coding  domain  were  synthesized  by  Whitehead  Scientific 
(Johannesburg, South Africa). Oligonucleotide primers for the  P. falciparum copper transport 
protein and Cox17 coding domains as well as P. yoelii Cox17 coding domain were synthesized 
by the Molecular and Cell Biology synthetic DNA unit at the University of Cape Town (Cape 
Town, South Africa). Synthetic peptides for all three copper transport proteins were synthesized 
by Auspep (Melbourne,  Australia),  whilst  those for  the two Cox17 metallochaperones were 
synthesized  by  GL  Biochem  (Shanghai,  China).  VersaMax™  ELISA plate  reader  was 
purchased from Molecular  Devices Corporation (California,  USA). Nunc Maxi Sorp™ 96-well 
ELISA plates  were from Nunc products (Roskilde,  Denmark).  The  DNA purification  kit  was 
purchased from PEQLAB Biotechnologie (Erlangen, Germany). An Avanti™ J-26 XPI centrifuge 
was from Beckman Coulter (California, USA). GeneAmp™ PCR thermocyler was from Applied 
Biosystems (California, USA). The Virosonic™ cell disruptor was purchased from VirTis (New 
York, USA).
2.3 Bioinformatics methods
This section describes the bioinformatics tools used in this study.
2.3.1 Sequence identification and analysis
Copper transport protein
To establish a parasite requirement for copper, the P. falciparum proteome (www.plasmodb.org) 
was BLASTp searched for the presence of copper-requiring protein orthologues (Table 3.1). 
The identification of a number of copper-requiring enzymes within the P. falciparum proteome 
suggested  a  need  for  copper  for  parasite  metabolic  function.  Sequences  for  a  putative 
Plasmodium  copper  transport  protein were similarly identified by a Basic  Logical Alignment 
Search Tool search for proteins (BLASTp) of PlasmoDB, using the  Theileria parva (Muguga 
stock) polymorphic immunodominant molecule (PIM) (GenBank: AAA99499).  Putative copper 
transport protein sequences were identified for eight species of the Plasmodium parasite. Each 
sequence was retrieved and saved as  a  text  file  in  FASTA format.  In  an effort  to  support 
sequence identity, each retrieved Plasmodium spp. sequence was aligned with sequences of 
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characterised copper transport proteins using the ClustalW™ server (Thompson et al., 1994). 
The  characterised  sequences  included  were  for  the Homo  sapiens (Accession  No. 
NP_001850),  Arabidopsis  thaliana (GenBank:  BAE98928)  and  Saccharomyces  cerevisiae 
(GenBank: AAB68064)  copper  transport  proteins.  To  identify  the  presence  of  three 
characteristic transmembrane domains in the retrieved Plasmodium spp. sequences, each was 
submitted to both the HMMTOP (Tusnády and Simon, 2001) and TMHMM 2.0  (Krogh et al., 
2001) topology prediction servers. The presence of potential signal sequences in each protein 
was established using the TMHMM server as well  as the SignalP 3.0 program (Center for 
Biological Sequence Analysis, Lyngby, Denmark). The presence of parasite specific targeting 
signals was determined using the PlasmoAP and PlasmoMit servers found at PlasmoDB as 
well as the PSEApred2 server for PEXEL motif prediction. The genome organisation of the two 
P.  falciparum copper  transport  protein  coding  domains  were  constructed  from  information 
retrieved from PlasmoDB and the nucleotide database of the National Center for Biotechnology 
Information  (NCBI).  P.  falciparum  expression  data  for  lactate  dehydrogenase,  S-
adenosylhomocysteine hydrolase, Cox11 and cytochrome-c oxidase subunit I were retrieved 
from PlasmoDB.
Cox17
The sequence of a putative Plasmodium spp. Cox17 copper chaperone was identified from the 
BLASTp search of PlasmoDB for copper-requiring protein orthologues. The specific sequence 
used to search PlasmoDB was the H. sapiens Cox17 sequence (GenBank: AAA98114). As with 
the identification of a putative Plasmodium spp. copper transport protein sequence, a putative 
Cox17  sequence  was  identified  in  the  same  eight  species  of  the  parasite.  To  identify 
characteristic Cox17 features in each retrieved sequence, they were aligned with characterised 
Cox17 sequences using the ClustalW™ server  (Thompson et  al.,  1994). The characterised 
sequences included were  the H. sapiens (GenBank:  AAA98114),  A. thaliana (Accession No. 
NP_566508) and S. cerevisiae (GenBank: CAA97453) Cox17 proteins. This alignment revealed 
the conservation of six cysteine residues known to be essential for Cox17 function. As with the 
copper  transport  proteins,  the  presence of  potential  signal  sequences in  each protein  was 
established using the TMHMM server as well as the SignalP 3.0 server (Center for Biological 
Sequence Analysis, Lyngby, Denmark). The presence of parasite specific targeting signals was 
determined using the PlasmoAP and PlasmoMit servers found at PlasmoDB as well as the 
PSEApred2 server for PEXEL motif prediction. The genome organisation  of the  P. falciparum 
Cox17 protein coding domain was constructed from information retrieved from PlasmoDB and 
the nucleotide database of the National Center for Biotechnology Information (NCBI).
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2.3.2 Homology modelling
A homology model of the putative  P. falciparum Cox17 metallochaperone (PF10_0252) was 
constructed using the NMR-solved structures of Homo sapiens Cox17, with and without copper 
bound [Protein Data Bank (PDB) ID's: 2RN8 (plus Cu+) and 2RN9 (minus  Cu+)]  (Banci  et al., 
2008b). Each of these structures were used individually to produce a PfCox17 model using the 
Swiss-pdb DeepView program (Guex and Peitsch, 1997). Once the desired HsCox17 structure 
was loaded into the DeepView program, the  PfCox17 sequence was loaded for subsequent 
mapping.  This  was achieved by aligning the  PfCox17 sequence to the  HsCox17 sequence 
(AAA98114) with the assistance of a ClustalW™ alignment (Thompson et al., 1994). Sequence 
insertions in the alignment resulted in unsolved gaps in the hypothetical  PfCox17 structure. 
These were accounted for  by inserting a fold that  placed the least  structural  strain on the 
protein model. The predicted folds are derived from solved protein structures having similar 
amino acid  sequence arrangements.  The final  hypothetical  protein  model  was checked for 
amino acid side chain or backbone clashes and corrected as necessary. 
2.3.3 Phylogenetic tree construction
For phylogenetic analysis of the retrieved sequences, the same approach was adopted for both 
the  putative  Plasmodium spp.  copper  transport  protein  and  Cox17  sequences.  The  eight 
Plasmodium sequences, for each respective protein, were aligned with the relevant sequences 
from the organisms listed in Table 2.1. Sequences were aligned using the  ClustalW™ server 
(Thompson et al., 1994) and a phylogenetic tree constructed from this alignment. The resulting 
tree diagram was copied as a JPEG image and edited, if necessary, with the GIMP™ image 
editor software.




Copper transport protein Cox17
Homo sapiens NP_001850 AAA98114
Mus musculus NP_780299 BAB32486
Rattus norvegicus NP_598284 NP_445992
Danio rerio NP_991280 NP_001004652
Arabidopsis thaliana BAE98928 NP_566508
Saccharomyces cerevisaie AAB68064 CAA97453
Theileria parva AAA99499 EAN30678
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2.3.4 Predict7™ antigenic peptide prediction
The production  of  synthetic  peptide  antigens  for  antibody  production  relies  on  the precise 
prediction of antigenic sites on a protein molecule (Saravanan and Kumar, 2009). Immunogenic 
regions  on  the  proteins  encoded  by  PY00413,  PY03823,  PF10_0252,  PF14_0211  and 
PF14_0369 were identified  using  the Predict7™ programme  (Cármenes et  al.,  1989).  The 
programme  calculates  various  features  of  an  amino  acid  sequence,  namely  antigenicity 
(Welling et al., 1985), hydrophilicity  (Hopp and Woods, 1983), flexibility  (Karplus and Schulz, 
1985),  surface  probability  (Emini et  al.,  1985),  hydropathy,  secondary  structure  and  N-
glycosylation sites. For this particular study, the respective protein sequences (saved as text 
files)  were  uploaded  into  Predict7™  and  regions  satisfying  the  more  important  criteria  of 
hydrophilicity,  surface  probability  and  side  chain  flexibility  were  selected  (Saravanan  and 
Kumar,  2009).  Furthermore,  when  selecting  a  peptide  it  was  important  that  the  selected 
sequence did not contain more than two lysine residues since multiple lysines can interfere with 
peptide specific antibody production due to their long side chains. For the copper transport 
proteins, peptide sequences were specifically chosen from the amino-terminal domain due to 
its extracellular location, presumably making it more accessible to antibodies. The prediction 
file for each protein was saved as a .xls file and the graphics of the three desirable properties 
plotted  using  Microsoft  Excel™  graphing  software.  Protein-protein  BLAST  searches  were 
carried  out  on  the  selected  peptides  to  ensure  the  sequence  was  absent  in  all  G.  gallus 
(antibody production host),  H. sapiens (P. falciparum host) and  M. musculus (P. yoelii host) 
native proteins.  If  necessary a cysteine residue was added to the amino-terminus of  those 
peptide sequences lacking a native cysteine at  this  position.  The cysteine residue enables 
conjugation to a carrier molecule and Sulfolink® affinity resin. The specific peptides selected for 
antibody production are shown in Table 2.2.
Table 2.2 Peptide sequences selected for anti-peptide antibody production in chickens
Protein name PlasmoDB identifier Peptide sequencea
P. yoelii copper transport protein PY00413 CSDKQSGDDECKPILD
P. yoelii Cox17 PY03823 CPLNTTEESKTα-Bu(C)Ab
P. falciparum copper transport protein I PF14_0211 CHSKNDDGVMLPMY
P. falciparum copper transport protein II PF14_0369 CNLQKEEDTVVQLQD
P. falciparum Cox17 PF14_0252 CPINNTNEANKGE
a Cysteines represented by a bold 'C' are indicative of residues added for coupling, whilst underlined three letter 
codes indicate the name by which the peptide is referred to
b α-Bu is the abbreviation for α-butyric acid, which is used to substitute any internal cysteine residues
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2.4 Biochemical and immunochemical techniques
This section describes the biochemical and immunochemical techniques used in this study.
2.4.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis (Laemmli, 1970) was 
used to analyse (i) Plasmodium yoelii or Plasmodium falciparum infected red blood cell lysates, 
(ii) recombinant protein expression and (iii) steps in the purification of recombinant proteins. 
2.4.1.1 Materials 
Monomer solution [30% (w/v) acrylamide, 2.7% (w/v) bis-acrylamide]. Acrylamide (73 g) and 
bis-acrylamide (2 g) were dissolved and made up to 250 ml with distilled water. The solution 
was stirred, filtered though Whatman No. 1 filter paper and stored in an amber coloured bottle 
at 4°C.
Separating gel buffer [1.5 M Tris-HCl, pH 8.8]. Tris (45.37 g) was dissolved in 200 ml of distilled 
water, titrated to pH 8.8 with HCl and the volume made up to 250 ml with distilled water. The 
solution was filtered through Whatman No. 1 filter paper and stored at 4°C.
Stacking gel buffer [500 mM Tris-HCl, pH 6.8]. Tris (3 g) was dissolved in 40 ml of distilled 
water, titrated to pH 6.8 with HCl and the volume made up to 50 ml with distilled water. The 
solution was filtered with Whatman No. 1 filter paper and stored at 4°C. 
10% (w/v) Sodium dodecyl sulfate (SDS). SDS (10 g) was dissolved, with gentle heating, and 
made up to 100 ml with distilled water. The solution was stored at room temperature (RT).
Initiator reagent [10% (w/v) ammonium persulfate]. Ammonium persulfate (0.1 g) was dissolved 
in 1 ml of distilled water and stored at 4°C. 
Tank buffer [250 mM Tris-HCl, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3]. Tris (6 g) and glycine 
(28.8 g) were dissolved in approximately 1 ℓ of distilled water with stirring. Before use, 10 ml of 
10% SDS was added to a litre of buffer.
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Reducing treatment buffer [125 mM Tris-HCl, pH 6.8, 4% (w/v) SDS, 20 % (v/v) glycerol, 10% 
(v/v) 2-mercaptoethanol]. Stacking gel buffer (2.5 ml), 10% SDS (4 ml) and glycerol (2 ml) were 
made up to 9 ml with distilled water. Bromophenol blue (35 μg) was added as a tracking dye 
and, before use, 2-mercaptoethanol was added at a 1:10 dilution. The solution was stored at 
RT.
Non-reducing sample buffer [125 mM Tris-HCl, 4% (w/v) SDS, 20 % (v/v) glycerol, pH 6.8]. 
Stacking gel buffer (2.5 ml), 10% SDS (4 ml) and glycerol (2 ml) were made up to 10 ml with 
distilled water. Bromophenol blue (35 μg) was added as tracking dye and the solution stored at 
RT.
Stain  stock  solution  [1% (m/v)  Coomassie  blue  R-250].  Coomassie  blue  R-250  (2  g)  was 
dissolved in 200 ml distilled water with  ≥ 1 h stirring at RT. The solution was filtered through 
Whatman No. 1 filter paper and stored at RT.
Staining solution [0.125% (m/v) Coomassie blue R-250, 50% (v/v) methanol, 10% (v/v) acetic 
acid]. Stain stock (62.5 ml) was mixed with methanol (250 ml) and acetic acid (50 ml) and made 
up to 500 ml with distilled water.
Destaining solution I [50% (v/v) methanol, 10% (v/v) acetic acid]. Methanol (500 ml) was mixed 
with acetic acid (100 ml) and made up to 1 ℓ with distilled water.
Destaining solution II [7% (v/v) acetic acid, 5% (v/v) methanol]. Acetic acid (70 ml) was mixed 
with methanol (50 ml) and made up to 1 ℓ with distilled water.
2.4.1.2 Method
Reducing or non-reducing SDS-PAGE was carried out as described by Laemmli (1970) using a 
Bio-Rad Mini Protean II™ vertical slab electrophoresis apparatus. Separating and stacking gels 
were  prepared  according  to  the  recipes  shown  in  Table  2.3.  The  gel-casting  unit  was 
assembled according to the manufacturers’ instructions and the prepared gels submersed in 
tank buffer in a Bio-Rad Mini Protean II™ vertical slab electrophoresis apparatus. 
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Table 2.3 Recipe for two Laemmli SDS-polyacrylamide gels 
Reagent
Separating gel Stacking gel
12.50% 10.00% 4.00%
Monomer solution 6.25 ml 5.00 ml 940 μl
Separating gel buffer 3.75 ml 3.75 ml -
Stacking gel buffer - - 1.75 ml
10% SDS 150 µl 150 µl 70 μl
Distilled water 4.75 ml 6.00 ml 4.30 ml
Initiator reagent 75 µl 75 µl 35 μl
TEMED 7.5 µl 7.5 µl 15 μl
Samples were loaded into the wells and electrophoresis was carried out at 36 mA (18 mA per 
gel slab). The gels were removed and stained with Coomassie Blue R-250 staining solution for 
≥ 1 h and then destained with successive changes of destain I and II. Once destained the gel 
was imaged with the BioRad VersaDocTM image documentation system. The molecular weight 
of the desired protein band(s) were determined using a graph of log molecular weight of the 
standards  versus  distance  migrated  (mm)  into  the  separating  gel.  The  molecular  weight 
standards  used  were  representative  of  either  a  BioRad  low  molecular  weight  marker 
[Phosphorylase B (97,400 Da); Serum albumin (66,200 Da); Ovalbumin (45,000 Da); Carbonic 
anhydrase (31,000 Da); Trypsin inhibitor (21,500 Da); Lysozyme (14,000 Da)] or a Fermentas 
unstained  protein  molecular  weight  marker  [β-galactosidase  (116,000  Da);  Bovine  serum 
albumin (66,200 Da);  Ovalbumin (45,000 Da);  Lactate dehydrogenase (35,000 Da);  Rease 
Bsp98I (25,000 Da); β-lactoglobulin (18,400 Da); Lysozyme (14,400 Da)].
2.4.2 Tricine-SDS-PAGE
Tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis (Schägger, 2006) was used 
to analyse (i) Plasmodium yoelii or Plasmodium falciparum infected red blood cell lysates and 
(ii) steps in the purification of recombinant His6-PyCox17.
2.4.2.1 Materials
Acrylamide-bisacrylamide  (AB)-3  stock  solution  [49.5%  (w/v)  acrylamide,  3%  (w/v)  bis-
acrylamide]. Acrylamide (48 g) and bis-acrylamide (1.5 g) were dissolved and made up to 100 
ml with distilled water. The solution was stirred, filtered through Whatman No. 1 filter paper and 
stored in an amber coloured bottle at 7 – 10°C.
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Gel buffer (3x) [3 M Tris-HCl, 0.3% (w/v) SDS, pH 8.45]. Tris (36.33 g) and SDS (0.3 g) were 
dissolved in 90 ml distilled water, titrated to pH 8.45 with HCl and made to a final volume of 100 
ml with distilled water. The solution was stored at RT.
Initiator reagent [10% (w/v) ammonium persulfate]. Ammonium persulfate (0.1 g) was dissolved 
in 1 ml of distilled water and stored at 4°C.
Anode buffer [0.1 M Tris-HCl, pH8.9]. Tris (12.11 g) was dissolved in 950 ml distilled water, 
titrated to pH 8.9 with HCl and made to a final volume of 1 ℓ with distilled water. The solution 
was stored at 4°C.
Cathode buffer [0.1 M Tris-HCl, 0.1 M Tricine, 0.1% (w/v) SDS, pH 8.25]. Tris (12.11 g), tricine 
(17.92 g) and SDS (1 g) were dissolved in in 950 ml distilled water. The pH of the solution 
should be close to 8.25 and should not be titrated (Schägger, 2006). The buffer was made to a 
final volume of 1 ℓ with distilled water and stored at RT.
Reducing treatment buffer (4x) [0.15 M Tris-HCl, pH 7, 12% (w/v) SDS, 30% (w/v) glycerol, 6% 
(v/v)  2-mercaptoethanol,  0.05%  (w/v)  Coomassie  blue  G-250].  Tris  (0.908  g),  SDS  (6  g), 
glycerol (15 g) and 2-mercaptoethanol (3 ml) were dissolved in 25 ml distilled water and titrated 
to pH 7 with HCl. Coomassie blue G-250 (0.025 g) was added to the solution and dissolved. 
The solution was then made to a final volume of 50 ml with distilled water.
2.4.2.2 Method
Reducing Tricine-SDS-PAGE was carried out as described by Schägger (2006)  using a Bio-
Rad Mini Protean II™ vertical slab electrophoresis apparatus. Separating and stacking gels were 
prepared according to the recipes shown in Table 2.4. The gel-casting unit  was assembled 
according to the manufacturers’ instructions and the prepared gels submersed in tank buffer in 
a Bio-Rad Mini Protean II™ vertical slab electrophoresis apparatus.
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Table 2.4 Recipe for two Tricine-SDS polyacrylamide gels
Reagent Separating gel (10%) Stacking gel (4%)
AB-3 3.00 ml 500 µl
Gel buffer 5.00 ml 1.5 ml
Glycerol 1.5 g -
Distilled water 6.00 ml 3.95 ml
Initiator reagent 75 µl 45 µl
TEMED 7.5 µl 4.5 µl
Electrophoresis was initially carried out at 30 V until the dye front entered the separating gel. 
The voltage was then increased to 90 V and electrophoresis continued until the dye front was 
approximately  0.5  cm from the bottom of  the  separating  gel.  The gels  were removed and 
stained with Coomassie Blue R-250 staining solution for  ≥ 1 h followed by destaining with 
successive  changes  of  destain  I  and  II.  Destained  gels  were  imaged  with  the  BioRad 
VersaDocTM image documentation system. The molecular weight of the desired protein band(s) 
were  determined  using  a  graph  of  log  molecular  weight  of  the  standards  versus distance 
migrated  (mm)  into  the  separating  gel.  The  molecular  weight  standards  used  were 
representative of a New England Biolabs broad range protein marker [Myosin (212,000 Da); 
MBP-β-galatosidase (158,194 Da); β-galatosidase (116,351 Da); Phosphorylase b (97,184 Da); 
Serum  albumin  (66,409  Da);  Glutamic  dehydrogenase  (55,561  Da);  MBP2  (42,710  Da); 
Thioredoxin reductase (34,622 Da); Triosephosphate isomerase (26,972 Da); Trypsin inhibitor 
(20,100 Da); Lysozyme (14,313 Da); Aprotinin (6,517 Da); Insulin A (3,400 Da); B chain (2,340 
Da)].
2.4.3 Western blot
Proteins resolved by SDS-PAGE gel electrophoresis can be electro-transferred onto a solid 
membrane such as nitrocellulose, PVDF or nylon for detection with protein-specific antibodies. 
The western blot method used in this study was conducted in accordance with the protocol 
described  by  Towbin et  al. (1979).  This  technique  was  employed  for  the  detection  of 
recombinant proteins in Escherichia coli  cell lysates and native proteins in Plasmodium cell 
lysates that were resolved by SDS-PAGE. 
2.4.3.1 Materials 
Transfer buffer [50 mM Tris, 200 mM glycine, 20% (v/v) methanol]. Tris (6.051 g), glycine (14.4 
g) and methanol (200 ml) were made up to 1 ℓ with distilled water and stored at 4°C.
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Ponceau S stain [0.2% (w/v) Ponceau S in 1% (v/v) acetic acid]. Ponceau S (20 mg) was 
resuspended in 1 ml of glacial acetic acid. The volume was made up to 100 ml with distilled 
water and stored at RT.
Tris buffered saline (TBS) [20 mM Tris-HCl,  pH 7.4, 200 mM NaCl]. Tris (2.42 g) and NaCl 
(11.69 g) were dissolved in 950 ml of distilled water, titrated to pH 7.4 with HCl and the volume 
made up to 1 ℓ with distilled water. The solution was stored at RT.
Blocking solution [5% (w/v) non-fat  powdered milk in TBS]. Locally sourced (Elite®)  fat-free 
powdered milk (5 g) was suspended in 100 ml of TBS. This solution was freshly prepared.
BSA-TBS [0.5% (w/v) BSA in TBS]. BSA (0.5 g) was dissolved in 100 ml TBS. This solution was 
freshly prepared.
Substrate reagent [0.06% (w/v) 4-chloro-1-naphthol, 0.0015% (v/v) H2O2, 20% (v/v) methanol in 
TBS]. A stock solution of 4-chloro-1-naphthol was prepared by dissolving 30 mg in methanol 
(10 ml). Two ml of this stock solution was made up to 10 ml with TBS and H 2O2 (4 µl of a 30% 
solution) was added, ensuring the solution was exposed to minimal light. This working solution 
was freshly prepared. 
2.4.3.2 Method
Following a SDS-PAGE run, one gel was stained with Coomassie blue R-250 as a reference 
gel whilst the other gel was electro-blotted to nitrocellulose. The nitrocellulose membrane-gel 
“sandwich” was placed in a blotting apparatus containing blotting buffer with the nitrocellulose 
membrane towards the anode. Protein was transferred to the membrane [(13 V, 40 mA, 16 h) 
or (70 V, 250 mA, 2 h)], visualised on the nitrocellulose with Ponceau S stain and the molecular 
weight marker proteins marked with a pencil. The Ponceau S stained nitrocellulose membrane 
was destained and unoccupied sites on the membrane blocked with blocking solution for 1 h. 
The nitrocellulose membrane was then washed three times with TBS (5 min/wash), followed by 
a 2 h incubation with the required dilution of the desired primary antibody in BSA-TBS. The 
nitrocellulose  membrane  was  again  washed  three  times  in  TBS  (5  min/wash)  and  then 
incubated  for  1  h  in  the  appropriate  dilution  of  secondary  antibody  in  BSA-TBS.  The 
nitrocellulose membrane was washed a further three times in TBS (5 min/wash) followed by 
addition of the substrate reagent. The membrane was incubated in substrate until a band(s), 
suggestive  of  the  targeted  protein,  became  apparent.  The  image  was  captured  with  the 
VersaDoc imaging system and the blot stored.
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2.4.4 Bradford standard protein assay
2.4.4.1 Materials 
Bradford dye reagent [0.06% (w/v) Coomassie Brilliant Blue G-250 in 2% (v/v) perchloric acid]. 
Coomassie Brilliant Blue G-250 (0.3 g) was resuspended in 500 ml of 2% (v/v) perchloric acid 
in distilled water. The solution was stirred for 1 h at RT and filtered through Whatman No.1 filter 
paper. The solution was stored in an amber glass bottle at RT. 
Phosphate buffered saline (PBS),  pH 7.2. NaCl (8 g),  KCl (0.2 g),  Na2HPO4 (0.917 g) and 
KH2PO4 (0.2 g) were dissolved in 950 ml of distilled water, titrated to pH 7.2 with HCl and made 
up to 1 ℓ with distilled water and stored at 4°C.
Ovalbumin stock solution [1.0 mg/ml]. Ovalbumin (1 mg) was dissolved in 1 ml of PBS and 
used to set up a standard curve from 0 to 50 μg. This curve was used for determination of 
unknown concentrations.
Protein standards [0 – 50 μg ovalbumin/100 μl of buffer]. Proteins standards were prepared 
from the ovalbumin stock by resuspending 10 to 50 μg ovalbumin in 100μl of buffer. Standards 
were prepared in 10 μg increments.
2.4.4.2 Method
In a 1.5 ml microfuge tube, dye reagent (900 μl) was mixed with the protein standard solutions 
(0.1 ml) and incubated at RT for 15 min. Each protein standard was prepared in triplicate and 
the absorbance value for each solution determined at 595 nm. The mean absorbance value for 
each standard was recorded and plotted against the amount of protein in an x-y scatter plot. 
Solutions having an unknown protein concentration were prepared in a similar manner to the 
protein  standards,  with  the  resulting  protein  concentration  derived  by  extrapolation  on  the 
standard curve.
2.4.5 Coupling synthetic peptides to rabbit albumin carrier for antibody production
Synthetic  peptides derived from the copper  transport  and Cox17 proteins  (P.  yoelii and  P. 
falciparum) were coupled to rabbit albumin and injected into chickens for anti-peptide antibody 
production. Peptides are coupled to a carrier protein due to their relatively small sizes. The 
molecular weight of the peptides ranged from 1500 – 2000 Da and were thus unlikely to be able 
to elicit a host immunogenic response alone (Saravanan and Kumar, 2009). The peptides were 
designed and synthesized with a terminal cysteine residue to provide a functional sulfhydryl 
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(SH) group for covalent attachment to the carrier protein and affinity matrix. Prior to coupling, 
peptides were treated with dithiothreitol (DTT) to produce free terminal SH residues, whilst the 
rabbit  albumin  carrier  was  activated  with  3-maleimidobenzoic  acid  N-hydroxysuccinimide 
(MBS). MBS is a heterobifunctional reagent that cross links peptides to carrier proteins through 
cysteines and free amino groups (Harlow and Lane, 1988). Reduced peptides were separated 
from DTT on a Sephadex G-10 resin and the MBS-rabbit  albumin complex separated from 
unreacted MBS on a Sephadex G-25 resin.
2.4.5.1 Materials 
Phosphate buffered saline (PBS), pH 7.2. As per Section 2.4.4.1
MEC Buffer [0.1 M NaH2PO4, pH 7.0, 0.02% (w/v) NaN3, 1 mM Na2-EDTA]. NaH2PO4 (11.998 g), 
Na2-EDTA (0.372 g)  and sodium azide (0.2 g)  were dissolved in  950 ml of  distilled water, 
titrated to pH 7.0 with NaOH and made up to 1 ℓ with distilled water.
Peptide reducing buffer [0.1 M Tris-HCl, pH 8.0, 1 mM Na2-EDTA]. Tris (2.24 g) and Na2-EDTA 
(0.372 g) were dissolved in 150 ml of distilled water, titrated to pH 8.0 with HCl and made up to 
200 ml with distilled water.
Ellman’s reagent buffer [0.1 M Tris-HCl, pH 8.0, 1 mM Na2-EDTA, 0.1% (w/v) SDS]. Tris (1.21 
g), Na2-EDTA (0.372 g) and SDS (1 ml of 10% SDS) were dissolved in 90 ml of distilled water,  
titrated to pH 8.0 with HCl and made up to 100 ml with distilled water.
Dithiothrietol [10 mM]. Dithiothrietol (7.71 mg) was dissolved in 5 ml of peptide reducing buffer.
2.4.5.2 Method
It has previously been determined that 4 mg of a synthetic peptide is sufficient to produce 4  to 
10  mg  of  affinity  purified  polyclonal  antibodies,  12  to  15  weeks  after  a  schedule  of  four 
immunisations in a chicken (Goldring and Coetzer, 2003). 
Calculations:
Peptides were coupled to rabbit albumin carrier at a peptide:carrier ratio of 40:1. The amount of 







4×10−3 g  peptide 
Mw  peptide 
×1000= carrier mg    
68200 is the molecular mass of rabbit albumin in Daltons.
Rabbit albumin carrier was activated with MBS at a carrier:MBS ratio of 1:40. The amount of 






Where 314.26 is the molar mass of MBS.
Activating the carrier with MBS:
The calculated quantity of MBS was dissolved in 100 μl of dimethylfluoride (DMF)and made up 
to 500 μl with PBS. This was combined with an equal volume of PBS containing the calculated 
quantity of rabbit albumin. The solution was mixed gently for 30 min at RT with a rotary mixer. 
The solution was then loaded onto a Sephadex G-25 size exclusion chromatography resin pre-
equilibrated with MEC buffer. The MBS-rabbit albumin complex was eluted with MEC buffer and 
the  eluted  fractions  collected  in  1  ml  volumes.  The  A280  of  each  collected  fraction  was 
determined and those with an absorbance ≥ 0.3 were pooled together. 
Reducing the peptide with DTT:
Peptide (4 mg) was solubilised in 50 μl of dimethylsulfoxide (DMSO) and the volume was made 
up to 500 μl with peptide reducing buffer. DTT reagent (500 μl) was combined with the peptide 
solution and this solution was incubated at 37°C for 90 min. The reduced peptide solution was 
then loaded onto a Sephadex G-10 size exclusion chromatography resin pre-equilibrated with 
MEC buffer. Reduced peptide fractions of  500 μl were collected and the presence of free SH 
groups determined with Ellman’s reagent (10 μl of eluted fraction + 10 μl of Ellman’s reagent). 
The set of fractions producing an intense yellow colour, with Ellman's reagent, were pooled 
together.
Reacting the reduced peptide with the MBS-activated carrier:
The pooled MBS-rabbit albumin fractions were combined with the pooled fractions of reduced 
peptide.  This  mixture  was  then  incubated  at  RT  for  3  h,  with  gentle  stirring.  Following 
incubation, the solution was aliquoted into four equal volumes and stored at -20°C.
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2.4.6 Preparation of immunogen for immunisation in chickens
For the initial immunisation, the peptide-carrier complex was emulsified in Freund’s complete 
adjuvant (FCA) and thereafter Freund's incomplete adjuvant (FIA) was used. FCA is made up 
of  heat  attenuated  Mycobacterium  tuberculosis mixed  in  mineral  oil  to  elicit  cell-mediated 
immunity, resulting in the production of antibodies against the peptide and carrier. On the other 
hand, FIA is mineral oil without heat attenuated M. tuberculosis. 
2.4.6.1 Method
The peptide-carrier complex solution was removed from -20°C and thawed at RT. Once thawed 
it was dispensed into a 20 ml scintillation vial and combined with an equal volume of FCA or 
FIA.  The  mixture  was  triturated,  using  a  2.5ml  syringe,  until  a  relatively  viscous  emulsion 
formed.  This  emulsion  was  subsequently  loaded  into  the  2.5ml  syringe.  Chickens  were 
immunised  intra-muscularly,  in  the  large  breast  muscles,  with  400  μl  to  500  μl of  the 
immunogen containing ~ 125 µg of the synthetic peptide. As mentioned, the first immunisation 
was prepared in FCA whilst the three subsequent booster immunisations were prepared with 
FIA.  Immunisations  were  carried  out  at  two-week  intervals.  Eggs  from each  chicken  were 
collected daily, labelled and stored at 4°C until the antibodies were isolated.
2.4.7 Isolation of immunoglobulin Y (IgY) from chicken egg yolk
The solubility of proteins in an aqueous environment depends largely on the surface availability 
of hydrophilic amino acids. These hydrophilic amino acids form hydrogen bonds with water 
molecules in the hydration shell  of  the protein. Dextran and polyethylene glycol (PEG)  can 
disrupt this interaction and are therefore widely used as protein precipitation agents. Dextran 
and PEG are preferentially  excluded from the hydration  shell  around proteins  bringing the 
protein solution to its solubility limit (Chun et al., 1967; Ingham, 1984; Polson et al., 1985). PEG 
is a linear, water-soluble, non-ionic polymer with a molecular weight varying from 200 to 20 000 
Da depending on the extent of polymerization. PEG can be used to extract proteins at room 
temperature without causing protein denaturation  (Ingham, 1984; Polson et al., 1985). PEG, 
with a molecular weight of 4 000 to 6000 Da, is routinely used in protein precipitation. Polymers 
larger than this offer no advantage, since their solutions are more viscous (Atha and Ingham, 
1981;  Ingham, 1984).  Since PEG has a minimal  effect  on protein stability  and precipitates 
protein in a relatively short time, it is the molecule of choice for protein isolation particularly 
compared to organic solvents and ammonium sulphate. 
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In this study, PEG 6000 (Mw ~ 6 kDa) precipitation was used to isolate IgY from eggs produced 
by chickens immunised with the synthetic peptide-rabbit  albumin complex. IgY was isolated 
using the method of Polson et al. (1985). Chickens were housed and cared for at the University 
of KwaZulu-Natal farms at Ukulinga, Pietermaritzburg. The use of chickens for this study was 
approved by  the University’s  ethical  committee,  with  the ethical  clearance project  number: 
AE/Goldring/05  for  2005  –  2006;  004/07/Animal  for  2007;  025/08/Animal  for  2008  and 
003/10/Animal for 2010.
2.4.7.1 Materials 
IgY isolation buffer [100 mM NaH2PO4, pH 7.6, 0.02% (w/v) NaN3]. NaH2PO4 (11.998 g) and 
NaN3 (0.2 g) were dissolved in 950 ml of distilled water, titrated to pH 7.6 with NaOH and made 
up to 1 ℓ with distilled water.
IgY Storage Buffer [100 mM NaH2PO4,  pH 7.6, 0.1% (w/v) NaN3].  NaH2PO4 (11.998 g) and 
NaN3 (1 g) were dissolved in 950 ml of distilled water, titrated to pH 7.6 with NaOH and made 
up to 1 ℓ with distilled water.
2.4.7.2 Method
Egg yolks were separated from albumin and carefully washed under slow running tap water to 
help remove the albumin. Yolk sacks were punctured and the yolk contents gently squeezed 
into a measuring cylinder to determine the total yolk volume. Isolation buffer, equivalent to two 
yolk volumes, was added to the yolk contents and mixed by stirring. Solid PEG was added to 
3.5% (w/v) and stirred continuously to ensure all the PEG dissolved. The precipitated vitellin 
fraction was removed by centrifugation (4420  g, 30 min, RT). The resulting supernatant was 
filtered through non-absorbent cotton wool and the filtrate volume determined. Solid PEG was 
added to the filtrate at 8.5% (w/v) and, as before, this was stirred thoroughly. The solution was 
centrifuged (12000 g, 10 min, RT) to pellet the precipitate, with the resulting supernatant being 
discarded. The pellet was dissolved in a volume of buffer equivalent to the original egg yolk 
volume and 12% (w/v) PEG added. This was again stirred thoroughly and then centrifuged 
(12000 g, 10 min, RT). The supernatant was again discarded and the final pellet dissolved in a 
volume of buffer equivalent to  one-sixth of the original yolk volume. The final IgY concentration 
was determined using the extinction coefficient E 1mg /ml
280nm
=1. 25  (Coetzer, 1985).
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2.4.8 Preparation of peptide-specific affinity matrices and purification of anti-peptide IgY
Affinity purification offers separation of biomolecules based on unique biological interactions. 
The matrix generally consists of polyacrylamide, dextran or agarose polymerized beads. The 
matrix is insoluble and is usually commercially synthesized to acquire specific functional groups 
such  as  aldehyde,  carboxylic  acid,  hydroxyl,  amine,  or  sulfhydryl  groups.  The  ligand  is 
immobilized on the matrix by means of several specific coupling reactions. Molecules to be 
purified,  adsorb  to  the  immobilized  ligands  when  passed  though  the  affinity  matrix.  The 
remaining components in the mixture are generally washed off the matrix with several washes 
of the appropriate column buffer. A buffer of low pH or high ionic strength, or a specific reagent, 
is used to disrupt the affinity-based interactions between the adsorbed molecules and ligand to 
elute the desired products. 
SulfoLink® Coupling Gel is a 6% beaded agarose that has been derived to have an iodoacetyl 
group spaced by a 12-atom structure (Pierce SulfoLink manual).  This enables the covalent 
bonding of molecules, such as peptides and proteins with free SH functional groups, to the 
iodoacetyl group on the agarose gel matrix. The 12-atom spacer is designed to decrease steric 
hindrance between the coupled ligand and the affinity-bound molecule, enhancing the binding 
of the molecule to its ligand. The molecule to be coupled must be in monomeric form without 
disulfide linkage. Thus the molecule is reduced with DTT to acquire free -SH reactive functional 
groups  prior  to  coupling.  The  reducing  agent  (DTT)  is  then  removed,  by  size  exclusion 
chromatography,  to  prevent  it  from out-competing the peptide for  binding to the iodoacetyl 
functional groups. The -SH group specifically reacts with the iodide, on the iodoacetyl functional 
group, to form a stable thioether bond. 
2.4.8.1 Materials 
Coupling buffer [50 mM Tris-HCl, pH 8.5, 5 mM Na2-EDTA]. Tris (12.1 g) and Na2-EDTA (3.72 g) 
were dissolved in 950 ml of distilled water, titrated to pH 8.5 with HCl and the volume made to 1 
ℓ with distilled water.
Blocking solution [50 mM L-cysteine in coupling buffer]. L-cysteine (2.2 g) was dissolved in 250 
ml of coupling buffer.
Wash solution [1 M NaCl]. NaCl (58.44 g) was dissolved in 1 ℓ of distilled water.
Equilibration buffer [100 mM NaH2PO4,  pH 7.6, 0.1% (w/v) NaN3].  NaH2PO4 (11.998 g) and 
NaN3  (1 g) were dissolved in 950 ml of distilled water, titrated to pH 7.6 with NaOH and the 
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volume made up to 1 ℓ with distilled water.
Affinity  column-washing  buffer  [100  mM  NaH2PO4,  pH  6.5,  0.02%  (w/v)  NaN3].  NaH2PO4 
(11.998 g) and NaN3 (0.2 g) were dissolved in 950 ml of distilled water, titrated to pH 6.5 with 
NaOH and the volume made up to 1 ℓ with distilled water.
Elution buffer [100 mM glycine, pH 2.8, 0.02% (w/v) NaN3]. Glycine (0.75 g) and NaN3 (0.02 g) 
were dissolved in 80 ml of distilled water, titrated to pH 2.8 with HCl and the volume made up to 
100 ml with distilled water.
Neutralising buffer [1 M NaH2PO4, pH 8.5, 0.02% (w/v) NaN3]. NaH2PO4 (11.998 g) and NaN3 
(0.02 g) were dissolved in 80 ml of distilled water, titrated to pH 8.5 with NaOH and the volume 
made up to 100 ml with distilled water.
2.4.8.2 Method
Coupling of peptides to SulfoLink™ affinity matrix
For  coupling  of  peptides  to  the  SulfoLink™  resin,  7.5  mg of  the  peptide  was  reduced  as 
described in Section 2.4.5. SulfoLink™ resin (2 ml of 50% slurry = 1 ml column volume) was 
dispensed into a BioRad Poly-Prep® affinity column. The resin was equilibrated with 5 column 
volumes of coupling buffer. The buffer was allowed to flow through the matrix until the meniscus 
was just above the matrix. The reduced peptide solution was added to the equilibrated resin 
and the column capped to close the inlet and outlet. The suspension was mixed on a rotary 
mixer (15 min, RT), and then incubated in a stationary, upright position (30 min, RT). The caps 
were removed and the outlet opened to allow the reaction by-products and uncoupled peptides 
to elute. The resin was washed with 5 column volumes of the coupling buffer, the outlet capped 
and 1 ml of the blocking buffer added to the matrix and the inlet capped. The suspension was 
mixed again on a rotary mixer (15 min, RT) and then allowed to stand (30 min, RT). The column 
was uncapped to allow the buffer to drain out. The matrix was washed with 5 column volumes 
of the wash solution and equilibrated with 5 column volumes of the equilibration buffer. The 
affinity matrix was stored at 4°C until use.
Affinity purification
Prior  to  purification,  the affinity  resin was equilibrated with 20 column volumes of  washing 
buffer. The isolated IgY (Section 2.4.7) was pooled and filtered through Whatman No.1 filter 
paper to remove insoluble materials that could clog the affinity column. The filtrate was cycled 
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through the resin overnight,  in  a reverse direction.  Unbound antibodies  were subsequently 
washed off the column with 20 column volumes of affinity column-washing buffer in a forward 
direction.  Bound  antibodies  were  eluted with  elution  buffer  and  1  ml  fractions  collected  in 
microfuge tubes containing 100 μl of neutralizing buffer.  The A280 of  collected fractions was 
determined and the elution profile of A280 against elution volume plotted. Fractions with A280 ≥ 
0.2 were pooled together and protein concentration determined. The affinity purified polyclonal 
anti-peptide IgY was stored at 4°C.
2.4.9 Enzyme linked immunosorbent assay for anti-peptide IgY titre
In this study, an indirect enzyme linked immunosorbent assay (ELISA) was used to determine 
the weekly anti-peptide IgY titres for each immunised chicken.
2.4.9.1 Materials 
Phosphate buffered saline (PBS), pH 7.2. As per Section 2.4.4.1
Blocking solution [0.5% (w/v) bovine serum albumin-PBS]. BSA (0.5 g) was dissolved in 100 ml 
of PBS.
Tween-PBS washing solution [0.1% (v/v) Tween-PBS]. Tween-20 (1 ml) was made up to 1 ℓ 
with PBS.
0.15 M citrate-phosphate buffer, pH 5.0. A solution of citric acid monohydrate (21.0 g/ℓ) was 
titrated with a solution of Na2HPO4 (28.4 g/ℓ) to pH 5.0.
Substrate solution [0.05% (w/v)  ABTS and 0.0015% (v/v)  H2O2 in  citrate-phosphate buffer]. 
ABTS (7.5 mg) and H2O2 (7.5 µl) were dissolved in citrate-phosphate buffer (15 ml).
2.4.9.2 Method
A 96-well microtitre plate (Nunc Maxi SorpTM) was coated with 150 µl of a 1 µg/ml solution of 
peptide in PBS for 3 h at 37°C and then overnight at 4°C. Following incubation the peptide 
solution  was  discarded,  the  plate  rinsed  with  Tween-PBS and  then  blocked  with  blocking 
solution (200 µl, 1 h, 37°C). After blocking, the plate was washed three times with Tween-PBS. 
Weekly isolates of immune IgY were prepared in blocking solution (100 μg/ml) and the plate 
incubated with 150 μl of these preparations. Included, as a control, was crude IgY isolated from 
pre-immune eggs. These primary antibody samples were incubated for 2 h at 37°C followed by 
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three  washes  with  Tween-PBS.  A rabbit-anti-chicken  IgY-Horse  Raddish Peroxidase  (HRP) 
conjugated secondary antibody was prepared in blocking solution (1:15 000 dilution), added to 
each well (150 μl) and incubated (1 h, 37°C). Following incubation, the plate was again washed 
three times with Tween-PBS. Substrate solution was prepared and added to each well (150 μl). 
The plate was incubated at RT, in the dark, until colour sufficiently developed. The absorbance 
of the substrate solution was recorded at 405 nm with the VersaMax™ ELISA plate reader.
2.5 Parasitological techniques
The rodent malaria parasites  P. yoelii, P. berghei, P. vinckei  and  P. chabaudi, provide useful 
models for laboratory studies of the  Plasmodium parasite's biology  (Carlton et al.,  2002). All 
four rodent malaria parasites can infect and be propagated in mice. These infections can be 
used to study the interaction between the host and erythrocytic stage of parasite development. 
This highlights just one of the aspects that make mouse malaria infections useful models for 
studying immunological, molecular and biochemical aspects of the Plasmodium parasite (Sanni 
et al., 2002). Variation does, however, exist between species and strains of the rodent-infecting 
parasites in terms of virulence. For example, certain strains of P. yoelii are lethal to mice (e.g. 
17XL), following infection, whilst other strains are non-lethal (e.g. 17XNL).
This  section describes techniques used for  the propagation,  isolation and purification of  P. 
yoelii  and  P. berghei. In these studies, the lethal  P. yoelii 17XL and  P. berghei ANKA strains 
were used. Parasites were propagated in 6 – 8 week old male BALB/c mice obtained from 
National  Health  Laboratory  Services,  Johannesburg,  South  Africa,  through  intraperitoneal 
injection of 100 µl of stabilate containing 1 x 107 parasitised mouse red blood cells (Burns et al., 
1989). Mice used in this study were kept in the university animal housing facility at a constant 
temperature of 19 – 22°C. Each animal was housed in an individual cage having a plastic 
bottom and steel mesh lid. Cages, saw dust, water and food were autoclaved prior to use. Food 
and water was provided ad libitum. Parasitemia was analysed every second day, post infection, 
by light microscopy of methanol-fixed, Giemsa-stained thin blood smears of tail blood (Warhurst 
and Williams, 1996).
2.5.1  Propagation  of  P.  yoelii  and P.  berghei  parasites  in  BALB/c  mice  and  cryo-
preservation
2.5.1.1 Materials 
Phosphate buffered saline (PBS), pH 7.2. As per Section 2.4.4.1




Parasites  were  propagated  in  male  BALB/c  mice  by  intra-peritoneal  injection  of  parasite 
stabilate (1 x 107 parasitised mouse red blood cells). The lower abdomen was cleaned with 
70% ethanol and the mouse held upside down for the organs to partially drop. The syringe 
(insulin syringe, 1 cc) was inserted ~ 0.5 cm into the skin and the stabilate slowly injected into 
the mouse. The syringe was slowly withdrawn, with rotation, to help prevent the stabilate from 
exuding following injection. The mouse was immediately returned to its cage and monitored for 
5 – 10 min post injection. Parasitemia was monitored daily by Giemsa staining of a thin smear 
of tail blood. The thin blood smear was air-dried, fixed in methanol for 1 min at RT and then left 
to dry at RT. The smear was stained with Giemsa for 20 – 30 min at RT, washed under slow 
running water,  air-dried and viewed at  1000× magnification (oil  immersion).  The number of 
infected RBC was expressed as a percentage of non-infected RBC. Once parasitemia reached 
a suitable level, mice were bled and the blood collected in a heparin-treated vacuum glass 
tube.  Parasite  infected  red  blood  cells  were  preserved  in  10%-glycerol-PBS  at  1  x  107 
parasitised-RBC (pRBC) per 100 µl of stabilate. The stabilate was labelled, flash-frozen and 
immediately stored in a liquid nitrogen cryo-tank. 
2.5.2 Isolation of P. yoelii and P. berghei parasites from infected mouse red blood cells
2.5.2.1 Materials 
Phosphate buffered saline (PBS), pH 7.2. As per Section 2.4.4.1
Saponin-PBS [0.05% (w/v) saponin in PBS]. Saponin (5 mg) was dissolved in 10 ml of PBS and 
kept on ice prior to use.
2.5.2.2 Method
At 30 – 40% parasitemia, an infected mouse was sacrificed and the blood collected into a 
heparin-treated vacuum tube and kept on ice. The blood was diluted with ice cold PBS (1:4) 
and passed through a Plasmodipur® filter to remove host white blood cells. The filtrate was 
centrifuged (800 g, 15 min at 4°C) to pellet the infected RBC. The pelleted cells were washed 
three times with ice cold PBS (five times the pelleted RBC volume) and then resuspended in 
five volumes of saponin-PBS. The cell suspension was incubated at RT for 30 min to allow for 
complete hemolysis, as indicated by a dark red colour. The suspension was centrifuged (3500 
g, 15 min at 4°C) to pellet the liberated, mixed stage parasites. The supernatant was carefully 
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aspirated,  leaving behind only  a small  volume of  the supernatant  so as not  to  disturb the 
parasite pellet. The parasite pellet was washed a further two times with five volumes of ice-cold 
PBS. This final pellet was resuspended in an equal volume of PBS, divided into aliquots and 
stored  at  -20°C.  Parasite  protein  lysate  was  prepared  from  these  isolated  parasites  by 
subjecting the sample to three freeze-thaw cycles, between 37°C and -196°C (liquid nitrogen 
for  2  min),  following  the  addition  of  Triton  X-100  (1%),  EDTA (5  mM)  and  PMSF (1mM). 
Samples were further disrupted by sonication on ice (5 cycles,  15 sec/cycle,  1 min on ice 
between cycles). The total parasite lysate was then centrifuged at 100,000 g for 1 h so as to 
separate the lysate into soluble and insoluble material. The respective fractions were separated 
from one another and used for western blotting studies. 
2.5.3 Immunofluorescence microscopy
2.5.3.1 Materials
Sodium carbonate-bicarbonate coating buffer [0.02 M Na2CO3, 0.02 M NaHCO3, 0.2% NaN3, 
pH 9.7].  Na2CO3 (0.168 g)  was made up to 100 ml with distilled water  (solution  A),  whilst 
NaHCO3 (0.105 g) and NaN3 (0.01 g) were made up to 50 ml with distilled water (solution B). 
Solution A was titrated against solution B to pH 9.7. 
Isotonic Tris buffer [0.15 M Tris-HCl, pH 7.5]. Tris (0.908 g) was dissolved in 40 ml of distilled 
water, titrated to pH 7.5 with HCl and made to a final volume of 50 ml with distilled water. The 
solution was sterilised by filtration through a 0.22 µm syringe filter prior to use.
0.9% NaCl. NaCl (0.9 g) was dissolved in 10 ml distilled water. The solution was sterilied by 
filtration through a 0.22 µm syringe filter prior to use.
Hank’s balanced salt  solution. Hank’s balanced salt  (0.475 g) and Na2CO3 (0.0175 g) were 
dissolved in 45 ml of distilled water, titrated to pH 7 and made up to a final volume of 50 ml with 
distilled water. The solution was sterilised by filtration through a 0.22 µm syringe filter prior to 
use.
THS solution. Isotonic Tris buffer (5 ml), Hank’s balanced salt solution (50 ml) and 0.9% NaCl 
(45 ml) were combined under sterile conditions and stored in a sterile bottle.
Phosphate buffered saline (PBS), pH 7.2. As per Section 2.4.4.1
Glutaraldehyde-PBS  [1%  (v/v)  glutaraldehyde  in  PBS].  Glutaraldehyde  (200  µl  of  a  50% 
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solution) was made up to 5 ml with PBS.
BSA-PBS solution [2% (w/v) BSA in PBS]. BSA (0.2 g) was dissolved in PBS (10 ml). 
DAPI solution [5 µg/ml in PBS]. DAPI (2.5 µl of a 2 mg/ml solution) was made up to 1 ml with 
PBS and kept away from light.
2.5.3.2 Method
Pre-treatment of  P. yoelii  -infected red blood cells (pRBC  )
Infected mouse blood was collected in a heparin-treated tube, an aliquot removed (100 µl) and 
centrifuged (800 g, 5 min, 4°C). The plasma was discarded and the packed cells resuspended 
in  100  µl  of  THS  solution.  Cells  were  again  collected  by  centrifugation,  the  supernatant 
removed and the cells washed a further four times with 100 µl of THS (800 g, 5 min, 4°C). The 
packed cells were resuspended to 1% haematocrit (30 µl packed cell volume in 3 ml of THS 
solution) and kept on ice.
Preparation of slides and fixing of pRBC
A 12-well slide was incubated with 20 µl of the coating buffer per well (30 min, RT) and the 
solution then aspirated. A small volume of the cell suspension was added to each well (~20 µl) 
and the cells were left to settle for 30 min at RT. Unbound cells were washed off the slide by 
inverting and rinsing the slide in a Petri dish containing THS solution. Bound cells were fixed by 
covering each well with glutaraldehyde-PBS (10 sec, RT). The fixing solution was removed by 
aspiration and the fixing step repeated. The slides were washed with distilled water, air-dried 
and stored desiccated at -20°C.
Immuno-detection of the  P. yoelii    putative copper transport protein and lactate dehydrogenase 
A slide was removed from storage at -20°C and allowed to equilibrate to RT inside a humidified 
Petri dish. BSA-PBS (20 µl) was added to each well and incubated at RT to block non-specific 
sites (1 h). The BSA-PBS solution was vacuum-aspirated and a solution of the desired primary 
antibody (20 µl  of  1 µg/ml anti-peptide IgY or  pre-immune IgY, in  BSA-PBS) added to the 
respective wells  and incubated for  2 h at  RT.  The primary antibody solution  was vacuum-
aspirated and wells washed three times with PBS. All wells were incubated with a donkey anti-
IgY-FITC conjugated secondary antibody (20 µl of a 1:5000 dilution, in BSA-PBS) for 1 h at RT 
(in the dark). The secondary antibody solution was vacuum-aspirated and the wells washed 
three times with PBS (in the dark). Cells were finally stained with DAPI solution, followed by 
three washes with PBS (in the dark). The slide was stored at 4°C overnight, in a desiccated 
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vacuum  chamber,  away  from  light  and  then  viewed  with  an  Olympus  AX70  fluorescent 
microscope using green and UV filters for FITC and DAPI, respectively. Images were captured 
with the CC12 Soft Imaging System™ colour camera and processed with analySIS™ software.
2.6 Molecular biology methods
This section describes the methods used to isolate Plasmodium parasite nucleic acids used for 
down stream applications. These applications included the polymerase chain reaction (PCR), 
ligation  and cloning,  subcloning,  analysis  of  expression  by  reverse transcriptase-PCR (RT-
PCR)  and  expression  of  recombinant  P.  yoelii, P.  berghei and  P.  falciparum  proteins.  The 
design of oligonucleotides used to PCR amplify the desired coding domains were based on 
sequences published on the PlasmoDB web site (www.plasmodb.org).
2.6.1 Agarose gel electrophoresis
2.6.1.1 Materials  
Na2EDTA [0.5 M, pH 8.0]. Na2EDTA (18.6 g) was dissolved in 80 ml of distilled water, titrated to 
pH 8.0 and the volume made up to 100 ml with distilled water.
 
50× TAE electrophoresis buffer. Tris (242 g) was dissolved in 500 ml of distilled water, with the 
addition of 0.5 M Na2EDTA solution (100 ml) and glacial acetic acid (57.1 ml). The solution was 
made up to 1 ℓ with distilled water and stored at RT. 
Ethidium  bromide  staining  reagent  [10  mg/ml  in  1×  TAE].  Ethidium  bromide  (0.1  g)  was 
resuspended  in  1×  TAE and  stirred  at  RT for  30  min.  The  dye  solution  was  filtered  with 
Whatman No.1 filter paper and stored in an amber bottle at RT.
10× sample loading buffer. Bromophenol blue (0.25 g) was resuspended in 33 ml of 1× TAE, 
glycerol added (60 ml) and the solution made up to 100 ml with 1× TAE. The reagent was 
stored at RT.
2.6.1.2 Method
For a 1% agarose gel, 0.3 g of agarose was weighed out and suspended in 30 ml of 1× TAE 
buffer. The agarose was completely melted and once the solution had cooled ethidium bromide 
was added to a final concentration of 0.5 µg/ml. The gel was poured and once set it was placed 
into an agarose gel electrophoresis tank containing 1× TAE buffer. The desired samples were 
combined  with  loading buffer  (9:1;  sample:10×  sample  loading  buffer)  and loaded into  the 
sample wells. Electrophoresis was carried out at 80 V and an image of the gel captured with 
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the VersaDocTM gel documentation system under ultraviolet light. The size of the DNA bands of 
interest were determined from a graph of log DNA standards (bp) against distance migrated 
(mm) from the well. The DNA standards used were representative of either a Promega 1 kb 
DNA stepladder (10,000 bp; 9,000 bp; 8,000 bp; 7,000 bp; 6,000 bp; 5,000 bp; 4,000 bp; 3,000 
bp; 2,000 bp; 1,000 bp) or a Fermentas MassRulerTM DNA ladder mix (10,000 bp; 8,000 bp; 
6,000 bp; 5,000 bp; 4,000 bp; 3,000 bp; 2,500 bp; 2,000 bp; 1,500 bp; 1,031 bp; 900 bp; 800 
bp; 700 bp; 600 bp; 500 bp; 400 bp; 300 bp; 200 bp; 100 bp; 80 bp).
2.6.2 Isolation of P. berghei total RNA 
2.6.2.1 Materials
DEPC-treated TE buffer [10 mM Tris (pH 8), 1 mM EDTA]. Tris (10 ml of 1 M solution, pH 8) 
was mixed with EDTA (2 ml of 0.5 M solution, pH 8). The volume was made up to 1 ℓ with 
distilled water. DEPC was added to 0.1% (v/v), incubated at 37°C overnight and autoclaved to 
remove residual DEPC.
Formamide gel-loading buffer. Formamide (160 µl) was mixed with DEPC-treated TE buffer (40 
µl) and bromophenol blue dye was added.
2.6.2.2 Method
For this study parasite RNA was isolated to confirm transcription of the amino terminal coding 
domain  of  putative  P.  berghei copper  transport  protein.  The  amplified  product  was  to 
subsequently be ligated into an expression vector and used for recombinant protein expression. 
P. berghei RNA was isolated using the Qiagen RNeasy® Plus Mini kit. The kit is designed to 
purify RNA from animal cells or tissues and is compatible with a wide range of cell types. The 
kit offers efficient purification of high-quality RNA with the selective removal of double-stranded 
DNA. Samples are lysed in a denaturing lysis buffer, to ensure inactivation of all RNases, and 
the lysate passed through a spin column to eliminate genomic DNA. Importantly, for this study, 
the procedure provides an enrichment of mRNA. Parasites were isolated from red blood cells, 
as per Section 2.5.2, and used for RNA isolation. Prior to isolation, the designated working 
area,  equipment  and  accessories  were  thoroughly  cleaned  and  sterilised  to  minimise  the 
introduction of unwanted RNases. In addition, all  polypropylene microfuge tubes used were 
certified  RNAse  and  DNAse  free.  All  steps  for  the  isolation  procedure  were  as  per  the 
manufacturer's instruction.  Isolated RNA was stored in  aliquots at  -70°C.  The purity  of  the 
isolated RNA was analysed by electrophoresis on a 1% agarose gel. The RNA sample (5 µl) 
was mixed with  formamide gel-loading buffer  (10 µl)  and incubated at  65°C for  10 min to 
denature  the  RNA.  Agarose  gel  electrophoresis  was  subsequently  performed.  After 
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electrophoresis the gel image was captured with the VersaDocTM gel documentation system 
under ultraviolet light. 
2.6.3 Isolation of P. yoelii and P. falciparum genomic DNA 
In this study, genomic DNA was isolated for molecular cloning of PCR-amplified fragments. For 
this reason the FermentasTM DNA purification kit was used with slight modification to produce 
higher DNA yields. This isolation kit is designed to isolate genomic DNA from various sources, 
such as whole blood, cell and tissue culture or bacterial culture. The kit is based on one step 
lysis and selective precipitation of genomic DNA under alkaline conditions. Although the kit is 
capable of extracting DNA from whole blood, purified P. yoelii  or P. falciparum parasites were 
used. For P. yoelii genomic DNA isolation, infected mouse blood was collected in a microfuge 
tube containing 0.5 ml of PBS, according to the manufacturer’s instruction. The blood cells 
were  washed  three  times  with  PBS before  isolating  the  parasites  (Section  2.5.2).  For  the 
isolation  of  P.  falciparum  DNA a  similar  approach  was  adopted  for  parasite  preparation, 
however, since these were cultured parasites it was not necessary to use a Plasmodipur® filter 
step.  P. falciparum parasitised red blood cells were pelleted, washed with PBS and parasites 
liberated  by  saponin  treatment  (Section  2.5.2).  DNA  isolation  was  followed  as  per  the 
manufacturer's instruction with a slight modification of the DNA precipitation step, which was 
carried out at -20°C for 30 min to enhance precipitation. The final DNA pellet was resuspended 
in sterile double distilled water (50 µl) and stored in aliquots at -70°C. DNA yield and purity was 
analysed by spectrophotometry and standard 0.5% agarose gel electrophoresis. 
2.6.4  Primers  for  PCR-based amplification  of  PBANKA_130290,  PY03823,  PF10_0252, 
PF14_0211 and PF14_0369 
Primers  were  derived  from  published  sequences  of  the  partially  sequenced P.  yoelii and 
completely sequenced  P. berghei  and  P. falciparum  genomes, in the  Plasmodium database. 
Web-based  bioinformatics  software  was  used  to  assist  with  primer  design  (Primer3  - 
http://frodo.wi.mit.edu/primer3/). Primers were engineered with relevant restriction sites used 
for cloning and expression of the desired PCR products. Secondary structures such as hair pin 
formation were explicitly avoided when designing primers. Table 2.5 lists primers used in this 
study.
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Table 2.5 Primers designed for PCR amplification




PyCtrFL-fwd ATG AAT ATA TGG AAA ATT ATA TAT ATT G PY00413 PCR and nested-PCR analysis to support the presence of 
a full-length PY00413 coding domain. The expected size 
of the amplicon is 1791 bp, including intronsPyCtrFL-rev TCA TAG ATG AAA AGC ATC CCC CCC C PY00413
PyCtrNe-fwd CAG TTT CGA TGA TCA ATG TGG AAT GAT TGC MALPY00116 Nested PCR analysis to support the existence of the full-
length  PY00413  coding  domain.  Expected  size  of 
amplicon is 2700 bpPyCtrNe-rev GCA AAT AAG TCC CCC AAA ATT GTA ATG MALPY00116
PbCtrNt-fwda atG AAT TCA TGA ATA TAT GGA AAA TTA TAT ATA TTG PBANKA_130290
RT-PCR analysis of the transcription of PBANKA_130290 
mRNA.  Amplicon  is  to  be  used  for  cloning  and 
recombinant  expression  of  the  putative  amino-terminal 
domain. Expected size of amplicon is 447 bpPbCtrNt-revb caG CGG CCG CTT CCC AAA ATT TGA ATA AAA TAA TAG PBANKA_130290
PfCtr211FL/Nt-fwda atG  AAT TCT TCA CTT TCG ATT TTG TGA GC PF14_0211 PCR  analysis  to  support  the  presence  of  a  full-length 
PF14_0211 coding domain. Expected size of the amplicon 
is 423 bp (no introns)PfCtr211FL-rev AGA TAA GCA GAA GAA AGA CC PF14_0211
PfCtr211Nt-revc caC TGC AGT TAA TTC TTT ACT TGA AAT ATG TC PF14_0211
PCR amplification of the putative amino terminal domain of 
PF14_0211, in conjunction with the forward primer above. 
Amplicon  is  to  be  used  for  cloning  and  recombinant 
expression. Expected size of the amplicon is 132 bp
PfCtr369FL/Nt-fwda atG AAT TCG ACA AAA GCG ACA ATA GTA TTT G PF14_0369 PCR  analysis  to  support  the  presence  of  a  full-length 
PF14_0369 coding domain. Expected size of the amplicon 
is 920 bp, including intronsPfCtr369FL-rev ACA TCC ACA ACA AGC TGG ATC PF14_0369
PfCtr369Nt-revc caC TGC AGT TAC GAT TTG GTT TCC CAT TTG PF14_0369
PCR amplification of the putative amino terminal domain of 
PF14_0369, in conjunction with the forward primer above. 
Amplicon  is  to  be  used  for  cloning  and  recombinant 
expression. Expected size of the amplicon is 282 bp
Py/PfLDH-fwd GGA TCT GGT ATG ATT GGA GGT GTT ATG GCC PY03885 Positive control  in PCR and RT-PCR analysis.  Expected 
size of the amplicon is 850 bp.Py/PfLDH-rev TTC GAT TAC TTG TTC TAC ACC ATT ACC ACC PY03885
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Table 2.5 continued




PyCox17-fwda atG AAT TCA TGG GAT TAG GTT TAA CTA AG PY03823
PCR  analysis  to  support  the  presence  of  a  full-length 
coding domain for a putative  P. yoelii copper chaperone, 
Cox17.  Amplicon  is  to  be  used  for  cloning  and 
recombinant expression. Expected size of the amplicon is 
192 bp
PyCox17-revb caG CGG CCG CAT CAA ACC CTT CAT TTC TTA GG PY03823
PfCox17-fwdd atG GAT CCA TGG GTA TGA GCT TGA ACA AAC PF10_0252 PCR  analysis  to  support  the  presence  of  a  full-length coding  domain  for  a  putative  P.  falciparum copper 
chaperone, Cox17. Amplicon is to be used for cloning and 
recombinant expression. Expected size of the amplicon is 
195 bp
PfCox17-revb caG CGG CCG CAT CAA AAC CTT CAC TCC TTA AAC PF10_0252
a underlined and highlighted bases indicate an EcoRI restriction site
b underlined and highlighted bases indicate a NotI restriction site
c underlined and highlighted bases indicate a PstI restriction site
d underlined and highlighted bases indicate a BamHI restriction site
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2.6.5 Polymerase chain reaction (PCR) 
For all PCR amplification experiments FIREPol® Taq polymerase was employed as the enzyme 
of  choice.  Taq polymerase was selected since it  introduces adenine (A)  overhangs during 
amplification, which are ideal for TA cloning into a relevant cloning vector. PCR was optimised 
for  each  set  of  primers  (Table  2.6).  Parameters  such  as  annealing  temperature,  MgCl2 
concentration and cycle number (limited to 35 cycles) were optimised over a broad range. The 
initial  denaturation  temperature  was  94°C  for  5  min  with  a  slightly  altered  extension 
temperature of 60°C used for all amplifications. The final elongation temperature was 72°C for 
7 min. For all reactions 100 μM of dATP, dCTP, dGTP and dTTP mix was used along with 1.0 U 
of FIREPol® Taq DNA polymerase. These conditions were similarly used for nested PCR, where 
a second PCR product is amplified from the product of the first reaction. For this technique the 
first product was amplified using primers PyCtrNe-fwd and PyCtrNe-rev, with a second product 
amplified from this using PyCtrFL-fwd and PyCtrFL-rev. Table 2.6 illustrates the optimised PCR 
conditions determined for each set of primers used in this study. The 10× PCR buffer used was 
detergent and MgCl2 free. PCR products of interest were separated on an agarose gel and 
purified (Section 2.6.7) before cloning.
Table 2.6 Primer properties, MgCl2 concentration and thermal cycling conditions used for PCR





Thermal cycle conditions [°C (time)] Cycles
PyCtrFL-fwd 44.8 0.5
2.5 94 (30 s) → 40 (30 s) → 60 (2 min) 35
PyCtrFL-rev 61.8 0.5
PyCtrNe-fwd 58.9 0.7
2.5 94 (30 s) → 50 (30 s) → 60 (2 min) 35
PyCtrNe-rev 55.2 0.7
PbCtrNt-fwd 53.1 0.5
2.5 94 (30 s) → 45 (30 s) → 60 (2 min) 30
PbCtrNt-rev 62.2 0.5
PfCtr211FL/Nt-fwd 58.7 0.8




94 (30 s) → 40 (30 s) → 60 (2 min) 30PfCtr369FL-rev 52.2 0.8
PfCtr369Nt-rev 63.9 0.8
PyCox17-fwd 56 0.8
2.5 94 (30 s) → 50 (30 s) → 60 (2 min) 30
PyCox17-rev 70.8 0.8
PfCox17-fwd 63 0.8
2.5 94 (30 s) → 50 (30 s) → 60 (2 min) 30
PfCox17-rev 70.1 0.8
Py/PfLDH-fwd 61.8 0.5
2.5 94 (30 s) → 50 (30 s) → 60 (2 min) 30
Py/PfLDH-rev 58.2 0.5
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2.6.6 Reverse  transcriptase  polymerase  chain  reaction  for  the  analysis  of 
PBANKA_130290 expression 
Reverse transcription polymerase chain reaction (RT-PCR) was carried out  with Promega's 
Improm  IITM Reverse  Transcription  System  kit  according  the  manufacturer’s  instruction.  P. 
berghei  total RNA isolated from purified parasites (Section 2.6.2) was used as template. The 
first strand cDNA synthesis was amplified, according to the manufacturer’s instructions, with the 
provided  oligodT  or  random  oligonucleotide  hexamers.  The  reverse  transcriptase  cDNA 
product, from both oligodT and random oligonucleotide hexamers, was subsequently used for 
PCR  amplification  using  the  following  primers:  PbCtrNt-fwd,  PbCtrNt-rev,  PyLDH-fwd  and 
PyLDH-rev (Table 2.5). The conditions for PCR were as per those described in Section 2.6.5 
and Table 2.6. The amplified PCR product was resolved on a 1% agarose gel and an image 
captured with the VersaDocTM image documentation system under ultraviolet light.
2.6.7 Purification of DNA from agarose gel 
In this study, purification of the desired PCR products and restriction endonuclease-digested 
expression vectors was carried out using the peqGOLDTM gel extraction kit. The extraction kit is 
designed to rapidly purify DNA fragments, resolved by agarose gel electrophoresis, using mini-
spin columns containing a silica membrane. The kit  is based on the capability of guanidine 
thiocyanate to denature the agarose gel, at 60 – 65°C, and extract the DNA fragment. The 
extracted DNA is then tightly bound to the silica membrane whilst the remaining reaction by-
products,  buffer  ions  and solubilised  agarose gel  flow through.  Following washing  with  an 
ethanol-based wash solution, the bound DNA fragment is concentrated into a smaller volume 
by elution with TE buffer or sterile distilled water as per the manufacturer’s instruction. The 
approximate  concentration  of  the  purified  sample  was  then  determined  by  agarose  gel 
electrophoresis. This was achieved by comparing the intensity of the purified band to those of 
the  Fermentas  DNA MassRulerTM molecular  weight  standards,  whose  concentrations  are 
known. Excision of the desired DNA fragment was achieved by viewing the agarose gel under 
UV light for ≤20 sec. This short exposure was adhered to so as to prevent UV-mediated cutting 
of DNA fragment. 
2.6.8 Ligation of purified cDNA fragments into a pGEM®-T cloning vector
The pGEM®-T cloning vector (Figure 2.1) is a 3000 bp linearised vector with a single 3 -́terminal 
thymidine overhang at  both ends.  These overhangs improve the efficiency of  PCR product 
ligation by preventing recircularisation of the vector and providing compatible overhangs for 
PCR products generated by the thermostable FIREPol®  Taq polymerase. This vector is high 
52
copy  number  and  contains  the  T7  and  SP6  RNA polymerase  promoters,  which  flank  the 
multiple cloning site (MCS) within the α-peptide coding region of the enzyme β-galactosidase. 
Insertion of a PCR product within this site results in the inactivation of the α-peptide, thereby 
allowing identification of recombinants by blue/white colony screening on indicator plates. To 
further assist with the selection of vector transformed cells,  pGEM®-T  contains the gene for 
ampicillin  resistance  (β-lactamase).  In  this  study,  gene  fragments  derived  from  RT-PCR 
amplification of P. berghei total RNA as well as PCR amplification of P. yoelii and P. falciparum 
genomic DNA (primers for amplification of putative amino-terminal coding domains and Cox17 
described in Table 2.5) were gel purified and ligated into  pGEM®-T. Plasmids containing the 
gene  of  interest  were  subsequently  propagated,  purified  and  the  gene  excised  from  the 
recombinant plasmid using the relevant restriction enzymes. The generated gene fragments, 
containing  non-cohesive  5'  and  3'  overhangs,  were  used  for  subcloning  into  the  desired 
expression vectors (Section 2.6.11).
Figure 2.1 Map of the pGEM®-T cloning vector 
The  pGEM®-T vector  contains the  lacZ gene,  encoding  the enzyme β-galactosidase,  which forms the basis  of 
blue:white colony screening used for the identification of positive colonies.  The desired insert  is ligated into the 
region between  SacII and  SpeI,  where the thymidine overhangs are located. Also included,  for targeted vector 
selection, is the ampicillin resistance gene (Ampr) (Adapted from pGEM®-T and pGEM®-T easy systems technical  
manual).
2.6.9 cDNA ligation using T4 DNA ligase
DNA ligation is a biochemical reaction specifically catalysed by DNA ligase.  This technique 
enables the ligation of PCR products or excised genomic DNA fragments into a plasmid vector 
that are in turn either used for recombinant expression of the protein encoded by the inserted 
DNA fragment or for the creation of a cDNA library  (Sambrook et al.,  1989a). The T4 DNA 
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ligase  and  10×  T4  DNA  ligase  buffer  used  in  these  experiments  were  obtained  from 
FermentasTM. 
2.6.9.1 Materials
10× T4 DNA ligase buffer, T4 DNA ligase, gel-purified PCR or RT-PCR amplicons, linearised 
and purified expression plasmid DNA and sterile double distilled water (ddH2O) were used.
2.6.9.2 Method
The desired cDNA insert was obtained by restriction endonuclease-digestion of the pGEM-T 
cloning vector and purified from an agarose gel as described in Section 2.6.7. As before, the 
approximate  concentration  of  the  purified  insert  was  determined  by  comparison  to  the 
Fermentas DNA MassRulerTM.  The final  volume of the ligation reaction was 10 µl,  with the 
purified cDNA insert and plasmid DNA added at a ratio of 4:1 (insert:plasmid). The additional 
components added to the ligation reaction are shown in Table 2.7. Prior to overnight incubation 
at  4°C,  the  reaction  components  were  mixed  with  gentle  flicking  followed  by  a  brief 
centrifugation step. The reaction mix was used directly for transformation of competent E. coli 
cells, without deactivation of the enzyme.
Table 2.7 Reaction parameters for DNA ligation
Component Quantity
10× T4 ligase buffer 1.0 µl
Purified cDNA 4× [plasmid]
Expression plasmid 0.25× [insert DNA]
T4 DNA ligase 2.5 U
Sterile ddH2O Variable
Total volume 10 µl
2.6.10 Isolation of plasmid DNA
Plasmid DNA was isolated by the phenol-chloroform-isoamyl alcohol method (Sambrook et al., 
1989b). The method is based on the principle that chromosomal and plasmid DNA, found in a 
bacterial lysate, can be differentially precipitated. Purity of the isolated plasmid was evaluated 
by agarose gel electrophoresis. 
2.6.10.1 Materials
GTE solution [50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM EDTA]. Glucose (1 g), Tris (0.3 g) 
and Na2EDTA (0.37 g) were dissolved in 80 ml of distilled water, titrated to pH 8 with HCl and 
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made to a final volume of 100 ml with distilled water. The solution was autoclaved and stored at 
4°C.
Lysis solution [1% (w/v) SDS, 0.2 M NaOH]. NaOH (0.08 g) and SDS (0.1 g) were dissolved in 
10 ml of distilled water. This solution was stored at 4°C and made fresh weekly.
Potassium acetate [3 M KOH, pH 4.8]. KOH pellets (16.8 g) were dissolved in 25 ml of acetic 
acid, the pH checked after neutralisation and adjusted to 4.8 with acetic acid as necessary. The 
solution was made up to a final volume of 100 ml with distilled water and stored at 4°C.
Phenol-chloroform-isoamyl alcohol [25:24:1 (v/v)]. Liquefied phenol (50 ml), chloroform (48 ml) 
and isoamyl alcohol (2 ml) were mixed together and stored at RT in an amber bottle.
Chloroform-isoamyl alcohol [24:1 (v/v)].  Chloroform (48 ml) and isoamyl alcohol (2 ml) were 
mixed together and stored at RT.
Sodium acetate [3 M NaOH, pH 5.5].  NaOH pellets (12 g) were dissolved in 25 ml of acetic 
acid, the pH checked after neutralisation and adjusted to 5.5 with acetic acid. The solution was 
made up to a final volume of 100 ml with distilled water and stored at 4°C.
70% (v/v) ethanol. Absolute ethanol (70 ml) was made up to 100 ml with distilled water and 
stored at -20°C. 
2.6.10.2 Method
E.  coli cells  (50  ml  overnight  culture)  containing  the  desired  plasmid  were  pelleted  by 
centrifugation (4000  g,  15 min,  4°C)  and the resulting  pellet  resuspended in  GTE solution 
(1/100th of  the original  culture volume).  RNAse (50  µg/ml)  and lysis  solution (0.5 ml)  were 
subsequently added and the cells mixed at RT for 5 min to help effect complete cell  lysis. 
Potassium acetate (1 ml) was added, mixed for 5 min and then centrifuged (11 500 g, 30 min, 
RT). The supernatant was carefully removed and transferred to a fresh DNAse-free tube. An 
equal volume of phenol-chloroform-isoamyl alcohol was added and mixed gently for 5 min. The 
mixture  was  centrifuged  (11  500  g,  30  min,  RT)  and  the  upper  aqueous  phase  carefully 
transferred to a fresh tube. An equal volume of chloroform-isoamyl alcohol was added and this 
was mixed for 2 min at RT.  The mixture was again centrifuged (11 500 g, 30 min, RT) and the 
upper  aqueous  phase  transferred  to  a  fresh  tube.  Sodium  acetate  (1/10th the  volume  of 
aqueous supernatant) and ice-cold absolute ethanol (2.5 volume of the aqueous supernatant) 
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were added to the aqueous supernatant, mixed and incubated at -20°C (1 h). The precipitated 
plasmid was pelleted by centrifugation (11 500 g, 30 min, 4°C), washed twice with ice-cold 70% 
ethanol and resuspended in sterile 1× TE buffer (50 µl). The purity of the isolated plasmid DNA 
was evaluated by agarose gel electrophoresis.
2.6.11 Expression plasmids used in the study
pET-23a
The pET-23a plasmid (Figure 2.2) was the initial expression vector used for the recombinant 
expression of the amino terminal domain of the putative  P. berghei copper transport protein 
(PbCtrNt). The 447bp gene fragment containing the amino terminal domain was ligated into the 
vector at the EcoRI and NotI restriction sites. The product was expected to have an addition of 
approximately 23 amino acid residues due the position of the insert relative to the start codon, 
which is situated at the NdeI restriction site (bp 238 on the plasmid). The host strain used for 
pET-23a expression was the E. coli BL21(DE3) pLysS strain. The recombinant construct is from 
here on referred to as pT-PbCtrNt. 
Figure 2.2 Map of the pET-23a expression plasmid 
The figure illustrates the restriction sites and important features of the pET-23a plasmid including the ampicillin 
resistant gene (Ap) and the multiple cloning region. The genes of interest were either inserted in the EcoRI and NotI 
(PbCtrNt; PyCox17) or BamHI and NotI (PfCox17) sites. Genes were inserted in frame with the C-terminal His6-tag 
and transcribed in the direction indicated by the solid black arrow (     ) housing the multiple cloning site (Adapted 
from Novagen manual).
In addition to the above, the pET23a construct was utilised for the recombinant expression of 
both the  P. yoelii and  P. falciparum putative Cox17 proteins. The  P. yoelii gene (192bp) was 
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ligated into the vector at the  EcoRI and  NotI  restriction sites, whilst  the  P. falciparum gene 
(195bp) was ligated into the BamHI and NotI restriction sites. As stated above, both products 
were expected to have an additional 23 amino acid residues. The host strain used for pET-23a 
expression  of  the  Cox17  constructs  was  the  E.  coli BL21(DE3)  strain.  The  recombinant 
constructs for P. yoelii and P. falciparum are referred to as pT23-PyCox17 and pT23-PfCox17, 
respectively.
pET-28a
In this study, pET-28a (Figure 2.3) was used for the recombinant expression of both the  P. 
yoelii and  P. falciparum  putative Cox17 copper chaperones.  The 192bp  P. yoelii gene was 
ligated into the vector at the  EcoRI and  NotI sites, whilst the 195bp  P. falciparum gene was 
ligated into the  BamHI and  NotI sites. Both products were expected to have the addition of 
approximately 41 amino acid residues due the position of the insert relative to the start codon, 
which is situated at the NcoI restriction site (bp 296 on the plasmid). The host strain used for 
pET-28a  expression  in  this  study  was  the  E.  coli BL21(DE3)  strain.  As  with  the  pET23a 
constructs, the P.  yoelii and P. falciparum pET28a constructs are from here on referred to as 
pT28-PyCox17 and pT28-PfCox17, respectively.
Figure 2.3 Map of the pET-28a expression plasmid 
The  figure  illustrates  restriction  sites  and  important  features  of  the  pET-28a  plasmid  including  the  kanamycin 
resistant gene (kan) and the multiple cloning region. The genes of interest were either inserted in the EcoRI and NotI 
(PyCox17) or  BamHI and  NotI  (PfCox17) sites.  Inserts were inserted in frame with the N-terminal  His6-tag  and 




pGex-4T-1 (Figure 2.4) was initially used for the recombinant expression of PbCtrNt in an effort 
to overcome insoluble recombinant protein production. The 447bp gene fragment, coding for 
the putative P. berghei amino terminal domain, was ligated into the vector at the EcoRI and NotI 
sites in frame with the N-terminal GST protein. The host strain used for expression was E. coli 
BL21. The construct is referred to as pGx-PbCtrNt. In addition to this, the pGex-4T-1 vector 
was used for the recombinant expression of PfCox17, following unsuccessful attempts with the 
two pET vectors described above. The 195bp PfCox17 gene was ligated into the BamHI and 
NotI sites in frame with the N-terminal GST protein. The host strain used for expression was E. 
coli BL21. The Cox17 construct is referred to as pGx-PfCox17.  
Figure 2.4 Map of pGEX-4T-1 expression plasmid
 
The figure illustrates the restriction sites of the multiple cloning region and other important features of the plasmid. 
These features include  the glutathione S-transferase  (GST) gene,  the ampicillin  resistant  gene (Amp r)  and  the 
inducible Ptac promoter. The genes of  interest were either inserted in the  EcoRI and  NotI  sites  (PbCtrNt) or the 
BamHI and NotI sites (PfCox17), in frame with the GST gene. (Adapted from GE Health care manual).
pMal-c2X and pMal-p2X
The pMal-2 series of expression vectors (Figure 2.5) were initially used for the same purpose 
as the pGex-4T-1 vector, to try to overcome the expression of insoluble PbCtrNt. Both pMal-2 
vectors contain the malE gene, encoding the highly soluble maltose binding protein (MBP). The 
difference between pMal-c2X and -p2X lies in the removal of the malE signal sequence in the 
pMal-c2X vector, resulting in cytoplasmic expression of the recombinant protein. The retention 
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of  the  malE signal  sequence in  the pMal-p2X vector  results  in  targeting  of  the  expressed 
recombinant protein to the cell periplasm. The 447bp gene fragment, coding for the putative P. 
berghei  amino terminal domain, was ligated into both the pMal-c2X and -p2X vectors at the 
EcoRI and PstI sites, in frame with the N-terminal MBP. The host strain used for recombinant 
expression was E. coli JM103 or BL21. The pMal-c2X construct is referred to as pMc-PbCtrNt 
and the pMal-p2X construct as pMp-PbCtrNt
In addition to the above,  the pMal-2 series of  vectors were also used for  the recombinant 
expression of the amino-terminal domains of the two putative  P. falciparum copper transport 
proteins  (PF14_0211  and  PF14_0369).  An  identical  approach  was  adopted  for  these  two 
proteins  where  the  respective  gene  fragments  (132bp  for  PF14_0211  and  282bp  for 
PF14_0369) were ligated into both the pMal vectors at the EcoRI and PstI sites, in frame with 
the N-terminal MBP. The host strain used for recombinant expression was E. coli JM103. The 
pMal-c2X constructs are referred to as pMc-PfCtr211Nt and pMc-PfCtr369Nt for PF14_0211 
and  PF14_0369,  respectively.  Similarly  the  pMal-p2X  constructs  are  referred  to  as  pMp-
PfCtr211Nt and pMp-PfCtr369Nt for PF14_0211 and PF14_0369, respectively. 
Figure 2.5 Map of the pMal-2x expression plasmids 
The figure illustrates the restriction sites of the polylinker region and other important features of the plasmid. These 
features include the malE gene, the ampicillin resistant gene (Ampr) and the inducible Ptac promoter. The genes of 
interest were inserted in the EcoRI and PstI sites, in frame with the malE gene for fusion to a maltose binding carrier 
protein (Adapted from the NEB pMALTM protein fusion and purification manual).
2.6.12 Restriction endonuclease digestion of plasmids
For  insertion  of  the  desired  gene  fragment  into  an  expression  vector  it  was  necessary  to 
prepare  the  expression  plasmids  by  restriction  digestion.  This  was  achieved  with  the  two 
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enzymes used to liberate the relevant fragment from the pGEM®-T cloning vector. The enzymes 
utilised for each respective preparation were specifically selected to create non-cohesive 5' and 
3'  overhangs  that  insure  correct  orientation  and  in  frame  ligation  of  the  gene  of  interest.  
Digestion of the plasmid does, however, result in the creation of free 5’-phosphate groups. The 
presence of this group allows for an undesirable re-circularisation of the plasmid when DNA 
ligase  is  introduced  for  gene  product  ligation.  This  unwanted  result  is  avoided  by 
dephosphorylating  the  digested  plasmid  with  shrimp  alkaline  phosphatase  (SAP)  prior  to 
ligation. Restriction enzyme digestion of the expression plasmid was confirmed by agarose gel 
electrophoresis,  following  which  the  digested  plasmid  was  gel  purified  (Section  2.6.7). 
Linearised plasmids were purified prior to ligation to eliminate nucleic acid fragments, buffer 
components, enzymes and nucleotides that can compromise the insertion of a target gene into 
the plasmid. The desired gene fragment,  to be subcloned into an expression plasmid, was 
initially ligated into the pGEM®-T vector (Section 2.6.8) for propagation in E. coli. This strategy 
reduces the likelihood of PCR-introduced mutations being carried into an expression vector 
following direct ligation of PCR products. The inserts are liberated from the cloning vector using 
the relevant restriction enzymes described in section 2.6.11. As previously mentioned, liberated 
gene fragments were gel purified prior to ligation for reasons mentioned above. 
2.6.12.1 Materials
EcoRI,  BamHI,  NotI  and  PstI restriction  enzymes,  shrimp  alkaline  phosphatase  (SAP), 
Fermentas  10×  Orange  BufferTM (Buffer  O)  and  recombinant/non-recombinant  super  coiled 
plasmid DNA were used.
2.6.12.2 Method
A single  E.  coli colony  harbouring  the  desired  expression  plasmid  or  cloning  vector  plus 
inserted fragment was used to inoculate 10 ml of LB medium plus antibiotic. This culture was 
grown overnight at 37°C with shaking (200 rpm). Cells were pelleted by centrifugation (4000 g, 
15 min, 25°C) and plasmid DNA isolated as described in Section 2.6.10. Once purified the 
plasmid  was  digested  as  follows:  10×  Buffer  O  (5  µl),  plasmid  DNA (44  µl)  and  the  first 
(EcoRI/BamHI) restriction enzyme (1 µl) followed by incubation at 37°C (2 h). The first enzyme 
was  deactivated  (65°C,  20  min)  and  digestion  confirmed  by  agarose  gel  electrophoresis 
(Section 2.6.1).  If  the digestion was successful  1 µl  of  the second enzyme (NotI/PstI)  was 
added directly to the mix and incubated (RT, overnight). Following this second incubation the 
enzyme was again  deactivated (85°C,  15 min).  For  preparation  of  the  expression vectors, 
shrimp alkaline phosphatase (SAP) (1 µl)  was added to the digestion mix and immediately 
incubated  (37°C,  30  min).  Gene  fragments  liberated  from  the  cloning  vector  were  not 
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dephosphorylated with SAP. The dephosphorylated plasmid and liberated DNA fragment were 
subsequently purified from an agarose gel (Section 2.6.7) before proceeding with the ligation 
reaction.
2.6.13 E. coli hosts used for cloning and expression of recombinant proteins
Table 2.8 E. coli host cell genotypes used for cloning and expression of recombinant proteins
E. coli strain Genotype Application
JM109 
F´  traD36 proA+B+ lacIq Δ(lacZ)M15/  Δ(lac-
proAB)  glnV44  e14- gyrA96  recA1  relA1 
ndA1 thi hsdR17(rK-mK+)
Maintenance  and  propagation  of 
recombinant  plasmids  for 
transformation into expression cells
BL21p F – ompT hsdSB ( rB– mB – )gal dcm
Expression  of  recombinant  pGEX-
4T-1
BL21(DE3)p F – ompT hsdSB ( rB– mB – )gal dcm (DE3)
Expression of recombinant pET-23a 
and pET-28a containing the putative 
copper chaperone Cox17
BL21(DE3) pLysSp
F  –  ompT hsdSB ( rB–  mB –  )gal  dcm (DE3) 
pLysS (CamR)
Expression of recombinant pET-23a 
vector containing PbCtrNt
JM103
endA1  glnV44  sbcBC  rpsL  thi-1  Δ(lac-
proAB) F'[traD36 proAB+ lacIq lacZΔM15]
Expression of recombinant pMal-c2X 
and pMal-p2X
p deficient in lon protease
2.6.14 Transformation and culturing of E. coli transformants
2.6.14.1 Materials
Super  O  ptimal broth with  C  atabolite repression (SOC medium) [2% (w/v) tryptone, 0.5% (w/v)   
yeast extract, 10 mM NaCl, 2.5 mM MgCl2, 10 mM MgSO4 and 20 mM Glucose]. Tryptone (0.5 
g), NaCl (0.015 g) and yeast extract (0.125 g) were dissolved in 25 ml of double distilled water 
and autoclaved. The medium was cooled to ~ 55°C and MgCl2.6H2O (125 µl), MgSO4 (500 µl) 
and glucose (1 ml) added. The final volume of the solution was made up to 50 ml with sterile 
(autoclaved) double distilled water. The media was aliquoted into sterile microfuge tubes and 
stored at -20°C.
MgCl2.6H2O [1 M]. MgCl2.6H2O (2.03 g) was dissolved in a final volume of 10 ml with 
double distilled water and filter sterilised through a 0.22 µm syringe filter. The solution was 
used for SOC medium.
MgSO4 [1 M]. MgSO4 (1.2 g) was dissolved in a final volume of 10 ml with double distilled 
water and filter sterilised through a 0.22 µm syringe filter. The solution was used for SOC 
medium.
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Glucose [1 M]. Glucose monohydrate (1.98 g) was dissolved in a final volume of 10 ml 
with double distilled water and filter sterilised through a 0.22 µm syringe filter. The solution 
was used for SOC medium.
LB-agar [1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1.5% (w/v) agar, 0.5% (w/v) NaCl, pH 
7.4]. Tryptone (10 g), yeast extract (5 g) and NaCl (5 g) were resuspended and dissolved in 900 
ml distilled water. The pH was adjusted to 7.4 with NaOH, agar (15 g) added and the volume 
made up to 1 ℓ with distilled water. The medium was autoclaved (121°C, 20 min), cooled to 
~55°C and the desired antibiotic added to the working concentration indicated in Table 2.9. The 
media was dispensed into sterile plastic culture plates, allowed to solidify and then sealed with 
Parafilm™. Plates were stored inverted at 4°C. 
LB medium [1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, pH 7.4]. Tryptone 
(10 g), yeast extract (5 g) and NaCl (5 g) were resuspended and dissolved in 900 ml distilled 
water. The pH was adjusted to 7.4 with NaOH and the volume made up to 1 ℓ with distilled 
water.  The  medium  was  autoclaved  (121°C,  20  min),  cooled  to  ~  55°C  and  the  desired 
antibiotic added to the working concentration indicated in Table 2.9. The desired volume of 
medium was dispensed into sterile Erlenmeyer flasks and used to culture E. coli cells.
Potassium acetate [1 M, pH 7.5]. Potassium acetate (9.8 g) was dissolved in 60 ml of double 
distilled water, titrated to pH 7.5 with KOH and the volume made up to 100 ml. The solution was 
sterilised by filtration through a 0.22 µm syringe filter. This reagent was used in frozen stock 
buffer and DTT-DMSO reagents.
Frozen stock  buffer  (FSB)  [100  mM KCl,  45  mM MnCl2.4H2O, 10 mM CaCl2.2H2O, 3  mM 
hexamine cobalt chloride (HACoCl3) 10 mM potassium acetate and 10% (w/v) glycerol, pH 6.2]. 
Potassium acetate (1 ml), KCl (0.74 g), MnCl2.4H2O (0.98 g), CaCl2.2H2O (0.15 g), HACoCl3 (80 
mg) and glycerol (10 g) were dissolved in 80 ml of double distilled water, titrated to pH 6.2 and 
the volume made up to 100 ml. The buffer was sterilised by filtration through a 0.22 µm syringe 
filter and used immediately for the preparation of competent E. coli cells.
DTT-DMSO [1 M DTT, 10 mM potassium acetate and 90% (v/v) DMSO]. Molecular biology 
grade DTT (1.54 g), potassium acetate (0.1 ml) and DMSO (9 ml) were made up to 10 ml with 
sterile double distilled water. This reagent was either used immediately or stored at -20°C.
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2.6.14.2 Method 
Preparation of competent cells
A single E. coli colony was grown overnight in 10 ml LB medium (37°C) and then diluted 1:100 
in fresh medium. This culture was grown at 37°C to an OD600 between 0.4 – 0.6 following which 
cells were pelleted (4000 g, 15 min, 4°C), drained thoroughly and gently resuspended in ice-
cold frozen stock buffer (1/10th of culture volume). This cell suspension was incubated on ice for 
15 min and then pelleted (4000 g, 15 min, 4°C). The cells were again gently resuspended in 
ice-cold frozen stock buffer (1/50th of culture volume) and 17.5 µl of DTT-DMSO added. This 
was gently mixed and then incubated on ice for 10 min. A further 17.5 µl of DTT-DMSO was 
added to the cell suspension, mixed gently and the suspension incubated on ice for 20 min. 
Aliquots of 50 µl were dispensed into cold, sterile microfuge tubes and the cells snap-frozen in 
liquid nitrogen (2 min). Aliquots were stored at -70°C until required.
Transformation of competent  E. coli   cells 
Ligation mix (5 µl) or plasmid DNA was added to an aliquot of competent cells, incubated on ice 
for 30 min and then heat shocked at 42°C for 60 sec. The cells were immediately returned to 
ice and incubated for 2 min. Following this, SOC medium (450 µl) was added to the cells and 
incubated at 37°C for 60 min with shaking. The cells were plated on duplicate LB-agar plates 
containing the desired antibiotic and incubated inverted, overnight at 37°C. 
2.6.15 Antibiotics used for positive selection and maintenance of E. coli transformants
Stock solutions of the ampicillin and kanamycin were prepared in double distilled water, whilst 
chloramphenicol was prepared in methanol. All solutions were sterilised by filtration through a 
0.22 µm syringe filter and aliquotted into sterile microfuge tubes, in a sterile environment, for 
storage at -20°C. Chloramphenicol was dissolved in methanol due to its insolubility in water. 
Table 2.9 illustrates the applications as well  as the concentration of the stock and working 
solutions of the antibiotics used in this study.
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Used  in  LB-agar  plates  as  well  as  overnight  and 
outgrowth cultures of  E. coli  cultures with ampicillin-
encoded  expression  vectors pET-23a,  pGEX-4T-1, 
pMal-c2X and pMal-p2X. It was similarly used for the 
selection of cells containing the pGEM®-T vector.
Chloramphenicol 35a 100
Used  in  LB-agar  plates  as  well  as  overnight  and 
outgrowth cultures of  E. coli  BL21(DE3) pLysS cells 
with the pLysS encoded plasmid. pLysS is used for 
tight  regulation  of  IPTG  induced  expression  of  the 
recombinant protein.
Kanamycin 30 30
Used  in  LB-agar  plates  as  well  as  overnight  and 
outgrowth  cultures  of  E.  coli  cells  containing  the 
recombinant pET-28a vector for expression.
a Stock solution prepared in 100% methanol
2.7 Recombinant protein expression and purification
This section describes all techniques employed for the recombinant expression and purification 
of  PbCtrNt,  PfCtr211Nt,  PfCtr369Nt,  PyCox17 and  PfCox17. The protocol used to establish 
copper binding to each of the respective recombinant proteins is also described. SDS-PAGE 
analysis  and  western  blotting  techniques  are  described  in  Sections  2.4.1  and  2.4.3, 
respectively.
2.7.1 Expression of pET, pGex-4T-1 and pMal-2 vector encoded recombinant proteins
2.7.1.1 Materials
2xYT medium [1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl, pH 7.2]. Tryptone 
(16 g), yeast extract (10 g) and NaCl (5 g) were dissolved in 900 ml distilled water. The pH was 
adjusted to 7.2 with NaOH and the volume made up to 1 ℓ with distilled water. The medium was 
autoclaved (121°C, 20 min), cooled to ~55°C and the desired antibiotic added to the working 
concentration indicated in Table 2.9. The desired volume of medium was dispensed into sterile 
Erlenmeyer flasks and used to culture E. coli cells.
M9 minimal medium [50 mM Na2HPO4, 20 mM KH2PO4, 20 mM NH4Cl, 10 mM NaCl, 2 mM 
MgSO4,  100   µ  M CaCl  2,  0.2% glucose]. Na2HPO4 (6.8 g), KH2PO4 (3.0 g),  NaCl (0.5 g) and 
NH4Cl (1.0 g) were dissolved in 990 ml of distilled water and autoclaved. The medium was 
cooled to ~55°C and MgSO4 (2 ml),  CaCl2 (100  µl)  and glucose (10 ml)  were added.  The 
desired antibiotic was then added to the working concentration indicated in Table 2.9 and the 
required volume of medium dispensed into sterile Erlenmeyer flasks for E. coli cell culture.
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MgSO4 [1 M]. MgSO4 (1.2 g) was dissolved in a final volume of 10 ml double distilled 
water and filter sterilised through a 0.22 µm syringe filter. The solution was used for M9 
minimal medium .
CaCl2 [1 M]. CaCl2 (1.11 g) was dissolved in a final volume of 10 ml double distilled water 
and filter sterilised through a 0.22 µm syringe filter. The solution was used for M9 minimal 
medium.
Glucose [20%]. Glucose monohydrate (2.0 g) was dissolved in a final volume of 10 ml 
double distilled water and filter sterilised through a 0.22 µm syringe filter. The solution was 
used for M9 minimal medium.
0.1 M PMSF stock  solution.  PMSF (0.174 g)  was dissolved in  100% isopropanol  (10 ml), 
aliquotted and stored at -20°C.
0.5 M Na2EDTA, pH 8. Na2EDTA (g) was dissolved in 90 ml of distilled water, titrated to pH 8 
with HCl and made to a final volume of 100 ml with distilled water.
10% (w/v)  NaN  3 stock solution.  NaN3 (5 g) was dissolved in 50 ml distilled water and stored at 
RT.
Cell  resuspension buffer  1 [50 mM NaH2PO4,  300 mM NaCl,  10 mM Imidazole,   5% (v/v) 
glycerol, 1 mM PMSF, 0.01% (w/v) NaN3, pH 8].  NaH2PO4 (0.6 g), NaCl (1.754 g), imidazole 
(0.068 g) and glycerol (5 ml) were dissolved in 90 ml of distilled water. The solution was titrated 
to pH 8 with NaOH followed by the addition of NaN3. The buffer was made up to a final volume 
100 ml with distilled water. Following cell resuspension and just prior to cell disruption, PMSF 
was added to a final concentration of 1 mM.
Cell resuspension buffer 2 [100 mM NaH2PO4,  300 mM NaCl, 10 mM Imidazole, 12 mM 2-
mercaptoethanol,  5% (v/v) glycerol, 1 mM PMSF, 0.01% (w/v) NaN3, pH 8]. NaH2PO4 (1.2 g), 
NaCl  (1.754 g),  imidazole  (0.068 g),  2-mercaptoethanol  (100  µl) and glycerol  (5  ml)  were 
dissolved in 90 ml of distilled water. The solution was titrated to pH 8 with NaOH followed by 
the addition of NaN3. The buffer was made up to a final volume 100 ml with distilled water. 
Following  cell  resuspension  and  just  prior  to  cell  disruption,  PMSF  was  added  to  a  final 
concentration of 1 mM.
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Phosphate buffered saline (PBS), pH 7.2. As per Section 2.4.4.1
pMal column buffer [100 mM NaH2PO4, 200 mM NaCl, 1 mM EDTA, 0.01% (w/v) NaN3, pH 7.4]. 
NaH2PO4 (11.998 g), NaCl (11.668 g) and EDTA (2 ml of 0.5 M Na2EDTA) were dissolved in 950 
ml of distilled water, titrated to pH 7.4 with NaOH and NaN3 added. The buffer was made to a 
final volume of 1 ℓ with distilled water.
Tris/sucrose buffer [200 mM Tris, 20% (w/v) Sucrose, pH 8]. Tris (12.11 g) and sucrose (100 g) 
were dissolved in 350 ml distilled water, titrated to pH 8 with HCl and made to a final volume of 
500 ml.
2.7.1.2 Method
Expression of His6- Pb  CtrNt, His  6- Py  Cox17, GST-  Pb  CtrNt, GST-  Pf  Cox17,   MBP-  Pb  CtrNt, MBP-  
Pf  Ctr211Nt  TD   and MBP- Pf  Ctr369Nt  TD  
Table 2.10 Culture conditions used for recombinant expression of constructs prepared for this 
study












pT-PbCtrNt BL21(DE3) pLysS Ampicillin and chloramphenicol LB 30 0.4 5
pT23-PyCox17 BL21(DE3) Ampicillin 2xYT 37 0.4 5
pT28-PyCox17 BL21(DE3) Kanamycin 2xYT 37 1 5
pT23-PfCox17 BL21(DE3) Ampicillin 2xYT 37 0.4 5
pT28-PfCox17 BL21(DE3) Kanamycin 2xYT 37 1 5
pGx-PbCtrNt BL21 Ampicillin LB 37 0.5 4
pGx-PfCox17 BL21 Ampicillin LB 37 0.5 4
pMc-PbCtrNt JM103/BL21 Ampicillin LB 30 0.3 4
pMc-PfCtr211Nt JM103 Ampicillin LB 30 0.3 4
pMc-PfCtr369Nt JM103 Ampicillin LB 30 0.3 4
pMp-PbCtrNt JM103 Ampicillin LB 30 0.3 16
pMp-PfCtr211Nt JM103 Ampicillin LB 30 0.3 16
pMp-PfCtr369Nt JM103 Ampicillin LB 30 0.3 16
* Refer to table 2.9 for antibiotic concentrations
The following describes a generic protocol followed for the expression of the five respective 
recombinant proteins being studied. Each construct was transformed (Section 2.6.14) into a 
selected E. coli host cell (Table 2.10) and positive colonies identified. A colony containing the 
desired plasmid construct was selected and prepared as a three-way steak on a LB-agar plate 
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supplemented with the relevant antibiotic/s (Table 2.9 and 2.10). Agar plates were inverted and 
cells  grown overnight  at  37°C.  A single  colony  was  selected  and  inoculated into  bacterial 
growth medium (5 ml), supplemented with the relevant  antibiotic(s)  (Table 2.9 and 2.10), and 
incubated overnight (16 h) at the desired temperature (Table 2.10) with shaking. The overnight 
culture was diluted (1:100) in fresh medium, with antibiotic(s), and incubated at the relevant 
temperature with shaking. The culture was grown until an optical density between 0.4 and 1.0, 
at 600 nm, was reached. Recombinant protein expression was induced with IPTG (Table 2.10) 
and ampicillin was added at the point of induction and every 2 h post-induction. This maintains 
a selective pressure, since ampicillin is metabolised and depleted from the medium by E. coli 
cells. In an effort to improve the soluble expression of correctly folded MBP-PbCtrNt, numerous 
alterations  to  the  expression  conditions  were  tested  (Table  2.11). Following  the  period  of 
induction, cells were harvested by centrifugation (4000 g, 15 min, 4°C). 














*Induction of MBP-PbCtrNt expression post-log growth phase (O.D.600 ≥ 2.0) was examined at both 15°C and 30°C.
Cells expressing His6-PbCtrNt or His6-PyCox17 were resuspended in cell resuspension buffer 1 
and 2, respectively.  The volume of buffer used was equivalent  to 1/20th the original culture 
volume. Egg white lysozyme (1 mg/ml) was added to cell resuspension buffer 2 only and this 
was  incubated  on  ice  (30  min).  Cells  expressing  GST-fusion  proteins  were  similarly 
resuspended in 1/20th the original culture volume but in this instance with PBS containing egg 
white lysozyme (1 mg/ml) and incubated on ice (30 min). MBP-fusion proteins, expressed from 
pMal-c2 plasmids, were resuspended in 1/20th the original culture volume with chilled pMal 
column buffer. Various buffer conditions were also tested for the purification of MBP-PbCtrNt 
(Table 2.12), in an attempt to reduce the purification of aggregated multimers. E. coli lysate was 
prepared by subjecting the cell  suspension to three freeze-thaw cycles,  between 37°C and 
-196°C (liquid nitrogen for  2 min),  followed by further disruption with sonication on ice (10 
cycles, 30 sec/burst, 1 min between bursts). Triton X-100 was added to suspensions containing 
GST-fusion proteins, to a final concentration of 1%, and this was incubated on ice (30 min). The 
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total cell lysate was separated into soluble and insoluble fractions by centrifugation (12000 g, 
30 min, 4°C) and all samples analysed for expression by SDS-PAGE/Tricine-SDS-PAGE and 
western blotting. 
MBP-fusion proteins exported to the periplasm were isolated as per the method of French et al. 
(1996). This method required that the cell pellet be resuspended in a volume of Tris/sucrose 
buffer equivalent to 1/5th the original culture volume. Both chicken egg white lysozyme (500 
µg/ml) and EDTA (400 µl of 0.5 M EDTA) were added to the resuspended pellet and incubated 
at RT with gentle agitation (15 min). An equivalent volume of ice-cold distilled water was then 
added.  This  was incubated on ice  with  stirring  (15 min),  following which spheroplasts  and 
unlysed cells were removed by centrifugation (13 000 g, 15 min, 4°C). As before, the isolated 
samples were analysed for expression by SDS-PAGE and western blotting.  















├, ♦  and ┼  indicate the corresponding pH at which the buffer species were used.
#DTT and Triton X-100 were tested separately as well as in combination with each other.
2.7.2 Purification of recombinant malaria parasite proteins
2.7.2.1 Materials
His6-tagged proteins:
Wash  buffer  [100  mM  NaH2PO4,  300  mM  NaCl,  20  mM  imidazole,  12  mM  2-
mercaptoethanol,   5% (v/v)  glycerol,  0.01% (w/v) NaN3,  pH 8].  NaH2PO4 (1.2 g),  NaCl 
(1.754 g), imidazole (0.136 g), 2-mercaptoethanol and glycerol were dissolved in 90 ml of 
distilled water. The solution was titrated to pH 8 with NaOH followed by the addition of 
NaN3 and made up to a final volume 100 ml with distilled water.
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His6-elution  buffer  [100  mM  NaH2PO4,  300  mM  NaCl,  250  mM  imidazole,  12  mM  2-
mercaptoethanol, 0.01% (w/v) NaN3, pH 8].  NaH2PO4 (1.2 g), NaCl (1.754 g), imidazole 
(1.70 g) and 2-mercaptoethanol were dissolved in 90 ml of distilled water. The solution was 
titrated to pH 8 with NaOH followed by the addition of NaN3 and made up to a final volume 
of 100 ml with distilled water.
GST-fusion proteins:
PBS-T [PBS plus 1% Triton X-100]. PBS was prepared as per Section 2.4.4.1 and Triton 
X-100 added to 100 ml of PBS.
GST-elution buffer [50 mM Tris-HCl, 10 mM reduced glutathione, pH 8]. Tris (0.303 g) and 
reduced glutathione (0.154 g) were dissolved in 45 ml distilled water, titrated to pH 8 with 
HCl and made to a final volume of 50 ml.
MBP-fusion proteins:
MBP-elution  buffer  [100 mM NaH2PO4,  200  mM NaCl,  1  mM EDTA,  10 mM Maltose, 
0.01% (w/v) NaN3, pH 7.4]. NaH2PO4 (1.2 g), NaCl (1.167 g), maltose (0.360 g) and EDTA 
(200 µl of 0.5 M Na2EDTA) were dissolved in 90 ml of distilled water, titrated to pH 7.4 with 
NaOH and NaN3 added. The buffer was made to a final volume of 100 ml with distilled 
water.
2.7.2.2 Method
All recombinant proteins produced in this study were purified by affinity chromatography, using 
the appropriate resin. His6-tagged proteins were purified using Ni-NTA resin, GST-fusions using 
glutathione-agarose and MBP-fusions using an amylose resin. Resin (~1 ml) was placed into a 
BioRad affinity column and pre-equilibrated with 10 column volumes of buffer. The Ni-NTA resin 
was equilibrated with cell resuspension buffer 2, glutathione agarose with PBS-T and amylose 
resin with pMal column buffer. Soluble bacterial lysate was filtered through Whatman No. 1 and 
then circulated over the affinity matrix (Figure 2.6) in a forward direction (flow-rate 0.5 ml.min -1), 
at 4°C. The resins were then washed with 20 column volumes of buffer (Figure 2.6) or until the 
A280 of the flow through reached a steady absorbance ≤ 0.01. Ni-NTA resin was washed with 
wash  buffer,  glutathione  agarose  with  PBS-T and  amylose  resin  with  pMal  column buffer. 
Bound protein was eluted (0.5 ml.min-1, 1 ml/fraction, 12 fractions) using the required elution 
buffer (Figure 2.6) and the A280 of each eluted fraction was recorded. Fractions with an A280 ≥ 
69
0.4 were pooled together and the purification profile analysed by SDS-PAGE (Section 2.4.1) or 
Tricine-SDS-PAGE (Section 2.4.2), as necessary. Purified protein pools were stored for short 
periods at 4°C or for longer periods at -20°C. The final protein concentration was estimated by 
the method of Bradford (Section 2.4.4).
Figure 2.6 Strategy used for the purification of the recombinant malaria parasite proteins




MEC buffer [100 mM NaH2PO4, 200 mM NaCl, 0.01% NaN3, pH7.5]. NaH2PO4 (11.998 g) and 
NaCl (11.700 g) were dissolved in 950 ml distilled water and the buffer titrated to pH 7.5 with 
NaOH. NaN3 was added and the buffer made to a final volume of 1000 ml with distilled water.
2.7.3.2 Method
For protein fractionation either the Sephacryl S-100 or S-300 resin was packed into a glass 
column and equilibrated with two column volumes of MEC buffer (flow rate ≈ 0.5 ml.min-1). The 
column  was  calibrated  using  blue  dextran  (2000  kDa),  bovine  serum  albumin  (66  kDa), 
ovalbumin (45 kDa) and myoglobin (18 kDa) dissolved in MEC buffer (flow rate ≈ 0.5 ml.min-1; 
collected 5 ml fractions). The calibrated MEC resins were used for MBP-PbCtrNt fractionation. 
An affinity purified sample of MBP-PbCtrNt (5.5 mg, 4 ml) was applied to the resin and eluted 
with MEC buffer (flow rate ≈ 0.5 ml.min-1; collected 5 ml fractions). Affinity purified MBP-PbCtrNt 
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samples containing either 1 mM DTT or 0.2% Triton X-100 were also fractionated using the 
Sephacryl S-100 resin, following the method described above.
2.7.4 Copper binding studies and the bicinchoninic acid assay
Copper  binding and  the oxidation  state  of  copper  bound  to  the recombinant  proteins  was 
assessed  using  the  bicinchoninic  acid  (BCA)  release  assay.  For  this  assay protein-copper 
complexes are disrupted by acid denaturation and the released copper detected in solution 
(Brenner and Harris,  1995). BCA is highly sensitive and specific for reduced copper,  Cu(I), 
forming an intense violet complex detectable at 354 nm (extinction coefficient, ε = 4.58 ± 0.1 x 
104 M-1 cm-1 at 354.5 nm). If oxidized copper, Cu(II), is present in solution then ascorbic acid 
must be added to the sample, following acid denaturation, to yield the Cu(I)-BCA complex. The 
formation of  the Cu(I)-BCA complex in the absence of ascorbic acid, suggests the protein-
bound copper ions were already in the reduced state. Recombinant proteins were also tested 
for their ability to reduce copper-catalysed ascorbic acid oxidation.
2.7.4.1 Materials
Ascorbic acid solution [100 mM Ascorbic acid]. Ascorbic acid (88 mg) was dissolved in 5 ml 
distilled water and stored at RT.
Copper stock solution 1 [10 mM CuCl2]. CuCl2.2H2O (8.5 mg) was dissolved in 5 ml distilled 
water and stored at RT. This solution was used for in vitro copper binding studies.
Copper stock solution 2 [1 M CuCl2]. CuCl2.2H2O (0.852 g) was dissolved in 5 ml distilled water 
and sterilised by filtration through a 0.22  µm syringe filter. This solution was used for  in vivo 
copper binding studies.
Na-P buffer [0.1 M NaH2PO4, 0.01% NaN3, pH 7.5]. NaH2PO4 (11.998 g) was dissolved in 950 
ml distilled water, titrated to pH 7.5 with NaOH and NaN3 added (1 ml of a 10% solution). The 
buffer was made to a final volume of 1 ℓ.
Reagent A [30% (w/v) Trichloroacetic acid]. Trichloroacetic acid (15 g) was dissolved in distilled 
water and made to a final volume of 50 ml. This reagent was stable at RT for up to 6 months.
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Reagent B [2 mM Ascorbic acid]. Ascorbic acid (3.5 mg) was dissolved in 10 ml distilled water. 
This reagent was prepared fresh before use.
Reagent C [0.15mM Bicinchoninic acid, 0.9 M NaOH, 0.2 M HEPES]. Purified bicinchoninic 
acid disodium salt (6 mg), NaOH (3.6 g) and HEPES (15.6 g) were dissolved in distilled water  
and made to a final volume of 100 ml. This reagent was stable at RT for up to 6 months.
H2Asc solution [240  µ  M ascorbic acid, pH 4.5]  . Ascorbic acid (2.2 mg) was dissolved in 45 ml 
distilled water, titrated to pH 4.5 with NaOH and made to a final volume of 50 ml 
2.7.4.2 Method
BCA release assay
The BCA release assay makes use of a HEPES-buffered BCA solution (Reagent C) with NaOH 
included to neutralise the TCA and bring the pH of the solution close to 7 (Brenner and Harris, 
1995). For the assay, the desired protein solution (750 µl) was pipetted into a 2.0 ml microfuge 
tube  and  Reagent  A added  (250  µl).  This  solution  was  vortexed,  to  ensure  mixing,  and 
centrifuged (12 000  g, 2 min) to pellet the protein precipitate. The resulting supernatant was 
aliquotted (4 x 250 µl) into fresh microfuge tubes. For this particular study Reagent B (50 µl) 
was added to two of the tubes, whilst the remaining two tubes received an equivalent volume of 
distilled water. This solution was mixed and Reagent C (200 µl) then added to each tube, mixed 
and allowed to incubate at RT (2 min) before reading absorbance at 354 nm. Standards and 
blanks were prepared in the same final volume (500 µl).
In vitro   copper binding 
Each purified recombinant protein was used at 10 µM for  in vitro copper binding studies.  For 
copper binding, duplicate samples of each protein were prepared and each was mixed with a 
volume of copper stock solution 1, equivalent to a 20-fold molar excess. To one of the samples 
ascorbic acid solution was added to a final concentration of 10 mM, whilst the other sample 
received an equivalent  volume of  distilled water.  Samples were mixed by brief  vortex and 
incubated at RT (15 min) with occasional agitation. Unbound copper was removed by dialysis 
against three changes of Na-P buffer (> 100-fold volume excess) at 4°C, two by 2 h and one 
overnight.  Following  dialysis,  protein  samples  were  collected  and  bound  copper  measured 
using the BCA release assay, described above. Solutions of CuCl2 (Na-P buffer), with or without 
the addition of ascorbic acid, were used as standards and affinity-purified  MBP served as a 
negative control. The statistical significance of copper binding was determined by Student's t-test.
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In vivo   copper binding 
To test the ability of the respective proteins to bind copper in vivo, cells harbouring the relevant 
recombinant plasmid were induced in the presence of 0.5 mM CuCl2. This concentration of a 
copper salt has previously been shown to have no significant effect on the growth rate of E. coli 
cells (Lutsenko et al., 1997). Copper stock solution 2 was specifically added to recombinant E. 
coli  cultures 1 h post-IPTG-induced expression, to a final concentration of 0.5 mM. Standard 
procedures  for  optimal  recombinant  protein  expression  were  followed  (Section  2.7.1)  and 
proteins were purified under identical conditions to the proteins expressed in the absence of 
copper (Section 2.7.2). Following purification, pooled His6-PyCox17 and GST-PfCox17 proteins 
were dialysed against three changes of Na-P buffer (>100-fold volume excess) at 4°C, two by 2 
h and one overnight. MBP-fusion proteins were analysed for copper binding directly proceeding 
purification. All proteins were adjusted to a concentration of 10 µM, for consistency, and then 
analysed  for  bound  copper  using  the  BCA release  assay  described  above.  The  statistical 
significance of  copper  binding and the effect  of  copper  on recombinant  protein  yield  were 
determined by Student's t-test.
Ascorbate oxidation assay
The ability of each recombinant protein to reduce the copper-catalysed oxidation of ascorbic 
acid was tested  in  vitro.  In a typical  experiment  a mixture was prepared containing H2Asc 
solution  to  a  final  concentration  of  120  µM  (500  µl),  copper  stock  solution  to  a  final 
concentration of 8 µM (0.8 µl) and 5 µM recombinant protein (variable) made to a final volume 
of 1 ml with distilled water.  The absorbance of this solution was monitored at 255 nm with 
readings taken every 5 s for 300 s. Reactions were carried out at RT.  
73
CHAPTER 3
Bioinformatic studies and antigenic peptide selection for the putative Plasmodium spp. 
copper transport and metallochaperone proteins
3.1 Introduction
Bioinformatics is the term attributed to the use of applied mathematics, statistics and computer 
science  to  help  solve  biological  problems and queries.  The field  incorporates  programmes 
aimed at:  (i) solving DNA and protein sequence alignments; (ii)  identifying novel genes; (iii) 
assisting with genome assembly;  (iv)  solving and predicting protein structure;  (v) predicting 
gene  expression  and  potential  protein-protein  interactions  and  (vi)  modelling  the  path  of 
evolution (Claverie and Notredame, 2003). This chapter describes the bioinformatic techniques 
used for the identification and preliminary characterisation of novel copper-requiring proteins in 
the  Plasmodium proteome.  To  assist  with  protein  characterisation,  antibodies  were  raised 
against antigenic epitopes of a putative copper transport protein and copper metallochaperone 
from the P. yoelii and P. falciparum parasites.
It  has  previously  been  shown  that  P.  falciparum  requires  a  copper  efflux  protein  (PfCuP-
ATPase) for control of cellular copper (Rasoloson et al., 2004). This suggested a requirement of 
copper for parasite metabolic function, however, how the parasite acquires extracellular copper 
remains to be confirmed. The current model suggests copper is acquired through the ingestion 
and digestion of host erythrocyte Cu/Zn superoxide dismutase (Cu/Zn SOD). This mechanism 
was based on the assumption that  an observed decrease in  host  erythrocyte  Cu/Zn SOD 
content  was a result  of  parasite consumption.  Digestion of  Cu/Zn SOD would result  in  the 
release of bioavailable copper for the parasite (Rasoloson et al., 2004). Another possible, but 
unexplored mechanism, is  copper uptake via a dedicated copper transport  protein.  Such a 
mechanism  has  previously  been  characterised  in  yeast,  plant,  human  and  other  related 
mammalian systems  (Dancis et  al.,  1994; Kampfenkel et  al.,  1995; Mackenzie et  al.,  2004; 
Zhou and Gitschier, 1997; Zhou et al., 2003). To establish the potential of the parasite utilising 
such  a  mechanism,  a  bioinformatics  approach  was  employed.  Additional  copper  binding 
proteins were also searched for. One of these proteins, the Cox17 metallochaperone, has been 
implicated in copper delivery to yeast cell mitochondria (Beers et al., 1997) for the activation of 
cytochrome-c oxidase (Horng et al., 2004).
The  in  silico  identification of  Plasmodium proteins involved in  copper  metabolism suggests 
native expression; however, this requires confirmation using biochemical means. The approach 
adopted for this study was based on the successful  characterisation of  P. falciparum protein 
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kinases with anti-peptide antibodies (Dorin et al., 2005; Nunes et al., 2007). When selecting a 
suitable epitope for anti-peptide antibody production, the following criteria were analysed: (i) 
surface probability  (Emini et al., 1985; Janin and Wodak, 1978) (ii) hydrophilicity  (Hopp and 
Woods,  1983) and  (iii)  flexibility  (Karplus  and  Schulz,  1985).  Flexibility  is  of  particular 
importance as this property increases the probability of the selected peptide assuming a similar 
spatial orientation to that found in the native protein. On the other hand, antigenicity (Welling et  
al., 1985) is of less importance since it is a combination of a peptide's hydrophilicity and surface 
probability. It  is also desirable that the  selected epitope lacks potential N-glycosylation sites 
since  polysaccharides  can  mask  the  selected  region  on  the  native  protein.  Also  of 
consideration, particularly with regard to  Plasmodium parasite proteins, is that the number of 
lysine residues in  the selected peptide are limited.  Antibodies raised against  peptides  with 
multiple lysine residues may cross-react with multiple Plasmodium proteins since a number of 
parasite proteins are lysine-rich.
A BLASTp  search  of  PlasmoDB,  for  a  putative  copper  transport  protein,  identified  coding 
domains for two potential transporters in most of the available parasite genomes. Examples of 
these  were  P.  berghei (PBANKA_102150  and PBANKA_130290)  and  P.  falciparum 
(PF14_0211 and PF14_0369). P. yoelii appeared to be one of the exceptions, only encoding a 
single copper transporter (PY00413). Searches for other copper-dependent proteins identified 
the  presence  of  another  gene  encoding  a  putative  metallochaperone,  Cox17,  in  all  the 
aforementioned parasite proteomes. Suitable antigenic epitopes were identified in five of the 
identified parasite proteins using the Predict7™ epitope prediction algorithm (Cármenes et al., 
1989). For each of the copper transport proteins, peptide sequences were selected from the 
extracellular  amino-terminal  domain.  Selected  peptides  were  ensured  to  exclude regions 
showing sequence similarity to proteins in the chicken, mouse and human proteomes so as to 
avoid potential recognition of host proteins by the antibodies. The synthesised peptides were 
coupled to a carrier protein and injected into chickens for antibody production.  The resulting 
antibodies were affinity purified and used for the detection of native parasite proteins.
3.2 Results
3.2.1 Putative copper requiring proteins of P. falciparum
Within mammalian and yeast cellular systems copper is an essential cofactor for the correct 
functioning  of  a  number  of  enzymes  (Puig  and  Thiele,  2002;  Sharp,  2003).  One of  these 
enzymes, cytochrome-c oxidase (CCO), is a key catabolic enzyme consisting of 13 subunits, in 
the mammalian isoform, that is located in the inner membrane of the mitochondrion (Tsukihara 
et al., 1996). Cytochrome-c oxidase functions as a terminal electron transfer complex in the 
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mitochondrial respiratory chain, transferring electrons from cytochrome-c to molecular oxygen 
(Ferguson-Miller and Babcock, 1996). The enzyme contains three functionally important copper 
ions located at its binuclear CuA and mononuclear CuB sites (Tsukihara et al., 1996). Copper, as 
a reactive metal, cannot freely access cytochrome-c oxidase with the metallation of the CuA and 
CuB sites requiring  the  copper  chaperones  Cox17,  Sco1  and  Cox11  (Horng et  al.,  2004). 
Identification  of  these  particular  copper  chaperones  and  other  copper-requiring  protein 
orthologues, within the  P. falciparum proteome, would support a requirement for copper, as 
previously suggested (Rasoloson et al., 2004). Following a BLASTp search of the Plasmodium 
database  (www.plasmodb.org),  ten  such  orthologs  were  identified  (Table  3.1).  These  were 
Cox11, Cox17, Cox19, Sco1, cytochrome-c oxidase subunits I, II, III, Vb and VIb as well as S-
adenosyl-L-homocysteine hydrolase (SAHH).  In  terms of  cytochrome-c oxidase and copper 
binding,  the identification of  cytochrome-c oxidase subunits I  and II  seems most  significant 
since these contain the  mononuclear  CuB and binuclear CuA sites that require copper as a 
essential cofactor (Tsukihara et al., 1996).
The Plasmodium genome appears to lack an identifiable class of metallothioneins as well as a 
Cu/Zn superoxide dismutase ortholog (Table 3.1). In yeast and mammalian cells, these proteins 
are essential for copper storage and free radical detoxification, respectively (Kim et al., 2008; 
Puig  and  Thiele,  2002;  Sharp,  2003) Their  apparent  absence  from  the  parasite  genome 
suggests one of two possibilities. Either the Plasmodium parasite evolved unique mechanisms 
to  deal  with  the  aforementioned  cellular  situations  thereby  losing  the  necessity  for  these 
proteins, or alternately, the sequence features of potential  Plasmodium orthologs were not of 
sufficient similarity to be identified by the mammalian and yeast sequences used to search 
PlasmoDB. The absence of a Cu/Zn superoxide dismutase metallochaperone does, however, 
suggests that an alternative parasite mechanism could exist for free radical detoxification. An 
absence of dopamine-β-monooxygenase and peptidylglycine monooxygenase orthologs from 
the Plasmodium genome (Table 3.1) was not unexpected since these enzymes are involved in 
processes specific  to  mammalian organisms  (Friedman and Kaufman,  1965;  Murthy et  al., 
1986).
76










Copper chaperone for superoxide 
dismutase (CCS)
CAG46726
Activates  cytosolic  Cu/Zn 
superoxide dismutase
No N/A
Cu/Zn Superoxide dismutase AAB05661 Free radical detoxification No N/A
Dopamine-β-monooxygenase PO9172 Catecholamine production No N/A
Peptidylglycine monooxygenase P19021 Bioactivation of peptide hormones No N/A
Metallothionein AAP97267
Storage of excess copper and other 
divalent metals
No N/A






Catalyses  the reversible  hydrolosis 




Implicated  in  the  formation  of  the 
CuB site of cytochrome-c oxidase
Yes PF14_0721
Cox17 AAA98114
Transfers  copper  to  Cox11  and 




Required for  cytochrome-c oxidase 




Implicated  in  the  formation  of  the 
CuA site of cytochrome-c oxidase
Yes PF07_0034
Cytochrome-c oxidase subunit I ACR77861
Part  of  the  functional  core  of  the 
enzyme  complex,  specifically 
forming the catalytic subunit
Yes mal_mito_2
Cytochrome-c oxidase subunit II ABU47824
Part  of  the  functional  core  of  the 
enzyme  complex,  transfers 
electrons from cytochrome-c to the 




Cytochrome-c oxidase subunit III ABJ99455
Part  of  the  functional  core  of  the 
enzyme  complex  and  one  of  the 
main  transmembrane  subunits  of 
cytochrome-c oxidase
Yes mal_mito_1
Cytochrome-c oxidase subunit Vb AAA52060
Zinc  binding  site  of  cytochrome-c 
oxidase
Yes PFI1365w
Cytochrome-c oxidase subunit VIb AAP35591
Potential  haem-binding  subunit  of 
cytochrome-c oxidase
Yes PFI1375w
3.2.2 Identification of a putative Plasmodium spp. copper transport protein
The identification  of  copper  binding  proteins  within  the  P.  falciparum proteome (Table  3.1) 
supports the likely parasite requirement for copper. A mechanism for copper acquisition does, 
however,  remain  to  be  identified.  As  mentioned,  the  current  hypothesis  is  that  copper  is 
acquired  via  the  ingestion  and  digestion  of  host  erythrocyte  Cu/Zn  superoxide  dismutase 
(Cu/Zn SOD). A mechanism not yet considered is copper acquisition via a dedicated copper 
transport protein. To identify a putative  Plasmodium copper transporter sequence, PlasmoDB 
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was BLASTp searched with the Theileria parva polymorphic immunodominant molecule (PIM) 
sequence, which possesses copper transport protein features. Sequences corresponding to a 
copper transporter were identified for eight  Plasmodium  species (spp.), including  falciparum, 
vivax, yoelii, berghei, chabaudi, galinaceum, reichenowi and knowlesi. All retrieved sequences 
were aligned with sequences of other characterised copper transport proteins (Ctr1), using the 
ClustalWTM server (Thompson et al., 1994), to identify features common to and characteristic of 
these transporters (Figure 1.5). These features include three transmembrane domains, copper-
binding methionine motifs within the extracellular amino-terminus and most importantly MxxxM 
(MX3M) and GxxxG (GX3G) motifs located in the second and third transmembrane domains 
respectively (Figure 1.5). Sequence alignment identified both the MX3M and GX3G motifs in the 
Plasmodium sequences  (Figure  3.1),  as  well  as  an  important  methionine  residue  located 
approximately 20 amino acids from the first putative transmembrane domain (data not shown) 
(Puig et al., 2002a). 
Hs              SFPHLLQTVLHIIQVVISYFL  M LIF  M TY  NGYLCIAVAA  G AGT  G YFLFS  -----WKKAVVV 183
Ms              SFPHLLQTVLHIIQVVISYFLMLIFMTYNGYLCIAVAAGAGTGYFLFS-----WKKAVVV 189
Tp              LLTHLFLFLIALCAYALDFLLMLVVMTFNVGVFFAVILGYSVGYVLSSLAYSTLRTQPNR 531
Cp              IKVICTNVLLTILYYFMHYLLMLIAMTFNWGLFFSVIIGLSIGYGIFELGSITKNECSCN 169
Pf_0211         PCQNVNYGFLSFLHYTIDYLLMLIVMTFNPYIFLSIMTGLSSAYLFYGHLI--------- 160
Pf_0369         FKNNSYRMLLSFVIYSWDYLLMLIVMTFNVGLFVAVVLGLSFGFFIFGNKFVSSKKCSPD 218
Pv              FKNNLTRSLLSFIIYSWDYLLMLIVMTFNVGLFFAVVVGLSIGFFLFGHKFVTCGKSSTD 339
Py              FKNNTIRMILSFIIYSWDYLLMLIVMTFNVGLFFAVILGLSFGYFLMGGKFVTCTNTSHS 259
Pb              FKNNMIRMILSFIIYSWDYLLMLIVMTFNVGLFFAVILGLSFGYFLMGEKFVACTKSSKC 221
Pc              FKHNTIRMILSFIIYSWDYLLMLIVMTFNVGLFFAVILGLSFGYFLMGNNFVSCTQNSNC 196
Pg              FKNNTIRMILAFIIYSWDYLVMLIVMTFNVGLFFSVIFGLAFGFFLFGSHFVTSKKCATT 199
Pk              FKNNLTRSALSFIIYSWDYLLMLIVMTFNVGLFVAVVVGLSIGFFLFGHKFVTCGSNSTD 289
Pr              FKNNSYRMLLSFVIYSWDYLLMLIVMTFNVGLFVAVVLGLSFGFFIFGNKFVSSKKCSPD 170
                         : :      :::**: **:*  : .::  * . .: : 
Figure 3.1 Alignment of essential protein motifs in  human, mouse,  Theileria and  Cryptosporidium copper 
transporter sequences with the Plasmodium sequences 
Alignment  of  the essential  copper  transporter  MX3M and  GX3G motifs.  Sequences are as follows:  Hs =  Homo 
sapiens;  Ms  =  Mus  musculus;  Tp  =  Theileria  parva;  Cp  =  Cryptosporidium  parvum;  Pf_0211  =  Plasmodium 
falciparum PF14_0211; Pf_0369 = P. falciparum PF14_0369; Pv = P. vivax; Py = P. yoelii; Pb = P. berghei; Pc = P. 
chabaudi; Pg = P. galinaceum; Pk = P. knowlesi; Pr = P. reichenowi (Refer to Section 2.3 for the sequence accession 
numbers).  Conserved  residues  are  indicated  by  *, whilst  : represents  a  conserved  substitution  and  .  a semi-
conserved substitution.  Underlined amino acids, in the  H. sapiens sequence, indicate the approximate position of 
transmembrane domains two and three, respectively.
Each of the Plasmodium sequences was analysed using the TMHMM (Krogh et al., 2001) and 
HMMTOP  (Tusnády and  Simon,  2001) transmembrane  domain  prediction  servers.  At  least 
three putative transmembrane domains were identified in each retrieved sequence. Figure 3.2 
is  representative of  the results  obtained from the TMHMM server  (Krogh et  al.,  2001) and 
depicts the predicted topology for the P. falciparum (PF14_0211) (Figure 3.2a) and P. berghei  
(Figure 3.2b) sequences in relation to the known topology of the  Saccharomyces cerevisiae 
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copper  transport  protein  (ScCtr1)  (Figure  3.2c).  As  previously  indicated  (Figure  1.5),  the 
presence of three predicted transmembrane domains would presumably result in an orientation 
whereby  the  amino-terminus  is  extracellular  and  the  carboxy-terminus  intracellular.  This 
prediction  is  in  close agreement  with the established topology of  ScCtr1 and other  known 
copper transport proteins, such as hCtr1  (Aller and Unger, 2006). It is, however, important to 
note the presence of a fourth predicted transmembrane domain in the P. falciparum plot (Figure 
3.2a), within the first 30 amino acids of the protein sequence. According to the TMHMM server, 
a transmembrane domain predicted within the amino terminus of a protein is suggestive of a 
signal  sequence  (Krogh et  al.,  2001).  This  prediction  was  supported  by  submitting  the 
PF14_0211 sequence to the SignalP server (data not shown), a signal peptide cleavage site 
prediction program (Emanuelsson et al., 2007). A similar signal peptide was identified for the 
other  Plasmodium sequences.  Interestingly,  analysis  of  each  sequence  for  an  apicoplast 
targeting signal (PlasmoAP server) indicated that only P. falciparum PF14_0369 contained such 
a sequence.
Figure 3.2 Topology prediction for two putative Plasmodium sp. copper transport proteins compared to the 
known topology of the S. cerevisiae copper transport protein.
TMHMM plots for P. falciparum PF14_0211 (A), P. berghei (B) and S. cerevisiae (C) copper transporter sequences 
are depicted. Represented in  all  panels are regions of  the protein  sequence predicted to be extracellular  (▬), 




3.2.3 Analysis of the coding sequences for two putative P. falciparum copper transport 
proteins
Identification of a putative copper transport protein sequence, within the Plasmodium proteome, 
required  a  preliminary  characterisation  of  the  protein  sequence.  Further  in  silico 
characterisation involves an analysis of the gene organisation of P. falciparum chromosome 14 
since it harbours the coding domains for both predicted P. falciparum copper transport proteins. 
In general it has been noted that P. falciparum chromosomes vary considerably in length with 
most variation occurring in the subtelomeric regions (Gardner et al., 2002). This variation is due 
to the fact that subtelomeric domains typically contain gene families encoding proteins essential 
to  host-pathogen interactions  and antigenic  variation.  These include the  var,  rif and  stevor 
families (Cheng et al., 1998; Kyes et al., 1999; Marti et al., 2004). However, it has also been 
demonstrated that there is a central “core” region within the 14 P. falciparum chromosomes that 
contain  a  number  of  gene  orthologs  conserved  in  the  three  rodent-infecting  Plasmodium 
species (Hall et al., 2005; Kelly et al., 2006). These conserved  P. falciparum  gene orthologs 
collectively totalled 4391 genes and in general the gene pairs were found to be under purifying 
selective pressure (Hall et al., 2005). Based on the finding that the gene encoding LDH is found 
within the “core” region of P. falciparum chromosome 13 (data not shown), it was presumed that 
coding domains found within the “core” region of other chromosomes could infer the protein has 
a  potentially  important  function.  With  this  is  mind the location  of  the  P.  falciparum copper 
transporter coding domains was evaluated (PF14_0211 and PF14_0369).
Figure 3.3 Location of the copper transporter coding domains on P. falciparum chromosome 14  
Chromosomal location of PF14_0211 (---) and PF14_0369 (―) coding domains on P. falciparum chromosome 14 (A) 
plus an exploded view of chromosome 14 gene organisation, relative to PF14_0211 (B) and PF14_0369 (C). In 
panels  B and  C the upper image represents gene organisation whilst the lower image highlights the presence of 
introns (―) and exons (■) within each respective coding domain. The corresponding base pair numbers (adjacent to 
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Chromosome 14 (Figure 3.3) has been predicted to contain a centromere at approximately 1,15 
Mbp from the left-hand telomere  (Kelly et  al.,  2006).  As seen in  figure 3.3,  the sequences 
encoding  the  two  copper  transport  proteins  are  located  relatively  close  to  this  predicted 
centromere,  at  approximately  0.89  Mbp  and  1.57  Mbp  for  PF14_0211  and  PF14_0369 
respectively.  Although  localisation  of  the  centromere  is  not  definitive  of  the  central  “core” 
conserved region, of chromosome 14, it is nevertheless suggestive of where this region might 
be.  The PF14_0211 coding domain  is  also located amongst  a number  of  hypothetical,  but 
importantly, conserved proteins according to PlasmoDB annotation (Figure 3.3). Similarly for 
PF14_0369 it  was noted that the surrounding gene organisation (Figure 3.3) appears to be 
conserved across the Plasmodium species thus far annotated (data not shown). This trend of 
conserved organisation has been previously documented for a number of other  Plasmodium 
proteins (van Lin et al., 2001).
The PF14_0211 and PF14_0369 coding domains displayed clear differences between their 
respective intron/exon organisation. Whilst PF14_0211 contains a single exon and no introns 
(Figure  3.3b),  PF14_0369  contains  two  exons  and  a  single  intron  (Figure  3.3c).  This 
intron/exon organisation was also present in the corresponding orthologous coding domains of 
other  Plasmodium spp.  The one exception was for  the  P. yoelii coding domain (PY00413), 
which was composed of two introns and three exons (data not shown). This conservation of 
gene organisation and chromosomal localisation, for the Plasmodium copper transport protein, 
suggests a likely role for this protein in parasite metabolic activity.
3.2.4 Identification of a putative Plasmodium spp. Cox17 copper metallochaperone
The copper  metallochaperone Cox17 has been implicated in  the  delivery of  copper  to  the 
mitochondrion  in  yeast  and  mammalian  cells  (Cobine et  al.,  2006a;  Leary et  al.,  2009).  
Characterisation of the Cox17 metallochaperone has made use of the  S. cerevisiae model, 
although mammalian isoforms have also been characterised. To date, a Cox17 chaperone has 
not  yet  been  annotated  or  characterised  in  any  Apicomplexan  organism.  To  identify  a 
Plasmodium Cox17 ortholog, the Arabidopsis thaliana Cox17 sequence was used to BLASTp 
search  PlasmoDB.  This  particular  sequence  was  selected  since  the  A.  thaliana genome 
appears closely related to the Plasmodium genome (Gardner et al., 2002) This search revealed 
a putative Cox17 sequence in the genomes of  P. falciparum,  vivax,  yoelii,  berghei, chabaudi, 
galinaceum,  reichenowi and  knowlesi. These were the same species predicted to encode a 
copper transporter. A ClustalWTM alignment of all retrieved parasite Cox17 sequences, with the 
sequences of known Cox17 proteins (Figure 3.4), was constructed to identify conserved amino 
acids.
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Hs  MPGLVDS-----NPAPPE------SQEKKPLK-P CC  A C PETKKARDACIIEKGE--EHCGHLIEAHKECMRALGFKI---- 63
Sc  MTETDKK-------QEQEN-----HAECEDKPKP  CC  V C KPEKEERDTCILFNGQDSEKCKEFIEKYKECMKGYGFEVPSAN 69
At  MTDQPAQN-GLIPPPTSEPSKAAASAETKPKKRICCACPDTKKLRDECIVEHGE--SACTKWIEAHKICLRAEGFNV---- 74
Pf  MGMSLNK------PINNTN---EANKGEVKKKKICCVCLETKKLRDECIVKLGE--EQCKKFIDDHNKCLRSEGFDIK--- 67
Py  MGLGLTK------PLNTT----EESKTCAKKKKICCVCLDTKKLRDECIVNLGE--EQCKKYINDHNQCLRNEGFDIK--- 66
Pv  MGFF-NW------PSKNTS---EEAKGGAAKKKICCVCLETKKLRDECIVKLGE--EQCRKYIEDHNQCLRDEGFDVK--- 66
Pb  MGLSLTK------PLNTT----EENKTCAKKKKICCVCLDTKKLRDECIVNLGE--EKCKKYIDEHNQCLRNEGFDIK--- 66
Pk  MGFFSNW------PFKNTS---EEAKGGAPKKKICCVCLETKKLRDECIVKLGE--EQCRKYIEDHNQCLRNEGFDVK--- 67
Pc  MGSSLT-------ILNTT----DESKTGAPKKKICCVCLDTKKLRDECIVKYGE--KKCKKYIDDHNRCLRNEGFDIK--- 65
Pg  MGTFLNK------PIKNTN---EEIKGE-KKKKICCVCLETKKLRDECIVKLGE--EQCKKFIDDHNQCLRNEGFDIK--- 66
Pr  MGMSLNK------PINNPN---EANKGEVKKKKICCVCLKTKKLKDECIVKLGE--KQCKKFIDDHNKCLRSEGFDIK--- 67
    *                                 **.*   *: :* **   *:  . * . *: :: *::  ** :
Figure 3.4 Alignment of conserved amino acids in human, yeast and Arabidopsis Cox17 sequences with the 
Plasmodium sequences
Cox17 sequences aligned are for Homo sapiens (Hs), Saccharomyces cerevisiae (Sc), Arabidopsis thaliana (At), P. 
falciparum (Pf), P. yoelii (Py), P. vivax (Pv), P. berghei (Pb), P. knowlesi (Pk), P. chabaudi (Pc), P. galinaceum (Pg) 
and  P.  reichenowi (Pr)  (Refer  to  Section  2.3  for  the  sequence  accession  numbers).  Essential  residues  are 
highlighted by colour. Conserved residues are indicated by *, whilst  : represents a conserved substitution and .  a 
semi-conserved substitution. The underlined sequence on the Hs and Sc sequences represents the Cox17 copper 
binding site.
A mutagenic  study  on  more  than  two-thirds  of  the  S.  cerevisiae Cox17  protein  sequence 
identified  that  only  one-sixth  of  these  mutants  produced  a  respiration-deficient  phenotype 
(Punter and Glerum, 2003). Surprisingly, only 40% of the conserved residue mutations had an 
adverse effect on Cox17 function. The conserved residues that were affected by mutation are 
Cys-23,  Cys-24,  Cys-26,  Arg-33,  Asp-34,  Cys-47  and  Cys-57  (Punter  and  Glerum,  2003). 
Alignment of the eight retrieved Plasmodium spp. sequences with the human and yeast Cox17 
sequences, established that these essential residues were conserved (Figure 3.4). The one 
exception was for the P. reichenowi sequence where a conserved substitution replaced Arg-33 
for  a Lys residue.  Considering sequencing of  the  P.  reichenowi genome is  incomplete this 
difference could be the result  of  a  sequencing error  or  artefact.  It  is  important  to  note the 
conservation of the CysCysXaaCys motif at amino acids 23 to 26 (S. cerevisiae numbering) in 
all  the  Plasmodium  sequences.  This motif  forms part  of  the Cox17 copper binding domain 
(underlined sequence in Figure 3.4) and is essential to its function (Abajian et al., 2004; Heaton 
et al., 2000; Punter and Glerum, 2003).
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Figure 3.5 P. falciparum Cox17 homology model
The Saccharomyces cerevisiae Cox17 structure (green) (Arnesano et al., 2005) is included for comparison (A).  P. 
falciparum Cox17 (brown) was modelled against the NMR-solved structure of Homo sapiens Cox17 (yellow) without 
(B) or with (C) copper  bound (Banci et al., 2008). The model was constructed by sequence alignment (D). In panels 
A to  C the amino (Nt) and carboxy (Ct) termini are labelled. Coloured residues, in all three panels, are shown as 
stick representations and correspond to the residues highlighted in D, although residue numbers differ in panel A as 
does an additional cysteine residue (coloured yellow). The underlined cysteine doublet in D is coloured white in all 
panels. Copper in panel C is shown by the red sphere (●).
To understand Plasmodium Cox17 function, the Homo sapiens Cox17 (hCox17) NMR structure 
(Banci et  al.,  2008b) was  used  as  a  template  to  model  the  hypothetical  structure  of  P. 
falciparum Cox17 (PfCox17) (Figure 3.5) with the Swiss-pdb DeepView program  (Guex and 
Peitsch, 1997). Both yeast and human Cox17 have a coiled coil-helix-coiled coil helix structural 
motif (Figure 3.5)  (Abajian et al., 2004; Arnesano et al., 2005; Banci et al., 2008b), which is 
predicted to be common to the related mitochondrial proteins Cox19 (Nobrega et al., 2002) and 
Cox 23 (Barros et al., 2004). From the homology model of PfCox17 this structural motif appears 
to be conserved, with a close resemblance observed between PfCox17 and both the apo and 
Cu-loaded  forms  of  hCox17  (Figure  3.5b  and  c,  respectively). Located  at  the  amino  and 
carboxyl  terminal  ends  of  each  helix  are  four  conserved  cysteine  residues  that  form  two 
interhelical disulfide bonds in yeast and human Cox17 (Figure 3.5,  red and  cyan highlighted 
residues). These conserved residues are also present in PfCox17 (Figure 3.5d) and appear to 
map closely to the corresponding residues in both apo and Cu-loaded hCox17 (Figure 3.5b and 
c, respectively). The conserved and essential Arg-32 and Asp-34 residues in hCox17 are also 
HsCox17         MPGLVDS---NPAPPESQEKKPLKPCCACPETKKARDACIIEKGEEHCGHLIEAHKECMR 57
PfCox17         MGMSLNKPINNTNEANKGEVKKKKICCVCLETKKLRDECIVKLGEEQCKKFIDDHNKCLR 60
                *   ::.   *.  .:. * *  * **.* **** ** **:: ***:* ::*: *::*:*
HsCox17         ALGFKI- 63
PfCox17         SEGFDIK 67










closely mapped by the corresponding residues in PfCox17 (Figure 3.5b and c). Copper binding 
to  hCox17  results  in  local  structural  rearrangements  around  the  two  copper-coordinating 
cysteine  residues  (Figure  3.5b  and  c,  white  highlighted  residues)  causing  the  normally 
unstructured and flexible amino terminus (Figure 3.5b) to become more structured and less 
flexible (Figure 3.5c) (Banci et al., 2008b). PfCox17 appears to closely resemble these changes 
in protein structure. The one clear difference between PfCox17 and hCox17 is the insertion of 
three  amino  acids  in  the  unstructured  amino  terminus  (Figure  3.5b  and  d).  However,  this 
appears to have little bearing on the structure predicted for PfCox17.
3.2.5 Analysis of the putative P. falciparum Cox17 metallochaperone coding sequence
Candidate P.  falciparum  chromosomal  centromeres  were  identified  by  etoposide-mediated 
topisomerase-II cleavage of the 14 chromosomes. Identified centromeres were classified as 
regions of ~2 kb in length with extremely high A+T content (>97%) and imperfect short tandem 
repeats (Kelly et al., 2006). For chromosome 10 the candidate centromere was suggested to be 
located 1.1  Mb from the  left-hand telomere,  however,  this  site  lacked an apparent  AT-rich 
domain.   Although  localisation  of  the  P.  falciparum  chromosome  10  centromere  was  not 
confirmed, the suggested location was used as a reference for the analysis of the putative P. 
falciparum Cox17 coding domain (PF10_0252). The PF10_0252 coding domain is predicted to 
be localised between bases 1 088 212 and 1 088 415 of chromosome 10 (Figure 3.6). This is in 
close association with  the candidate centromere. As previously suggested, conservation of a 
protein coding domain within the apparent “core” region of a chromosome could be suggestive 
of  metabolic  importance  (Section  3.2.3).  Analysis  of  the  PF10_0252  intron/exon  structure 
indicated the presence of a single 204bp exon with an absence of introns (Figure 3.6b).  A 
similar gene organisation was observed for all retrieved Plasmodium Cox17 sequences (data 
not shown).
Figure 3.6 Localisation of the Cox17 coding domain in P. falciparum chromosome 10 
PF10_0252 (---) coding domain localisation on P. falciparum chromosome 10 (A). An exploded view of chromosome 
10 gene organisation relative to PF10_0252 (B); the upper image depicts surrounding genes whilst the lower image 
depicts the intron (―)/exon (■) structure of the PF14_0252 coding domain. The corresponding base pair numbers 
(adjacent to the coloured arrowheads) are shown above the 5’ and 3’ termini.
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3.2.6 Transcription levels of a P. falciparum copper transporter and metallochaperone
Each  stage  of  the  P.  falciparum  parasite's  developmental  life  cycle  was  examined  for  the 
expression of each copper transporter, as well as for those proteins related to cytochrome-c 
oxidase, and  compared to lactate dehydrogenase (LDH) expression (Figure 3.7). Analysis of 
the LDH data indicated relatively consistent expression throughout the erythrocytic stages of 
the parasite's life cycle, although expression did appear to decrease slightly during the latter 
stages of development (Figure 3.7a). LDH expression is lowest during the gametocyte stage, 
whilst expression in sporozoites is relatively comparable to expression during the erythrocytic 
stages  of  development  (Figure  3.7a).  Compared  to  LDH,  the  two  copper  transporters 
(PF14_0211 and PF14_0369) showed reduced levels of expression with an apparent peak in 
expression during schizont  development  (Figure 3.7b and Figure 3.7c).  Expression of  both 
copper transporters during sporozoite and gametocyte development was very similar, but at a 
lower levels compared to peak protein expression. Expression of cytochrome-c oxidase subunit 
I showed a similar trend to the copper transporters, peaking at the schizont stage (Figure 3.7e). 
Unlike copper transporter expression, however, cytochrome-c oxidase peak expression did not 
decrease  during  the  gametocyte  stage  but  did  decrease  during  the  sporozoite  stage  of 
development (Figure 3.7e). Similar to LDH, Cox17 expression was relatively consistent through 
all stages of the erythrocytic life cycle. This consistency in Cox17 expression was also evident 
for the sporozoite and gametocyte stages of development (Figure 3.7d). However, in contrast to 
LDH, Cox17 was expressed at significantly reduced levels for all  stages of development.  A 
similar  expression  pattern,  to  Cox17,  was  noted  for  the  related  Cox11  and  Sco1  copper 
metallochaperones (data not shown). Taken together, this expression data supports a parasite 
requirement for copper acquisition, distribution and utilisation through the different stages of 
parasite development.
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Figure 3.7 Relative expression of  P. falciparum copper-dependent protein orthologs compared to lactate 
dehydrogenase.
mRNA  expression  profiles  for  P.  falciparum  A lactate  dehydrogenase  (PF13_0141),  B PF14_0211  copper 
transporter,  C PF14_0369  copper  transporter,  D Cox17  (PF10_0252)  and  E  cytochrome-c  oxidase  subunit  I 
(mal_mito_2). For each graph the y-axis represents the affymetrix MOID expression value normalized by experiment 
(www.plasmodb.org).  Labels  on the x-axis  are:  S = sporozoites,  ER = early  rings,  LR = late  rings,  ET = early 
trophozoites,  LT  =  late  trophozoites,  ES  =  early  schizonts,  LS  =  late  schizonts,  M  =  merozoites  and  G  =  
gametocytes.  Parasites were synchronised by  sorbitol or  temperature.  Data for  gametocyte samples represents 
synchronisation  by  sorbitol  only  whilst  data  for  sporozoites  represents  the  average  of  two  replicates.  The 
represented data is in accordance with the dataset determined by Le Roch et al. (2003).
3.2.7  Phylogenetic analysis of the  Plasmodium copper transporter and Cox17 protein 
sequences
Phylogenetic  trees were generated by aligning the eight  Plasmodium copper transporter  or 
Cox17  protein  sequences  with  the  sequences  of  seven  characterised  copper  transporter 
(Figure 3.9) or Cox17 (Figure 3.10) proteins, respectively. In both trees all eight  Plasmodium 
species were found to form a related cluster. For the copper transporters this cluster included 
Theileria parva whilst the same was not true for Cox17. Although displaying slight differences 
between proteins, the close relation between Plasmodium parasites and T. parva is expected 
considering both parasites belong to a large monophyletic  assemblage of  entirely  parasitic 
organisms,  the  Apicomplexans  (Escalante  and  Ayala,  1995).  Interestingly,  an  event  of 
divergence was noted for the P. falciparum PF14_0211 sequence from the other Plasmodium 
copper transporters. Although evidently related to one another, the divergence of PF14_0211 
from PF14_0369 in particular suggests these proteins share a similar mechanism but could 
possibly perform their roles at separate cellular destinations. The identification of an apicoplast 
targeting signal in the PF14_0369-encoded protein, and not the PF14_0211-encoded protein, 











being targeted to different  locales in a cell  has previously been established for  the human 
copper transporters Ctr1 and Ctr2 (Rees et al., 2004; van den Berghe et al., 2007).
Figure 3.8 Phylogenetic analysis of the Plasmodium copper transport protein sequences with mammalian, 
yeast, plant and Apicomplexan parasite copper transporter sequences 
Eight  Plasmodium copper  transport  protein  sequences  were  aligned  with  the  sequences  of  seven  previously 
identified copper transport proteins from H. sapiens, M. musculus, R. norvegicus, D. rerio, S. cerevisiae, A. thaliana  
and T. parva (Refer to Section 2.3 for the sequence accession numbers). All 15 sequences were aligned using the 
ClustalWTM server (Thompson et al., 1994) and a phylogenetic tree constructed.
For both the copper transporter (Figure 3.8) and Cox17 (Figure 3.9) trees, the three rodent 
malaria parasites cluster together as P. vivax does with P. knowlesi and P. falciparum with P. 
reichenowi and  P.  galinaceum.  Similar  evolutionary  relationships  have  previously  been 
observed  from  the  phylogenetic  analysis  of  the  cytochrome  b  and  small  subunit  rRNA 
sequences  (Rathore et  al.,  2001).  The  last  of  the  aforementioned  clusters  has  also  been 
similarly  noted for  the small  subunit  rRNA sequences  (Escalante and Ayala,  1994).  These 
various  clusters  collectively  indicate  the  relatedness  of  the  sequences,  with  the  events  of 
divergence suggesting probable adaptations to accommodate for specific host conditions. As 
expected, all  Plasmodium species show a relatively distant relation to the mammalian, yeast 
and plant reference species used. Similar results were obtained for a phylogenetic analysis of 
LDH sequences (data not shown).
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Figure 3.9 Phylogenetic analysis of the Plasmodium Cox17 metallochaperone sequences with mammalian, 
yeast, plant and Apicomplexan parasite Cox17 metallochaperones 
Cox17 metallochaperone sequences from eight  Plasmodium  species were aligned with the sequences of seven 
previously identified Cox17 metallochaperones from H. sapiens, R. norvegicus, M. musculus, D. rerio, A. thaliana, S.  
cerevisiae, and T. parva (Refer to Section 2.3 for the sequence accession numbers). All 15 sequences were aligned 
using the ClustalWTM server (Thompson et al., 1994) and a phylogenetic tree produced using the same server.
3.2.8 Selection of immunogenic peptides for antibody production in chickens
To demonstrate the native expression of each parasite protein being studied, a protein-specific 
antibody-based  approach  was adopted  (Martin et  al.,  2009a).  Anti-peptide  antibodies  were 
raised  against  peptides  from  the  parasite  copper  transport  protein  and  Cox17 
metallochaperone.  Peptides were identified using the Predict7TM  program  (Cármenes et  al., 
1989) and subsequently synthesised. Peptides were selected from the single P. yoelii and two 
P.  falciparum copper  transport  proteins,  as  well  as  the  P.  yoelii and  P.  falciparum Cox17 
metallochaperones. For each of the three copper transport proteins, peptide sequences were 
selected from the amino-terminal domain as this is predicted to be extracellular (Figure 3.2) and 
thus likely to be more accessible to antibodies in its native state.  Cox17 is a soluble protein 
localised to the cell cytoplasm and inner-mitochondrial space (Beers et al., 1997) providing a 
greater number of accessible epitopes. 
Predict7TM analysis  of  the  copper  transport  protein  sequences  (Figure  3.10)  identified  the 
following peptides:  CSDKQSGDDECKPILD for the P. yoelii protein, CHSKNDDGVMLPMY for 
PF14_0211  and  CNLQKEEDTVVQLQD for  PF14_0369.  Peptides  identified  for the  Cox17 
sequences  (Figure  3.11)  were  CPLNTTEESKT  C  A, for  the  P.  yoelii protein,  and 
CPINNTNEANKGE, for the P. falciparum protein (For each peptide the three underlined amino 
acids represent the abbreviated laboratory reference name of the peptide and corresponding 
antibodies). For the  P. yoelii Cox17-specific peptide (KTC), the  internal cysteine residue was 
substituted for  an α-aminobutyric acid group so as to avoid the formation of internal disulfide 
bonds  and  allow  for  specific  amino  terminal  cross-linking  to  rabbit  albumin. Each  peptide 
sequence was subjected to a BLASTp search against the Gallus gallus, Mus musculus, Homo 
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sapiens and Plasmodium parasite proteomes, with no significant matches identified (data not 
shown). This search was performed to ensure antibodies would be generated in the chicken 
host and that the resulting antibodies would be specific to the target protein, meaning they 
would not bind to other parasite or host proteins.
Figure  3.10 Selection  of  immunogenic  peptides  from  the  amino-terminal  domains  of  three  putative 
Plasmodium copper transport proteins
Predict7TM analysis  of  the  amino-terminal  sequences  of  a  P.  yoelii (A)  and  two  P.  falciparum copper  transport 
proteins, PF14_0211 (B) and PF14_0369 (C).  The selected peptides are identified by the boxed region in each 
panel. For each Predict7TM analysis hydrophilicity (―), surface probability (―) and flexibility (---) are plotted.
MBS coupling of peptides requires a terminal cysteine residue. This can either be native to the 
sequence or included during peptide synthesis. For the copper transport protein peptides, the 
P. yoelii and PF14_0211 amino terminal cysteine residues are native to the protein, whereas a 
cysteine residue was added to the amino terminus of PF14_0369. It was also necessary to add 





































































































































a cysteine residue to the amino terminus of both Cox17 peptides. Peptides conjugated to the 
rabbit albumin carrier were then injected into chickens.
Figure 3.11 Selection of immunogenic peptides from the Plasmodium metallochaperone Cox17
Predict7TM analysis of the putative Cox17 metallochaperone sequences for P. yoelii (A) and P. falciparum (B). The 
selected peptides are identified by the boxed region in each panel. For each Predict7TM analysis hydrophilicity (―), 
surface probability (―) and flexibility (---) are plotted.
3.3 Discussion
Proteins involved in copper import and export are associated with a number of pathway-specific 
copper  metallochaperones  that  deliver  copper  to  specific  targets  in  a  cell  (O'Halloran  and 
Culotta,  2000;  Rosenzweig,  2001;  Kim et  al.,  2008).  To  date,  mechanisms  for  copper 
homoeostasis have not been extensively characterised for the malaria parasite. What has been 
established is that the parasite expresses a copper P-type ATPase (PfCuP-ATPase) for the 
efflux of excess copper (Rasoloson et al., 2004). Rasoloson et al. (2004) also suggested that 
more  elaborate  copper  homeostatic  pathways,  particularly  for  copper  acquisition  and 
distribution are likely to be present. The current study explored these potential pathways using 
a bioinformatics analysis of the Plasmodium database (PlasmoDB).
3.3.1 Identification of a putative Plasmodium spp. copper transport protein and Cox17
A BLASTp search of PlasmoDB was executed using the sequences of previously identified and 
characterised copper-dependent proteins. This yielded positive results for some, but not all, of 























































































the sequences used (Table 3.1). Perhaps one of the more important proteins identified was a 
subunit of a cytochrome-c oxidase complex that requires copper for the formation of the active 
protein  (Table  3.1).  In  the  presence  of  oxygen,  energy  production  in  eukaryotic  cells  is 
predominantly generated by mitochondrial oxidative phosphorylation (Iwata et al., 1995). This 
process  is  driven  by  an  electron-transport  chain  composed  of  a  number  of  complex 
mitochondrial  membrane  proteins,  of  which  cytochrome-c  oxidase  is  the  terminal  enzyme 
(Cobine et  al.,  2006a). Deficiencies in cytochrome-c oxidase activity have been linked to a 
number  of  human  diseases  including  encephalomyopathies,  Leigh  syndrome,  hypertrophic 
cardiomyopathies and fatal lactic acidosis  (Diaz, 2010). This highlights the importance of this 
enzyme to human cells and suggests the possibility that this enzyme is likely to be important in 
Plasmodium metabolism. This is supported by the identification of Cox11, Cox17, Cox19 and 
Sco1  metallochaperone  orthologs,  which  transfer  and  insert  copper  into  the  cytochrome-c 
oxidase  complex.  The  identification  of  a  copper-requiring  S-adenosyl-L-homocysteine 
hydrolase  ortholog  was  also  significant  since  this  protein  has  been  established  as  being 
important  to  parasite  survival  since  enzyme  inhibition  interferes  with  parasite  proliferation 
(Bujnicki et al., 2003; Creedon et al., 1994). Taken together, these results suggest a parasite 
requirement for copper.
A physiological role for copper, in the  Plasmodium parasite, has previously been suggested 
from studies  using  the  intracellular  copper  chelator  neocuproine.  Treatment  of  an  in  vitro 
parasite culture with nanomolar concentrations of neocuproine inhibited parasite transition from 
rings to trophozoites (Rasoloson et al., 2004). However, the mechanism by which the parasite 
acquires copper has not yet been established. Two possible mechanisms exist.  The first  is 
copper  acquisition  via  parasite  ingestion  and  digestion  of  host  erythrocyte  Cu/Zn  SOD 
(Rasoloson et al., 2004), whilst the other is via a dedicated copper transport protein, similar to 
that identified in yeast and mammalian cells (Dancis et al., 1994; Lee et al., 2000; Lee et al., 
2002). Following extensive research, characteristic sequence features have been identified for 
this family of proteins. The most notable features include a methionine-rich amino terminus, 
three transmembrane domains and essential MX3M and GX3G motifs in the second and third 
transmembrane domains respectively  (Aller et  al.,  2004; Puig et  al.,  2002a) (Figure 1.5).  A 
BLASTp  search  of  PlasmoDB  identified  candidate  copper  transporter  sequences  for  eight 
species of the Plasmodium parasite. Alignment of the retrieved sequences with sequences of 
known copper transporters identified the essential and largely definitive MX3M and GX3G motifs 
in  all  eight  Plasmodium  species (Figure  3.1).  Methionine motifs  were also  identified in  the 
predicted amino terminal  domain  of  these  proteins.  These motifs  are  important  for  protein 
function (Eisses and Kaplan, 2005; Guo et al., 2004; Puig et al., 2002a) but are not unique to 
the copper transport proteins. 
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A topological analysis of each sequence identified the presence of three putative membrane-
spanning  domains  (Figure  3.2).  This  too  is  considered  a  definitive  feature  of  the  copper 
transport  proteins  (Dancis et  al.,  1994).  It  is,  however,  important  to  note  that  three 
transmembrane domains are unable to form a functional channel or pore through which ions 
can be transported (Nose et al., 2006). It was therefore proposed, and subsequently verified, 
that  copper transport  protein monomers create a channel  by associating in  a homotrimeric 
complex  (Aller  and  Unger,  2006;  De  Feo et  al.,  2009).  This  copper-permeable  pore 
consequently  forms a pathway that  permits  the controlled movement  of  copper  across the 
membrane and into the cell. Given the importance of trimer formation to protein function (Aller 
et  al.,  2004),  a  similar  formation is  likely  to  exist  for  the  Plasmodium copper  transporters. 
Supporting this likelihood, was the recent finding that the first transmembrane domain of the 
copper  transporter  serves  as  an adaptor  that  allows evolutionarily  distant  copper  transport 
proteins to adopt a similar, but not identical, overall structure (De Feo et al., 2010).
The  presence  of  a  putative  Plasmodium copper  transport  protein  sequence  suggests  a 
dedicated system for copper acquisition in the parasite. This is supported by the presence of 
sequences for orthologs of cytochrome-c oxidase and its associated metallochaperones Cox11, 
Cox17 and Sco1 (Table 3.1). Cox17 is of particular interest since this protein localises to the 
cell cytoplasm and inner mitrochondrial space and is thought to be involved in shuttling copper 
from the copper transporter to the mitochondrion  (Beers et  al.,  1997). This mechanism has 
been re-evaluated (Cobine et al., 2006a; Lutsenko, 2010), however, the importance of Cox17 to 
cell  survival  (Takahashi et  al.,  2002) has not  been disputed.  To better  understand parasite 
copper pathways and homoeostasis, the Cox17 sequence was studied. Eight species of the 
Plasmodium parasite contained Cox17 metallochaperone sequences, suggesting a conserved 
presence and role for this protein. ClustalWTM alignment of the  Plasmodium sequences, with 
other  Cox17  sequences,  highlighted essential  and  conserved  motifs  that  are  important  to 
protein function  (Figure 3.4). These include the CysCysXaaCys motif, which coordinates the 
cuprous ion  to Cox17  (Abajian et  al.,  2004),  plus  additional  cysteine residues required for 
structural  disulfide  bond  formation  (Figure  3.5).  From  the  homology  model  for  PfCox17  it 
appears that these conserved cysteine residues adopt a similar conformational orientation to 
the corresponding residues in human Cox17, resulting in  PfCox17 forming a coiled coil-helix-
coiled  coil  helix  structural  motif  (Figure  3.5b  and  c).  This  is  a  common feature  of  related 
mitochondrial  proteins  (Barros et  al.,  2004;  Nobrega et  al.,  2002),  which  suggests  that 
Plasmodium Cox17 is likely to be involved in copper delivery to the parasite mitochondrion. 
This modelling project was, however, prepared on a rudimentary level and thus requires further 
analysis to confirm the observed and inferred result.
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Each Plasmodium Cox17 sequence was further examined for the presence of potential signal 
sequences and transmembrane regions.  Characterisation of  S. cerevisiae Cox17 found the 
protein to be localised to the cell cytosol as well as the inner mitochondrial space (Beers et al., 
1997). A signal sequence directing the protein to the inner mitochondrial space is, however, 
absent raising the question as to how Cox17 is directed to the mitochondrion. Only recently 
was  a  possible  mechanism  behind  this  targeting  action  identified.  Through  a  unified 
electrospray ionization mass spectrometry (ESI-MS) based strategy it was demonstrated that 
Cox17, amongst other copper chaperones, is driven toward its partner proteins by exploiting 
gradients of increasing copper binding affinity (Banci et al., 2010). Thus an absence of a signal 
peptide in the retrieved Plasmodium sequences would, to some degree, support the likelihood 
of these proteins being representative of Cox17 metallochaperones. Additionally, Cox17 is not 
known  to  anchor  to  cell  or  mitochondrial  membranes,  therefore  the  absence  of  long 
hydrophobic  stretches  of  amino  acids  was  expected.  Each  sequence  was  systematically 
analysed by SignalP,  PlasmoAP, PlasMit  (Bender et  al.,  2003), TMHMM and HMMTOP. As 
predicted,  none of  the retrieved sequences returned a positive result  for  any of  the above 
evaluations. Overall, the presence of both the Cox17 copper chaperone and copper transport 
protein supports a physiological need for copper by the malaria parasite.
3.3.2 Chromosomal location of the copper transporter and Cox17 coding domains 
Due  to  the  considerable  length  variation  of  P.  falciparum chromosomes,  the  majority  of 
research has focussed on elucidating subtelomeric structure and function as well as the roles of 
the encoded proteins (Kyes et al.,  2001). Consequently, the remainder of the chromosome is 
left  relatively  poorly  defined  (Gardner et  al.,  2002;  Kooij et  al.,  2005).  Recently,  though, 
candidate  centromeres were  identified  for  all  14  P.  falciparum chromosomes.  Centromeres 
were defined as regions approximately 2 kb long, with extremely high A+T content (>97%) and 
imperfect short tandem repeats (Kelly et al., 2006). The location of the candidate centromeres 
was inferred as being indicative of the probable “core” region of each parasite chromosome. 
This “core” region has been found to contain a number of conserved gene orthologs in other 
parasite species, suggesting an important role for these proteins in parasite metabolism (Hall et  
al., 2005). For example, the coding domain for the essential enzyme lactate dehydrogenase is 
found in the “core” region of P. falciparum chromosome 13. The relative position of this coding 
domain  appeared  to  be conserved within  a  predicted  “core”  of  other  Plasmodium species' 
chromosomes (data not shown), thereby supporting the notion that gene conservation within 
the  chromosome  “core”  suggests  importance  to  parasite  metabolism.  The  chromosomal 
location of the copper transporter and Cox17 coding domains was therefore assessed to see if 
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they reside in the “core” of the respective chromosomes to which they are localised.
For  the  P.  falciparum parasite,  both  copper  transporter  coding  domains  are  localised  to 
chromosome 14 (Figure 3.3) whereas the Cox17 coding domain is found on chromosome 10 
(Figure 3.6). For these respective chromosomes the candidate centromere of chromosome 14 
was more confidently identified than that for chromosome 10 (Kelly et al., 2006). The respective 
coding domains, for both copper transporters and Cox17, were found to be in close proximity to 
the  predicted  centromeres.  This  gene  localisation  appeared  conserved  amongst  the  other 
Plasmodium species  analysed.  As  indicated,  the  chromosomal  position  of  a  selected 
Plasmodium parasite gene can serve to indicate the potential importance of the protein for the 
parasite.  Localisation  to  the  subtelomeric  or  telomeric  domains  is  suggestive  of  a  gene 
encoding a protein necessary for antigenic variation and therefore undergoing a high turnover 
rate. On the other hand, genes with a more centromeric localisation are presumed to encode 
for metabolically essential proteins. Through this reasoning it was inferred that the localisation 
of both P. falciparum copper transporter and Cox17 coding domains suggests an important role 
for these proteins to the parasite.
3.3.3 Phylogenetic analysis of the Plasmodium copper transporter and Cox17 amino acid 
sequences
Phylograms of the copper transporter and Cox17 sequences showed that in both instances the 
Plasmodium species formed a distinct clade (Figure 3.8 and 3.9), confirming their affiliation to 
the same genus. This was, however, more apparent for the copper transport proteins since the 
rodent-infecting parasites form a separate, but closely related branch for the analysis of Cox17 
(Figure 3.9). A similar observation has been made for other parasite proteins, suggesting that 
these species  do not  cluster  closely  with other  Plasmodium related clades  (Escalante and 
Ayala,  1994).  Rodent-infecting  Plasmodium  species  are,  however,  known  to  show  a 
monophyletic relation with respect to one another (Perkins and Schall, 2002), as was observed 
for both analyses. Regarding the relationships seen for the other species, it was noted that the 
results for the copper transporter and Cox17 were similar to results obtained from studies of the 
Plasmodium small subunit rRNA (Rathore et al., 2001; Escalante and Ayala, 1994). From these 
studies it  was identified that  P. falciparum is  monophyletic with  P. reichenowi but  shares a 
distant common ancestor with the avian parasite P. galinaceum. Furthermore it was found that 
P. vivax is only distantly related to  P. falciparum and generally clusters with monkey-infecting 
species P. knowlesi (Rathore et al., 2001; Escalante and Ayala, 1994), which is again similar to 
the results seen from both analyses. A close relationship between P. vivax and P. knowlesi is 
also in agreement with the recent findings that P. knowlesi can infect humans with a potentially 
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fatal outcome (Cox-Singh et al., 2010).
 
The respective  Plasmodium sequences were also compared to other copper  transporter  or 
Cox17  metallochaperone  protein  sequences  from  an  unrelated  organism.  Considering  the 
Apicomplexan parasites are evolutionarily distant from the Chordates (Templeton et al., 2004), 
it  was not  surprising that  shown on a separate and distantly related branch was a cluster 
containing  H. sapiens,  M. musculus,  R. norvegicus and  D. rerio  (Figure 3.8 and 3.9). This is 
also in agreement with the taxonomic relationships established between these organisms, by 
both morphological and sequence comparisons  (Baldauf et al., 2000; Gardner et al.,  2002). 
Both phylograms also suggest a close evolutionary relationship between the A. thaliana Copt1 
sequence  and  the  Plasmodium species  (Figure  3.8),  supporting  the  suggestion  that  the 
genome of P. falciparum is more similar to that of A. thaliana than to other taxa (Gardner et al., 
2002). However, this relationship was less evident from an analysis of Cox17 (Figure 3.9). For 
the  copper  transporter  sequences  (Figure  3.8)  a  direct  relation  was  seen  between  the 
Plasmodium species  and  another  Apicomplexan  parasite,  T.  parva.  The  Cox17  sequences 
showed  a  slightly  differing  result  (Figure  3.9),  but  both  parasites  still  indicated  a  close 
relationship.
3.3.4 Peptide selection
It has previously been demonstrated that a novel protein can be identified through an initial in 
silico  analysis, followed by a biochemical and genetic characterisation (Reininger et al., 2005; 
Dorin et al., 2005). To assist with the characterisation of the identified proteins, anti-peptide 
antibodies were to be generated. By using the Predict7TM algorithm (Cármenes et al., 1989), 
peptides were selected from each of the three putative copper transport proteins (Figure 3.10) 
as well  as the two Cox17 metallochaperones (Figure 3.11).  The synthesised peptides were 
conjugated  to  a  rabbit  albumin  carrier  protein  for  injection  into  chickens.  The  resulting 
antibodies  were  to  be used  for  immunolocalisation  of  the  respective  proteins.  Establishing 
protein  location  will  be  important  to  understanding  protein  function,  particularly  for  the  P. 
falciparum  copper transporters, since each transporter is predicted to be located in different 
parasite  membranes.  PF14_0211  is  predicted  to  be  targeted  to  the  parasite  membrane 
whereas PF14_0369 is predicted to be targeted to the apicoplast membrane. This difference, in 
predicted location, suggests PF14_0211 could function to acquire extracellular copper whilst 
PF14_0369 might be involved in mobilising copper stores. Similar roles have been predicted for 
the human copper transporters Ctr1 and Ctr2 (Rees et al., 2004; van den Berghe et al., 2007). 
In  addition,  establishing  the  membrane  orientation  of  the  copper  transporters  will  help 
determine  the  directional  transport  of  each  protein.  This  could  be  achieved  by  generating 
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antibodies against a peptide from the transporter's carboxyl terminus to be used in conjunction 
with  the  anti-peptide  antibodies  generated  against  the  peptide  selected  from  the  amino 
terminus. A similar approach has been used to establish the orientation of human Ctr1 (Klomp 
et al., 2003).
Mechanisms  for  Plasmodium parasite  copper  homoeostasis  were  suggested  following  the 
identification of  a  P.  falciparum  copper  efflux protein  (Rasoloson et  al.,  2004).  Until  now a 
dedicated mechanism for  parasite  copper  acquisition  has not  been established.  A BLASTp 
search of PlasmoDB identified sequences corresponding to putative copper transport proteins 
in eight species of the  Plasmodium parasite. Each of these sequences was found to contain 
sequence  features  common  to  other  copper  transporters.  Also  identified,  from  a  BLASTp 
search, were a number of putative metallochaperone proteins, including Cox17. An analysis of 
the parasite Cox17 metallochaperone sequences identified amino acids conserved amongst 
the characterised yeast and mammalian Cox17 proteins suggesting a conservation of protein 
function.  To establish native expression and localisation,  of  these copper-requiring  parasite 
proteins, anti-peptide antibodies were to be raised against peptides selected from the identified 
P. yoelii and  P. falciparum protein orthologs. Establishing putative protein function was to be 
achieved by recombinantly expressing the amino terminal domain of the putative Plasmodium 
copper transporter to determine its ability to bind copper. A similar copper binding study was to 
be carried out using a recombinant form of the full-length Plasmodium Cox17 ortholog.
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CHAPTER 4
The Plasmodium spp. putative copper transport protein: Native protein expression and 
copper binding studies with the recombinant amino-terminal domain
4.1 Introduction
The  high  redox  activity  of  copper  has  resulted  in  mammalian  and  yeast  cells  developing 
complex systems to maintain and control cellular copper levels  (Kim et al., 2008; Rae et al., 
1999;  Rosenzweig,  2002).  In silico  identification of a putative  Plasmodium  copper transport 
protein and associated metallochaperones (Chapter 3) suggests that similar pathways may be 
present  to  maintain  Plasmodium parasite  copper  homeostasis.  PCR  amplification  and 
sequencing  of  the  genes  predicted  to  encode  each  parasite  protein  enables  recombinant 
expression of these proteins for functional studies. Successful PCR amplification also suggests 
the  presence  of  a  native  coding  domain  for  the  corresponding  protein.  Native  protein 
expression,  in  the  parasite,  can  then  be  confirmed  through  specific  anti-peptide  antibody 
recognition.  This  approach  has  proven  successful  for  the  characterisation  of  Plasmodium 
protein kinases (Dorin et al., 2005; Merckx et al., 2003), lactate dehydrogenase (Hurdayal et  
al.,  2010) and  membrane-bound  transport  proteins  (Narum et  al.,  2001;  Rasoloson et  al., 
2004).
The structural properties and function of a protein, having a hypothetical function, can only be 
confidently  inferred  from  biochemical  and  cell  biological  experimentation.  This  requires 
relatively  large quantities  of  the  protein,  which are  difficult  to  obtain  from a native  cell  by 
standard  protein  isolation  methods.  Consequently  systems  have  been  developed  for  the 
heterologous expression of target proteins. One expression system, which still remains one of 
the most attractive, is the Gram-negative bacterium Escherichia coli. The attraction of E. coli is 
its  ability  to  rapidly  multiply  to  high  cell  densities  on  inexpensive  substrates,  its  well 
characterised genetics and the availability of numerous plasmid vectors and mutant host strains 
(Baneyx, 1999). The E. coli system has also been successfully used for the characterisation of 
numerous Plasmodium protein kinases (Dorin et al., 2005; Merckx et al., 2003; Nunes et al., 
2007), glycolytic enzymes (Brady and Cameron, 2004; Turgut-Balik et al., 2004; Winter et al., 
2003) and surface-related proteins (Narum et al., 2001; Rasoloson et al., 2004; Rodrigues et  
al., 2003).
Identification of the genes encoding mammalian copper transport proteins made use of a yeast 
functional complementation system (Lee et al., 2000; Zhou and Gitschier, 1997). This system 
employs mutant  S. cerevisiae cells lacking high affinity copper uptake due to  Ctr1 and  Ctr3 
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gene inactivation (Lee et al., 2000; Zhou and Gitschier, 1997).  Hence a restoration of normal 
cell growth to mutant cells, transfected with the candidate gene, confirmed the gene encoded a 
protein functioning as a copper transporter. Using a similar approach it would seem likely that 
the function of  the protein encoded by the candidate  Plasmodium copper  transporter  gene 
could  be  confirmed.  However,  a  setback  to  this  approach  is  the  finding  that heterologous 
expression of full length Plasmodium membrane proteins is difficult (Krishna et al., 2001; Martin 
et al.,  2009a; Vedadi et  al.,  2007). Consequently  the recombinant expression of  the amino 
terminal  copper-binding  domain  of  the  Plasmodium  copper  transporter  was  selected.  This 
extracellular domain is predicted to be important for copper acquisition as well as for copper 
access to and from the pore of the characterised copper transporters  (De Feo et al., 2009; 
Jiang et al., 2005; Larson et al., 2010).
Knowledge of the pathways for copper homoeostasis in the Plasmodium parasite is limited. It 
has, however, been demonstrated that the parasite requires intracellular  copper for survival 
(Meshnick et al., 1990; Rasoloson et al., 2004). A dedicated mechanism for copper acquisition 
has, however, not yet been characterised. Through an  in silico based approach, a sequence 
corresponding to a putative Plasmodium copper transport protein was identified (Section 3.2.2). 
These proteins are known to function as the primary regulators of copper access into cells 
(Dancis et al., 1994; Lee et al., 2000; Zhou and Gitschier, 1997). This study therefore aimed to 
confirm the presence of native P. berghei and P. falciparum copper transporter coding domains, 
and their  corresponding proteins,  using PCR and anti-peptide  antibody based approaches, 
respectively. Furthermore protein function was to be inferred from in vitro and in vivo copper-
binding studies  using a  recombinant  amino-terminal  domain  of  both  the  P.  berghei and  P. 
falciparum proteins.
4.2 Results
4.2.1  Confirmation  of  a  putative  Plasmodium copper  transporter  coding  domain 
sequence
Initial  attempts  at  identifying  a  parasite  copper  transporter  coding  domain,  as  well  as  the 
encoded native protein, made use of the rodent-infecting malaria parasite model. This model 
parasite serves as a useful comparative tool as it is capable of reproducing much of the biology 
of human malaria parasites (Carlton et al., 2002; Hall et al., 2005; van Lin et al., 2001). In the 
first instance,  P. yoelii parasite DNA was isolated from parasitised BALB/c mouse blood and 
used  as  a  template  for  amplification  of  the  putative  copper  transporter's  full-length  coding 
domain by PCR. The target sequence was predicted to contain two introns and three protein-
coding exons (data not shown), producing a sequence approximately 1791 bp long. Agarose 
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gel analysis of the PCR amplicons revealed a product approximately 1800 bp in size (Figure 
4.1a), corresponding to the predicted size. PCR amplification of the LDH coding domain was 
included as a positive control with an amplification product approximately 815 bp in size (Figure 
4.1a).  This amplicon was in agreement with the predicted size of  the targeted LDH coding 
domain region. As a further control, DNA was isolated from uninfected BALB/c mouse blood 
and used as a template for PCR amplification. All reactions using this template DNA returned 
negative results (data not shown).
Figure 4.1 PCR and reverse transcriptase-PCR amplification of the coding domains for putative P. yoelii and 
P. berghei copper transporters
A PCR amplification, from P. yoelii genomic DNA, of the coding domains for lactate dehydrogenase (lane 1) and the 
putative copper transport protein (lane 3). Lanes 2 and 4 are controls using DNA isolated from uninfected mouse 
blood. B Nested PCR of the putative P. yoelii copper transport protein coding region. Lane 1 primary PCR product, 
lane 3 secondary PCR from lane 1. Lanes 2 and 4 negative controls. C BamHI digestion to support P. yoelii amplicon 
identity. Lane 1, gel purified amplicon of the putative  P. yoelii  copper transporter coding region. Lane 2,  BamHI 
digestion of lane 1 amplicon with arrows highlighting digested products. The upper arrow in lane 2 is 1050 bp, lower 
arrow 750 bp. D Reverse transcriptase-PCR amplification, from P. berghei RNA, of the coding domains for the amino 
terminus of a putative P. berghei copper transporter (lane 1) and for LDH (lane 2). All PCR products were analysed 
on 1% (w/v) agarose gels. Molecular mass markers (M) are on the left of each gel (see materials and methods for 
details).
The identity of the P. yoelii 1800bp amplicon was supported by nested PCR (Figure 4.1b) and 
BamHI enzyme digestion (Figure 4.1c). For nested PCR, a 2700bp region encompassing the 
predicted copper transporter coding domain was amplified from genomic DNA and from this the 
1800bp  product  was  amplified  (Figure  4.1b).  The  1800bp  amplicon  was  subsequently  gel 
purified  and  digested  with  BamHI.  BamHI  digestion  yielded  two  products  (Figure  4.1c),  of 
1050bp and 750bp, which corresponded well with the predicted sizes. For functional studies of 
the  murine  malaria  parasite's  copper  transporter,  the  predicted  amino  terminus  was  to  be 
recombinantly expressed and its copper binding ability assessed. Since the number of copper 
transporters encoded by the P. berghei  and P. falciparum genomes is similar,  P. berghei was 
selected as the murine malaria parasite model organism. The relevant portion of the P. berghei 
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copper transporter's coding domain was therefore amplified by reverse transcription-PCR (RT-
PCR)  from  a  P.  berghei RNA pool.  Amplification  yielded  a  450bp  product  (Figure  4.1d), 
indicating native transcription of the targeted coding domain. As before, amplification of the 
LDH coding domain served as a positive control and yielded a product of the expected size. 
The putative copper transporter amino terminal amplicon was ligated into the pGEM®-T vector 
and  sequenced. Sequencing  data  correlated  well  with  the  P.  berghei  nucleotide  sequence 
available at PlasmoDB, showing 99% identity (Figure 4.2). In silico translation of this sequence 
yielded  an  amino  acid  sequence  with  98% identity  to  the  PlasmoDB sequence  (data  not 
shown).
PbCtrNt_vect      ATGAATATATGGAAAATTATATATATTGTTTTAATTATAAACTCTTCATTTGTGGTGAAT 60
PbCtrNt_plas      AAGAATATATGGAAAATTATATGCATTGTTTTAATTATAAACTCTTCATTTGTGGTAAAT 60
                  * ********************  ******************************** ***
PbCtrNt_vect      GTAAATTGTGAGTCCAATGATAAAAATGATGATACTAAAAACAACAAAAATATGGGTTGT 120
PbCtrNt_plas      GTAAATTGTGAGTCCAATGATAAAAATGATGATACTAAAAACAACAAAAATATGGGTTGT 120
                  ************************************************************
PbCtrNt_vect      GGTGGTGGTACTAATAAATCACTGCCATCCGTAAACAAACCGCTAAATAGTTGTTGCAGT 180
PbCtrNt_plas      GGTGGTGGTACTAATAAATCACTGCCATCCGTAAACAAACCGCTAAATAGTTGTTGCAGT 180
                  ************************************************************
PbCtrNt_vect      GGTAAACGATCGGGAAATGATGAGTGCAAACCAATATTAGATCTCAATCACATAGGAAGT 240
PbCtrNt_plas      GGTAAACGATCGGGAAATGATGAGTGCAAACCAATATTAGATCTCAATCACATAGGAAGT 240
                  ************************************************************
PbCtrNt_vect      GAAGGCAAAAACAAAATTCCATTTATTTACAAATGCTGTATAAATCATGATACATATGAA 300
PbCtrNt_plas      GAAGGCAAAAACAAAATTCCATTTATTTACAAATGCTGTATAAATCATGATACATATGAA 300
                  ************************************************************
PbCtrNt_vect      AACATAATTAATGAGCACTTTAATGAAGAAAATCAAAACAATGCAACCGATGCCCCCAAA 360
PbCtrNt_plas      AACATAATTAATGAGCACTTTAATGAAGAAAATCAAAACAATGCAACCGATGCCCCCAAA 360
                  ************************************************************
PbCtrNt_vect      AAATTGAATATGATGATGAGTGATTTATCTATGCCTATGTCATTTCAGAATACTACCCAT 420
PbCtrNt_plas      AAATTGAATATGATGATGAGTGATTTATCTATGCCTATGTCATTTCAGAATACTACCCAT 420
                  ************************************************************
PbCtrNt_vect      ACTATTATTTTATTCAAATTTTGGGAA 447
PbCtrNt_plas      ACTATTATTTTATTCAAATTTTGGGAA 447
                  ***************************
Figure 4.2  Alignment of the RT-PCR amplified putative  P. berghei copper transporter's  amino terminus 
coding sequence with the PlasmoDB sequence
The  sequenced  P.  berghei copper  transport  protein  amino-terminus  (PbCtrNt_vect)  and  PlasmoDB  sequence 
[PbCtrNt_plas  (PBANKA_130290)]  were  aligned  with  the  ClustalW  program 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Using a similar approach, the putative  P. falciparum  copper transporter coding domain was 
amplified. Here, both the full length and amino terminus coding domains were targeted, whilst 
amplification  of  the  LDH coding domain  served as  a  positive  control.  A LDH product  was 
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amplified from the  P. falciparum  genome that was approximately 820bp in size (Figure 4.3), 
which was similar  to  the  results  obtained for  P.  yoelii  and  P.  berghei  (Figure  4.1).  Having 
identified that two potential copper transport proteins are expressed by P. falciparum (Section 
3.2.2), it was necessary to probe for the presence of both coding domains (PF14_0211 and 
PF14_0369) in the parasite genome. Agarose gel analysis of the respective PCR reactions 
indicated amplification products of approximately 410bp for the full length PF14_0211 domain 
and 890bp for the full length PF14_0369 domain (Figure 4.3). The size of each PCR product 
corresponded well  with  the predicted sizes  of  each  coding domain,  which were 423bp  for 
PF14_0211 and 920bp for PF14_0369. Since  P. falciparum  DNA was isolated from cultured 
parasites, the PCR control used in this instance was a reaction containing no template. These 
control reactions produce no amplicons (data not shown).
Figure  4.3 PCR amplification  of  the  coding  sequences  for  two  putative  P.  falciparum copper  transport 
proteins and their predicted amino termini
The full-length and amino terminus coding domains for PF14_0211  (lanes 3 and 4, respectively) and PF14_0369 
(Lanes 1 and 2, respectively) were PCR amplified from P. falciparum  genomic DNA and analysed on a 1% (w/v) 
agarose gel. Lane 5 is the P. falciparum LDH control. Molecular mass markers (M) are shown to the left of the gel 
(See materials and methods for details). 
To confirm the identity of the P. falciparum amplicon, the amplicons corresponding to the amino 
termini  of  the putative  P.  falciparum copper  transporters were cloned and sequenced.  The 
PF14_0211 amplicon was approximately 150bp and the PF14_0369 amplicon 290bp (Figure 
4.3), which was in agreement with the predicted sizes.  Sequencing of each product identified 
that both amplicons corresponded well with the respective PlasmoDB sequences, with 98% 
identity for PF14_0211 and 100% for PF14_0369 (Figure 4.4).  In silico translation of  these 
sequences  yielded  amino  acid  sequences  with  97% and  100% identity  to  the  PlasmoDB 
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A.
PfCtr211Nt_vect      TTCACTTTCGATTTTGTGAGCAGCAGTTGTTGTCATTCAAAAAATGACGATGGAGTTATG 60
PfCtr211Nt_plas      TTCACTTTCGATTTTGTGAGCAGCAGTTGTTGTCATTCAAAAAATGACGATGGAGTTATG 60
                     ************************************************************
PfCtr211Nt_vect      TTACCTATGTATTTTTCAAATAATGGAAATATAAAAATGTTATTTGACATATTTCAAGTA 120
PfCtr211Nt_plas      TTACCTATGTATTTTTCAAATAATGAAAATATAAAAATGTTATTTGACATATTTCAAGTA 120
                     ************************* **********************************
PfCtr211Nt_vect      AAAAAT 126
PfCtr211Nt_plas      AAGAAT 126
                     ** ***
B.
PfCtr369Nt_vect      GACAAAAGCGACAATAGTATTTGTAAACCTTCTGTTAAAATATCATGTGCTCACAATTGT 60
PfCtr369Nt_plas      GACAAAAGCGACAATAGTATTTGTAAACCTTCTGTTAAAATATCATGTGCTCACAATTGT 60
                     ************************************************************
PfCtr369Nt_vect      TGTAAGAATAAATTATCTTTTATGTATAATTGTTGGAAACACTATGATAAATATAGTAAT 120
PfCtr369Nt_plas      TGTAAGAATAAATTATCTTTTATGTATAATTGTTGGAAACACTATGATAAATATAGTAAT 120
                     ************************************************************
PfCtr369Nt_vect      ATAATAAAAGATAATTTACAAAAAGAAGAAGATACAGTTGTTCAATTACAAGATCATGAT 180
PfCtr369Nt_plas      ATAATAAAAGATAATTTACAAAAAGAAGAAGATACAGTTGTTCAATTACAAGATCATGAT 180
                     ************************************************************
PfCtr369Nt_vect      AATATTGATATTGTCGAACATGTTGAAACTATGCCAATGTCCTTTCAGCTGACTACACAC 240
PfCtr369Nt_plas      AATATTGATATTGTCGAACATGTTGAAACTATGCCAATGTCCTTTCAGCTGACTACACAC 240
                     ************************************************************
PfCtr369Nt_vect      ACAATTATTTTATTTAACAAATGGGAAACCAAATCG 276
PfCtr369Nt_plas      ACAATTATTTTATTTAACAAATGGGAAACCAAATCG 276
                     ************************************
Figure 4.4  Alignment of the sequenced amplicons for PF14_0211 and PF14_0369 putative copper transport 
protein amino terminus coding domains with the PlasmoDB sequences 
A PF14_0211  (PfCtr211Nt_vect)  and  B PF14_0369  (PfCtr369Nt_vect)  amino  termini  amplicons.  PlasmoDB 
sequences are PfCtr211Nt_plas and PfCtr369Nt_plas,  respectively.  Sequences were aligned using the ClustalW 
program (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
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4.2.2  Immunolocalisation  of  the  murine  and human malaria  parasite  putative  copper 
transporters
Detection  of  the  native  parasite  copper  transport  protein  employed  antibodies  generated 
against peptides designed in Section 3.2.8 (Figure 3.10).
4.2.2.1 Anti-peptide antibody production
Figure 4.5 Anti-peptide antibody responses against the CSD, PMY and LQD peptides over 12 weeks  
Anti-peptide antibody production against the CSD (A), PMY (B), and LQD (C) peptides was monitored by ELISA over 
a 12 week period.  In all panels peptide-specific antibody production is shown for for chicken 1 (▬) and chicken 2 
(▬). Also shown is the antibody production against the rabbit albumin carrier for chicken 1 (▬) and chicken 2 (▬).
Antibody titres against each peptide were monitored by ELISA over a 12-week period. For both 
the CSD (Figure 4.5a) and LQD (Figure 4.5c) peptide conjugates, one chicken was found to 
produce a poor antibody response. For the PMY peptide conjugate both immunised chickens 
appeared to produce similar and relatively strong antibody responses (Figure 4.5b).  For all 
three peptides, the antibody response was detectable around week four, peaking at week eight 
and tailing off by the end of week twelve (Figure 4.5). Anti-peptide antibody titres followed a 
similar  pattern  to  the  antibody  titres  against  the  rabbit  albumin  carrier  protein.  Following 
antibody production the chicken antibodies were isolated from egg yolks, pooled and affinity 
purified on a peptide-specific matrix. Bound antibodies were eluted from the matrix (Figure 4.6) 
and pooled for  each respective peptide.  Antibodies generated against  the putative  P. yoelii 















































copper  transporter  peptide  (CSD)  were  also  expected  to  recognise  the  corresponding  P. 
berghei protein,  since only  three of  the  16 amino acids  in  this  peptide  are not  conserved 
between species. The final yield for the copper transporter antibodies was 3.78 mg for anti-
CSD, 12.1 mg for anti-PMY and 13.4 mg for anti-LQD antibodies.
Figure 4.6 Affinity purification profiles for anti-CSD, -PMY, and -LQD antibodies 
Representative purification profiles of antibodies raised against the CSD (A), PMY (B) and LQD (C) peptides are 
shown above. Shown in all panels are the purification profiles for antibodies purified from eggs collected 4 to 8 
weeks post-inoculation of chicken 1 (▬) and chicken 2 (▬). 
4.2.2.2 Detection and localisation of the malaria parasite copper transporters
The  amplification  of  putative  murine  malaria  parasite  copper  transporter  coding  domains 
(Figure  4.1),  in  particular  the  RT-PCR amplification  and sequencing of  a portion  of  the  P. 
berghei  coding domain, supports the idea of native expression of a malaria copper transport 
protein. It is, however, important to confirm expression through detection of the native protein. 
As mentioned, this was to be achieved using anti-peptide antibodies produced for this study 
(Section 4.2.2.1). Infected red blood cell lysate was prepared and separated into soluble and 
insoluble  fractions  (Section  2.5.2),  separated  on  a  10%  SDS-polyacrylamide  gel  and 
transferred to a nitrocellulose membrane (Figure 4.7). As a control, a pan-specific anti-peptide 
antibody against parasite LDH was used to probe the soluble, “cytoplasmic” fraction. The anti-
LDH  antibody  detected  a  band  in  the  soluble  fraction  at  approximately  35  kDa,  which 
corresponded with its predicted size and location (Figure 4.7b).  For detection of a putative 
murine malaria parasite copper transporter, a blot of P. yoelii lysate was probed with anti-CSD 
antibodies generated against a peptide in the protein's amino terminus. A prominent protein 
band  was  detected  at  approximately  32  kDa  (Figure  4.7c),  corresponding  well  with  the 
predicted size of  the putative transporter.  In contrast  to LDH, the band corresponding to a 
putative  copper  transporter  was  only  present  in  the  insoluble  fraction.  This  suggests  a 
membrane association for the transport protein. Importantly neither protein was detected in the 
uninfected mouse red blood cell lysate.










































Figure  4.7 Anti-peptide  antibody detection  of  lactate  dehydrogenase  and the  putative  copper  transport  
protein in P. yoelii infected mouse red blood cell lysate.
P. yoelii infected BALB/c mouse red blood cell  lysate was separated into soluble (lane 2) and insoluble (lane 3) 
fractions and analysed with uninfected lysate (lane 1) by 10% SDS-PAGE (A). Western blot of A probed with a pan-
specific LDH anti-peptide antibody (B) or the copper transporter specific (CSD) anti-peptide antibody (C). Molecular 
mass markers (M) are indicated on the left of each image (see materials and methods for details).
To confirm native expression and verify localisation of this putative transporter, the anti-CSD 
anti-peptide  antibodies  were  used  for  immunofluorescent  microscopy  studies  (Figure  4.8). 
Murine malaria parasites were again used as the initial model organism, with the pan-specific 
anti-LDH antibodies providing a reference and internal control. For LDH, the green fluorescent 
signal appears to be localised to the parasite cytoplasm (Figure 4.8a) whereas the putative 
copper transporter signal appears to be associated with the periphery of the parasite (Figure 
4.8b). The stage of parasite development captured for LDH appears to be representative of the 
trophozoite stage of parasite development  (Bannister et al., 2000). Expression of LDH at this 
stage is predicted to be relatively abundant  (Figure 3.8a) and the strong fluorescent  signal 
obtained  supports  this.  For  the  copper  transport  protein,  the  fluorescent  signal  was 
predominantly visible at the ring and trophozoite stages of parasite development. This clear 
difference in the signals obtained for LDH and the transporter, suggests different sites of protein 
localisation. Localisation of the putative copper transporter's fluorescent signal to the periphery 
of the parasite suggests a probable association with a parasite membrane. Such an association 
could be predicted since three putative transmembrane domains were identified in the protein's 
amino acid sequence (Figure 3.3).  However, the location of the putative copper transporter 
could not be confirmed since another antibody, specific to a well  characterised membrane-
bound transport protein, was not available. The blue fluorescent signal, visible in all panels of 
figure 4.8, is a result of DAPI staining of parasite genomic DNA. Control experiments using 


























Figure 4.8 Anti-peptide antibody localisation of lactate dehydrogenase and the putative copper transport 
protein in P. yoelii infected mouse blood by immunofluorescent microscopy
A Localisation of lactate dehydrogenase (LDH) and  B the putative copper transport protein in  P. yoelii  infected 
mouse red blood cells. LDH was detected with pan-specific anti-peptide antibodies and the copper transporter with 
anti-CSD  anti-peptide  antibodies.  Primary  antibodies  were  detected  with  a  donkey  anti-chicken  IgY  antibody 
conjugated to  fluorescein isothiocyanate (FITC).  Nuclear  material  was stained with  4,6-diamidino-2-phenylindole 
(DAPI).
Since the rodent-infecting Plasmodium species serve as useful research models (Carlton et al., 
2002; Hall et al., 2005; van Lin et al., 2001), detection and localisation of a putative copper 
transporter within the P. yoelii parasite infers the expression of the P. falciparum ortholog. Anti-
peptide antibodies raised against the two  P. falciparum copper transporters (Section 4.2.2.1) 
were therefore used in  blotting and immunofluorescent microscopy studies to confirm protein 
expression  and  location.  However,  attempts  to  detect  the  native  P.  falciparum copper 
transporters by western blot proved unsuccessful  (P.  falciparum D10 frozen parasite culture 
was obtained from Professor P.J. Smith, Division of Clinical Pharmacology, University of Cape 
Town, South Africa). Even when the more sensitive enhanced chemiluminescence (ECL) assay 
was employed, a positive signal was not attainable. Similarly, detection of the native proteins by 
immunfluorescence was not possible since a  P. falciparum culture has not established in the 
research facilities used for this study.
4.2.3  Recombinant  expression  of  the  putative  P.  berghei  and P.  falciparum  copper 
transport protein amino terminal domains
The approach adopted in this study was to recombinantly express the amino terminal domain of 
the putative Plasmodium copper transport protein for use in copper binding experiments. This 





Feo et al., 2009; Larson et al., 2010), particularly under copper-limiting conditions (Eisses and 
Kaplan, 2002; Puig et al., 2002a). A similar approach was also adopted for the characterisation 
of human and  P. falciparum proteins predicted to function in the efflux of excess intracellular 
copper  (Lutsenko et  al.,  1997;  Ralle et  al.,  2004;  Rasoloson et  al.,  2004).  These  studies 
demonstrated the ability of a recombinant amino terminus to bind copper, thereby supporting 
the protein's predicted function. The steps involved in the preparation of the expression vectors 
used in this study are summarised in Figure 4.9.
Figure 4.9 Cloning and sub-cloning strategies for the recombinant expression of Plasmodium spp. proteins
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For the recombinant  expression of  the  putative  P. berghei copper transport  protein's amino 
terminus (PbCtrNt), a 447bp product was amplified by RT-PCR (Figure 4.1d), gel purified and 
ligated  into  the  pGEM®-T cloning  vector  (Figure  4.9).  Following  transformation  into  E.  coli 
JM109 cells, positive colonies were identified by blue:white colony screening and confirmed by 
colony PCR. Positive colonies were grown in Luria-Bertani (LB) broth, the plasmid isolated and 
the insert excised by restriction digestion with either  EcoRI and  NotI (pET23a/pGex-4T-1) or 
EcoRI  and  PstI  (pMal-c2/-p2).  The  excised  fragment  was  gel  purified  and  ligated  into  an 
expression  vector  digested  with  the  appropriate  restriction  enzymes.  Initial  attempts  at 
recombinant  expression  of  PbCtrNt made  use  of  the  pET23a  vector  transformed  into 
Escherichia  coli BL21(DE3)pLysS  cells.  Successful  recombinant  protein  expression  was 
confirmed from an analysis of the fractionated cell  lysate on a SDS-polyacrylamide gel and 
western blot (Table 4.1). Although expression was successful, the expressed product was found 
in bacterial inclusion bodies. This result indicates protein misfolding and therefore required that 
the recombinant protein be refolded in vitro to obtain a soluble product. Refolding is, however, 
considered relatively undesirable due to poor recovery, the necessity for extensive optimisation 
of  refolding conditions and the possibility  that  the resolubilisation procedure may affect  the 
integrity of the refolded protein (Sørensen and Mortensen, 2005b). Consequently, recombinant 
expression  using  the  soluble  glutathione  S-transferase  (GST)  and  maltose  binding  protein 
(MBP) fusion partners was a more desirable option. 
Table 4.1 Recombinant expression of the amino terminal domain of the putative P. berghei copper 





Recombinant protein Western blot detection
Soluble Insoluble Periplasmic α-CSD α-His α-GST α-MBP
pET23a BL21(DE3) pLysS No Yes n/a + + n/a n/a
pGex-4T-1 BL21 No Yes n/a + n/a + n/a
pMal-c2 JM103/BL21 Yes Partial n/a + n/a n/a +
pMal-p2 JM103 Yes Partial No + n/a n/a +
Although  the pMal-c2  and  pMal-p2  PbCtrNt  MBP-fusions  were predominantly  produced  as 
soluble products (Table 4.1 and Figure 4.10), fusion of PbCtrNt to GST was still produced as an 
insoluble  product  (Table  4.1).  However,  expression  of  the  pMal-p2  construct  produced  an 
unexpected result. Expression of a fusion protein using the pMal-p2 vector is expected to result 
in protein targeting to the cell  periplasm (NEB pMal Manual). In this instance, however, the 
expressed  protein  (MBP-PbCtrNt)  was  retained  in  the  cell  cytoplasm (Table  4.1).  For  this 
reason,  the  pMal-c2  expressed  protein  was  selected  for  further  analysis.  Small-scale 
experiments indicated that a 61kDa MBP-PbCtrNt product was purified and was recognised by 
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both the anti-CSD and anti-MBP antibodies (Figure 4.10). Although designed against the  P. 
yoelii  protein, the anti-CSD anti-peptide antibodies were expected to recognise the P. berghei 
homolog since there is only a difference of three amino acids between the respective peptides. 
The estimated size of the expression construct was also found to correspond well  with the 
construct's  predicted  size  of  60kDa.  However,  there  was  a  significant  amount  of  protein 
degradation as highlighted by the presence of protein bands that appear to be less than 61kDa 
in size (Figure 4.10b). The addition of a range of protease inhibitors, in the process of protein 
isolation, did not impact on the amount of protein degradation detected. This suggested that 
either truncated products were synthesised or that the transcribed product was degraded within 
the E. coli cell cytoplasm, prior to purification.
Figure 4.10 Recombinant expression of the putative  P. berghei copper transport protein's amino terminus 
fused to the maltose binding protein (MBP-PbCtrNt)
Small-scale expression and purification of  MBP-PbCtrNt,  analysed by 10% SDS-PAGE (A).  Recombinant  MBP-
PbCtrNt was probed with anti-MBP (B) and anti-CSD (C) antibodies. In all three panels: lane 1, uninduced E. coli; 
lane 2, IPTG induced total cell protein; lane 3, soluble fraction; lane 4, insoluble fraction. Lanes 5 to 8 are fractions 
from amylose affinity chromatography: lane 5, unbound amylose resin eluate; lane 6 and 7, wash steps; lane 8 
amylose-bound MBP-PbCtrNt. Molecular mass markers (M) are indicated on the left of each image (see materials 
and methods for details).
In an effort to reduce possible protein degradation, the E. coli BL21 strain was used as the host 
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expression of MBP-PbCtrNt (Figure 4.11). This was particularly evident from a comparison of 
the anti-MBP blots of MBP-PbCtrNt expressed in  E. coli  JM103 and BL21 cells (Figure 4.11). 
Interestingly,  MBP-PbCtrNt  expressed  and  purified  from  both  JM103  and  BL21  cells  also 
produced  a  high  molecular  weight  product  having  a  size  that  appears  to  be  greater  than 
116kDa (Figure 4.11).  As with the 61kDa MBP-PbCtrNt product,  the high molecular  weight 
species was recognised by both anti-MBP (Figure 4.11b/d) and anti-CSD antibodies (data not 
shown). Therefore, in an attempt to eliminate the degraded products and high molecular weight 
aggregates, of MBP-PbCtrNt, a number of variables affecting expression and purification were 
tested for their effect on the purity of the recombinant protein (Table 4.2).
Figure 4.11 Expression of recombinant MBP-PbCtrNt in Escherichia coli JM103 and protease deficient BL21 
cells
MBP-PbCtrNt expressed and purified from E. coli  JM103 cells was analysed by 10% SDS-PAGE (A) and western 
blotting with anti-MBP antibodies (B). Similarly, MBP-PbCtrNt expressed and purified from protease deficient E. coli 
BL21 cells was analysed by 10% SDS-PAGE (C) and western blotting with anti-MBP antibodies (D). In all panels, 
lanes 1 to 5 represent five amylose purified samples. Molecular mass markers (M) are indicated on the left of each 
image (see materials and methods for details).
A variety of culture conditions can affect proteolytic activity and protein expression (Makrides, 
1996).  To  test these  variables,  E.  coli BL21  host  cells  transformed with  the  pMc-PbCtrNt 
construct were used and three different growth media tested. These were M9 minimal medium, 
Luria-Bertani broth and 2xYT broth. Each of these media contain different concentrations of 

































However,  these media made no observable improvement or  alteration to the expression of 
MBP-PbCtrNt (Table 4.2). Following pMal-2 manual recommendations, LB broth was selected 
for subsequent analyses. Another important factor affecting recombinant protein expression is 
cultivation temperature. Expression of MBP-PbCtrNt was therefore tested at 15°C, 22°C (room 
temperature) and 30°C following initial tests at 37°C. Changes to the cultivation temperature 
were, however, found to make no noticeable improvement to the quality of the amylose purified 
samples,  regardless  of  the  temperature  employed  (Table  4.2).  A further  factor  that  affects 
expression is the host cell density at which expression is induced. Changes to this variable 
were therefore tested.








LB a a a
NONE of the tested 
conditions were found 
to improve the 
observed banding 
pattern of purified 
MBP-PbCtrNt▲





15°C* a n/d a
22°C a n/d a
30°C* a a a
OD600 
~0.6 a n/d a




Acetate├ a n/d a
Phosphate♦┼ a a a









8 M Urea▲ a a n/d
Buffer pH
4├ a a a
5.8♦ a a a
7.4♦┼ a a a
8♦┼ a a a
aindicates that the method listed in the corresponding column was used to analyse the MBP-PbCtrNt samples
*Induction of MBP-PbCtrNt expression post-log growth phase (O.D.600 ≥ 2.0) was examined at both 15°C and 30°C.
├, ♦  and ┼  indicate the corresponding pH at which the buffer species were used.
#DTT and Triton X-100 were tested separately as well as in combination with each other.
▲The chaotropic agent urea was the only additive affecting the MBP-PbCtrNt multimers.
Initiation of recombinant protein expression post-log growth phase (OD600≥ 2.0) has been found 
to produce increased amounts of soluble, high quality protein (Flick et al., 2004). The effect of 
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initiating MBP-PbCtrNt expression post-log phase was therefore tested for cells grown at both 
15°C  and  30°C  (Table  4.2).  Initial  experiments  made  use  of  the  more  standard  growth 
temperature of 30°C combined with the initiation of expression at OD600≥ 2.0 instead of 0.6. 
Western blot analysis of the amylose purified protein established this alteration again made no 
clear  improvement  to  the  quality  of  the  final  product.  Therefore  in  an  attempt  to  establish 
whether  expression  of  MBP-PbCtrNt  could  be  improved  by  significantly  decelerating  cell 
growth, expression in host cells was induced at a temperature of 15°C when the OD600 was ≥ 
2.0. Unfortunately, this approach made no discernible difference compared to the experiment 
carried out at 30°C. Taken together, these results suggest that alterations to the cell culture 
conditions, affecting MBP-PbCtrNt expression, make no improvements to the amylose purified 
product.
To determine the effect the buffering species could have on protein purification, phosphate, Tris 
and acetate buffers were tested. The phosphate buffer was tested at pH 5.8, 7.4 and 8 whilst 
the Tris buffer was tested at pH 7.4 and 8, due to its pKa. The acetate buffer was used to test 
the lowest  pH value of  4 (Table  4.2).  Tris  and phosphate buffers are common lysis  buffer 
components  generally  used between pH 7 and 8,  hence their  selection.  Use of  a  pH 5.8 
phosphate buffer and pH 4 acetate buffer was based on the finding that the human copper 
transport protein shows increased rates of copper uptake under low extracellular pH conditions 
(Lee et  al.,  2002).  Additionally  a  MBP-fusion  with  the  amino-terminal  domain  of  a 
Cryptosporidium parvum ATPase was successfully purified at pH 6 (LaGier et al., 2001). Hence 
the effects a similar pH might have on purification of the recombinant amino terminus of the P. 
berghei copper transport protein were examined. However, none of these three buffers were 
found  to  improve  the  quality  of  purified  MBP-PbCtrNt.  Following  pMal-2  manual 
recommendations, the Tris buffer was chosen as the standard buffer for further experiments.
A second concern with the final product, was the presence of high molecular weight multimers 
(Figure 4.11). Reducing agents, such as dithiothreitol (DTT), are often included in lysis buffers 
to prevent protein oxidation and thus prevent the formation of recombinant protein aggregates 
and multimers upon cell lysis  (Gräslund et al., 2008). To test whether reducing agents could 
disrupt MBP-PbCtrNt multimers, DTT, ranging in concentration from 1 to 50 mM, was included 
in the Tris buffer (Table 4.2). However, even at concentrations as high as 50 mM, DTT did not 
disrupt MBP-PbCtrNt multimers. For this reason, Triton X-100 was also tested in the lysis buffer 
since it can assist with recombinant protein solubilisation and reduces non-specific binding to 
the affinity resin (The QIAexpressionist, 2001). A concentration limit of 0.2% was selected for 
Triton X-100 and was tested alone as well as in combination with 1 mM DTT. Neither of the 
conditions examined were found to make an observable difference.
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Figure 4.12 Disruption of MBP-PbCtrNt aggregates under reducing conditions following urea solubilisation
MBP-PbCtrNt cell lysates were analysed on 12.5% SDS-PAGE gels under non-reducing (A) and reducing conditions 
(C). Samples were blotted and probed with anti-CSD antibodies for non-reducing (B) and reducing conditions (D). In 
all panels lane 1 represents total cell protein, lane 2 the soluble fraction and lane 3 the insoluble fraction. Molecular 
mass markers (M) are indicated on the left of each image (see materials and methods for details).
The formation of recombinant protein aggregates and multimers has previously been observed 
for other MBP-fusion proteins. When fused to MBP, the human papillomavirus E6 oncoprotein 
(MBP+E6) was produced as a soluble,  but  misfolded protein aggregate that  could only  be 
solubilised by 6 M guanidinium chloride or 9 M urea  (Nominé et al., 2001b). To test whether 
similar conditions could help with MBP-PbCtrNt purification, the cell lysate was prepared in the 
presence of  8 M urea (Table 4.2),  following expression,  and the resulting cellular  fractions 
analysed on a SDS-PAGE gel under both non-reducing and reducing conditions and blotted 
onto nitrocellulose (Figure 4.12).  Blots of the samples examined under reducing conditions, 
indicated that the addition of urea disrupts the high molecular weight protein aggregates (Figure 
4.12d).  Under non-reducing conditions these aggregates were not  disrupted (Figure 4.12b), 
suggesting that disulfide bonds were involved in aggregate formation. This is likely since the 
amino  terminal  domain  of  the  putative  P.  berghei copper  transport  protein  is  predicted  to 
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A.
M  N  I  W  K  I  I  Y  I  V  L  I  I  N  S  L  F  V  V  N  V  N  C  E  S  N 
D  Q  N  D  G  T  T  S  N  K  K  N  T  G  C  C  G  G  T  N  K  P  L  P  S  V 
N  K  P  L  K  S  C  C  S  D  K  Q  S  G  D  D  E  C  K  P  I  L  D  L  N  H 
I  G  S  K  G  K  N  K  I  P  F  I  Y  K  C  C  I  N  H  D  I  Y  E  S  I  I 
N  E  H  F  S  E  E  N  Q  S  N  T  T  G  G  P  E  K  L  N  M  M  M  G  N  L 
S  M  P  M  S  F  Q  N  T  T  H  T  I  I  L  F  K  F  W  E
B.
F  T  F  D  F  V  S  S  S  C  C  H  S  K  N  D  D  G  V  M  L  P  M  Y  F  S 
N  N  E  N  I  K  M  L  F  D  I  F  Q  V  K  N  R  Y
C.
D  K  S  D  N  S  I  C  K  P  S  V  K  I  S  C  A  H  N  C  C  K  N  K  L  S 
F  M  Y  N  C  W  K  H  Y  D  K  Y  S  N  I  I  K  D  N  L  Q  K  E  E  D  T 
V  V  Q  L  Q  D  H  D  N  I  D  I  V  E  H  V  E  T  M  P  M  S  F  Q  L  T 
T  H  T  I  I  L  F  N  K  W  E  T  K  S  A  L
Figure 4.13 Highlighted cysteine residues in PbCtrNt, PfCtr211NtTD and PfCtr369NtTD
Cysteine residues are  underlined and highlighted in the recombinant amino terminal  domain for the putative  P. 
berghei copper transporter (A) and the two truncated amino terminal domains of the putative P. falciparum copper 
transporters, PF14_0211 (B) and PF14_0369 (C).
The MBP-PbCtrNt multimers, predominantly evident in blots of purified protein (Figure 4.11), 
appears  to  be  a  result  of  protein  aggregate  formation.  To test  whether  the  multiple  MBP-
PbCtrNt related products could be separated, an amylose purified sample was fractionated by 
molecular  exclusion  chromatography  (MEC)  on  both  SephacrylTM S-100  and  S-300  resins 
(Figure 4.14). Both MEC experiments showed identical results, with MBP-PbCtrNt eluting in a 
single peak corresponding with the void volume of the resin (Figure 4.14b). Analysis of the 
eluted  sample,  by  both  SDS-PAGE  and  western  blot,  confirmed  that  the  multiple  protein 
species present in the purified MBP-PbCtrNt sample had not been fractionated (Figure 4.14). 
Similar to previous results (Table 4.2), the addition of 1 mM DTT or 0.2% Triton X-100 had no 
effect  (data not  shown).  From the SephacrylTM S-300 chromatogram, the protein aggregate 
appears to be greater than 1.5 x 106 Da suggesting that the MBP-PbCtrNt aggregate consists 
of a minimum of 25 protein monomers. Taking the problems encountered with the recombinant 
expression of MBP-PbCtrNt into consideration, the truncated amino terminal domains of two 
putative P. falciparum copper transport proteins were prepared for recombinant expression. 
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Figure 4.14 Fractionation of MBP-PbCtrNt aggregates by molecular exclusion on a SephacrylTM S-100* resin
A Resin calibration using blue dextran (peak 1; 2 x 106
 
Da), bovine serum albumin (peak 2; 66000 Da), ovalbumin 
(peak 3; 45000 Da) and myoglobin (peak 4; 17000 Da). B Elution profile for MBP-PbCtrNt. C MBP-PbCtrNt fractions 
analysed by 10% SDS-PAGE, transferred to nitrocellulose and probed with anti-MBP antibodies (D). For gel and blot 
analysis, lane 1 contained the amylose purified starting sample, whilst lanes 2 – 6 contained the eluted fractions 
containing protein (180 to 200 ml eluant). Shown to the left  of the gel and blot images are the molecular mass 
markers (see materials and methods for details). *Fractionation of amylose purified MBP-PbCtrNt on a SephacrylTM 
S-300 resin produced the same result.
The coding sequences, used for expression of the P. falciparum proteins, were PCR amplified 
with the exclusion of predicted signal sequences found within the first 60 nucleotides. A similar 
approach to that taken for the expression of the putative P. berghei copper transport protein's 
amino terminus was adopted (Figure 4.9). The PCR amplicons corresponding to the coding 
domains of the truncated (TD) amino terminus of PF14_0211 and PF14_0369 (Figure 4.3) were 
gel  purified and ligated into the  pGEM®-T cloning vector  (Figure 4.9). The constructs were 
transformed into a cloning cell, positive colonies identified and cultivated, plasmids isolated and 
the insert excised by EcoRI and PstI digestion (Figure 4.9). For the recombinant expression of 
the  P. falciparum proteins the pMal-2 expression system was again used.  Both pMal-c2 and 
pMal-p2 constructs were prepared and transformed into JM103 host cells for expression of the 
truncated PF14_0211 and PF14_0369 amino terminal domains.
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Figure  4.15 Recombinant  expression and  purification  of  the  amino terminal  domain  of  two  putative  P. 
falciparum copper transport proteins fused to maltose binding protein 
The amino terminal domains of PF14_0211 (A and B) and PF14_0369 (C and D) were expressed as recombinant 
MBP fusion proteins from the pMal-c2X vector and analysed by 10% SDS-PAGE (A and C). Samples were blotted to 
nitrocellulose and probed with anti-MBP antibodies (B and D). In panels A and B: lane 1, uninduced total cell protein; 
lane 2, total cell protein; lane 3, soluble fraction; lane 4, unbound protein eluate; lane 5, the wash fraction; lane 6, 
amylose bound protein. In panels C and D: lane 1, total cell protein; lane 2, soluble fraction; lane 3, unbound protein 
eluate; lane 4, the wash fraction; lane 5, amylose bound protein. Molecular mass markers (M) are indicated on the 
left of each image (see materials and methods for details).
Following  induction  of  both  PF14_0211  (MBP-PfCtr211NtTD)  and  PF14_0369  (MBP-
PfCtr369NtTD) expression, the bacterial cell lysates were analysed by SDS-PAGE and western 
blot (Figure 4.15). Positive expression of both constructs was evident from SDS-PAGE analysis 
of a small-scale purification, with a 46kDa product purified for MBP-PfCtr211NtTD (Figure 4.15b) 
and a 55kDa product purified for MBP-PfCtr369NtTD (Figure 4.15d). These sizes corresponded 
well with the predicted sizes of 48kDa for MBP-PfCtr211NtTD and 54kDa for MBP-PfCtr369NtTD. 
The additional 42kDa product present in the purified MBP-PfCtr369NtTD  fraction (Figure 4.15d 
and 4.16d) is likely to be MBP lacking the fused protein. This could have been caused by fusion 
protein degradation, leaving a stable MBP-sized breakdown product (pMal manual). An anti-
MBP blot  of  the  relevant  samples  also  indicated  the  presence  of  high  molecular  weight 
aggregates (Figure 4.15), similar to those observed for MBP-PbCtrNt (Figure 4.11). These were 
particularly  evident  for  MBP-PfCtr369NtTD samples  (Figure  4.15d).  Although  aggregation 
appears less prevalent  in the images captured from the MBP-PfCtr211NtTD analysis (Figure 
4.15b), faint bands, presumably representative of aggregates, were evident in the original blots. 
These  results  suggest  that  removal  of  the  signal  peptide  alone  did  not  reduce  or  inhibit 
aggregation of the recombinant proteins. A sequence property believed to have affected MBP-
PbCtrNt expression was the presence of eight cysteine residues (Figure 4.13a). Analysis of the 
truncated  P.  falciparum amino terminal  sequences identified that  PF14_0211 contained two 
cysteines (Figure 4.13b) whereas PF14_0369 contained five cysteines (Figure 4.13c). Since 
disulfide bond dependent folding of heterologous proteins can be actively catalysed in the E. 
coli cell periplasm (Baneyx, 1999), MBP-PfCtr211NtTD and MBP-PfCtr369NtTD expression was 
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targeted to this compartment using the malE leader sequence of pMal-p2X.  
Figure 4.16 Recombinant expression and purification of the amino terminal domain of two  P. falciparum 
copper transport proteins fused to maltose binding protein containing the malE leader sequence
Periplasmic expression and purification of MBP-PfCtr211NtTD (A) and MBP-PfCtr369NtTD (C) analysed by 10% SDS-
PAGE. MBP-PfCtr211NtTD (B) and MBP-PfCtr369NtTD (D) samples were blotted to nitrocellulose and probed with 
anti-MBP antibodies. In all panels: lane 1, total cell protein; lane 2, supernatant following sucrose treatment; lane 3, 
periplasmic contents; lane 4, unbound amylose resin eluate; lane 5, wash fraction; lane 6, amylose bound protein. 
Molecular mass markers (M) are indicated on the left of each image (see materials and methods for details). 
Following  MBP-PfCtr211NtTD and MBP-PfCtr369NtTD periplasmic expression,  the contents of 
the  E.  coli periplasm was  isolated  by  osmotic  shock  and  analysed.  Western  blot  analysis 
confirmed the export of both recombinant proteins to the periplasm with an apparent absence 
of protein aggregation (Figure 4.16b and 4.16d). In addition, each sample indicated a reduction 
in recombinant protein degradation when expressed in the periplasm (Figure 4.16). Therefore, 
in contrast to the difficulties faced with cytoplasmic expression, targeting MBP-PfCtr211NtTD and 
MBP-PfCtr369NtTD expression  to  the  cell  periplasm  appeared  to  reduce  both  recombinant 
protein aggregation and degradation. Furthermore, the successful  periplasmic expression of 
MBP-PfCtr211NtTD and  MBP-PfCtr369NtTD,  compared  to  unsuccessful  attempts  for  MBP-
PbCtrNt, suggested that amino terminal signal peptides of  Plasmodium proteins can interfere 
with E. coli targeting of heterologous proteins to the periplasm. Importantly, these initial small-
scale experiments confirmed that MBP-PfCtr211NtTD and MBP-PfCtr369NtTD could be purified 
from  the  osmotic  shock  fluid  using  amylose  affinity  chromatography.  Both  the  MBP-
PfCtr211NtTD and  MBP-PfCtr369NtTD constructs  were  therefore  prepared  for  large-scale 
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Figure 4.17 Amylose affinity purification of MBP-PfCtr211NtTD and MBP-PfCtr369NtTD from the periplasm of E. 
coli JM103 cells
Steps in the purification of MBP-PfCtr211NtTD (A) and MBP-PfCtr369NtTD (B) analysed by 10% SDS-PAGE. Lane 1, 
total cell suspended in Tris/sucrose buffer; lane 2, total cell protein diluted in distilled water; lane 3, the periplasmic 
fraction; lane 4, unbound amylose resin eluate; lanes 5 – 10, eluted fractions.  Molecular mass markers (M) are 
indicated on the left of each image (see materials and methods for details).
Optimal conditions for MBP-PfCtr211NtTD expression were determined to be induction with 0.3 
mM  IPTG  at  30°C,  whilst  MBP-PfCtr369NtTD expression  was  induced  using  the  same 
concentration of IPTG but at room temperature. Both recombinant proteins were expressed 
overnight  at  the  respective  temperatures. The  periplasmic  contents  of  the  host  cells  was 
subsequently released using a simple, two-step osmotic shock method described by French et  
al. (1996). Each protein was purified by amylose affinity chromatography with reduced protein 
degradation  and  no  protein  aggregates  (Figure  4.17).  Each  recombinant  protein  was  also 
recognised by the respective anti-peptide antibodies (Figure 4.18). The anti-peptide antibody 
blot for MBP-PfCtr369NtTD also supports the notion that the 42kDa band in the purified sample 
is likely to be representative of MBP which results from fusion protein degradation. Considering 
the predicted function of the P. falciparum proteins is the same as that for MBP-PbCtrNt, each 
of these recombinant proteins was tested for copper binding in vivo and in vitro.
Figure 4.18 Anti-peptide antibody recognition of MBP-PfCtr211NtTD and MBP-PfCtr369NtTD
10% SDS-PAGE analysis of affinity purified MBP-PfCtr211NtTD (A) and MBP-PfCtr369NtTD (C) probed with anti-PMY 
(B) and anti-LQD (D) anti-peptide antibodies, respectively. In all panels: lane 1, periplasmic fraction; lane 2, unbound 
amylose resin eluate; lanes 3 and 4, amylose-affinity purified samples. Molecular mass markers (M) are indicated on 
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4.2.4  Copper  binding  studies  with  MBP-PbCtrNt,  MBP-PfCtr211NtTD and  MBP-
PfCtr369NtTD
The MBP-PbCtrNt  aggregate was tested for  its ability  to  bind copper  in  vitro using 10  µM 
purified recombinant protein incubated with a 20-fold molar excess of copper in the presence or 
absence of the reducing agent ascorbic acid. Ascorbic acid was added to determine whether 
the  amino  terminal  domain  of  the  P.  berghei  copper  transporter  preferentially  bound  the 
cuprous (Cu+) or cupric (Cu2+) ion. Following overnight dialysis, bound copper was detected 
using the copper-specific BCA release assay (Brenner and Harris, 1995). BCA is only capable 
of forming a detectable purple complex when bound to the cuprous ion, therefore ascorbic acid 
is included in the assay to ensure copper ion detection (Figure 4.19a)  (Brenner and Harris, 
1995).  This  property  was  utilised to  help  establish  the copper-binding  preference of  MBP-
PbCtrNt.  Following  copper  binding  and  overnight  dialysis,  the  BCA  release  assay  was 
conducted with or without a second treatment of ascorbic acid (Figure 4.19b). Thus if ascorbic 
acid  was  required  for  the  formation  of  a  purple  BCA complex  it  suggests  that  Cu2+ is 
preferentially bound. Alternatively, if ascorbic acid supplementation was not required for colour 
formation then it suggests Cu+ is the preferred substrate. With this in mind copper binding to 
MBP-PbCtrNt was analysed.
Figure 4.19 Recombinant protein copper binding studies using the BCA release assay for copper detection
A. Standard protocol for the BCA assay, used for the detection of copper in solution.  B.  In vitro copper binding to 
recombinant protein, in the presence or absence of ascorbic acid using a modified BCA assay to determine the 
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Results from the in vitro copper-binding experiments indicated that MBP-PbCtrNt had a binding 
preference for Cu+ since copper binding appeared to be dependent on the addition of ascorbic 
acid  during  incubation  with  free  CuCl2  (Figure  4.20a, +).  This  was  supported  by  omitting 
ascorbic acid from the BCA release assay, which still resulted in the formation of the purple 
BCA-Cu+  complex (Figure 4.20a,  +, open bar). The exclusion of ascorbic acid from the initial 
CuCl2  incubation step resulted in a 76% reduction in the amount of BCA-Cu+ complex formed 
(Figure  4.20a, –),  which  was  statistically  significant  according  to  Student's  t-test  (p-value 
<0.05).  These  in vitro  studies were subsequently followed up with an  in vivo copper binding 
study. Recombinant MBP-PbCtrNt was expressed in the presence or absence of 0.5 mM CuCl2, 
which is a concentration of copper salt that does not affect E. coli cell growth (Lutsenko et al., 
1997). Following amylose purification, MBP-PbCtrNt was analysed for binding of copper using 
the BCA release assay,  as described above.  As seen in  figure 4.20b,  copper  binds  MBP-
PbCtrNt in vivo with the detection of bound copper appearing dependent upon the addition of 
extracellular copper. Adding extracellular copper resulted in a statistically significant increase in 
the  amount  of  copper  bound  to  MBP-PbCtrNt,  as  determined  by  Student's  t-test  (p-value 
<0.05). As with the in vitro analysis, the oxidation state of the bound copper was determined by 
either including (solid bars, Figure 4.20b) or excluding (open bars, Figure 4.20b) ascorbic acid 
from the BCA release assay. As with copper binding in vitro, the preferred oxidation state of in 
vivo bound copper appears to be Cu+ (Figure 4.17). Importantly, in the control experiments for 
both in vivo and in vitro conditions, copper did not show significant levels of binding to the MBP 
carrier protein (Figure 4.20). These results suggest the amino terminal domain of the P. berghei 
copper transport  protein binds copper. Although MBP-PbCtrNt appears to be predominantly 
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Figure 4.20 Copper binding to MBP-PbCtrNt in vitro and in vivo
A 10  µM affinity-purified MBP-PbCtrNt or MBP was incubated with CuCl2 in the presence (+) or absence (–) of 
ascorbic acid in vitro. The BCA release assay was used to detect copper with (solid bars) or without (open bars) the 
addition of ascorbic acid. The BCA-Cu+ complex was detected at 354 nm. The concentration of the copper standard 
(CuCl2  only) was equimolar to the amount of protein used. B 0.5 mM CuCl2  was added to the cell growth medium 
after  the  induction  of  recombinant  protein  expression.  Following  affinity  purification,  copper  bound  in  vivo was 
detected by the BCA release assay with (solid bars) or without (open bars) the addition of ascorbic acid. As before 
the BCA-Cu+ complex was detected at 354 nm. ** denotes statistical significance, as determined by Student's t-test 
(p-value <0.05). Results are means ± S.E. of triplicate measurements from each duplicate dialysis bag.
For  in  vitro copper  binding  studies  with  MBP-PfCtr211NtTD and  MBP-PfCtr369NtTD,  the 
conditions used were the same as those used for MBP-PbCtrNt.  Protein-bound copper was 
again detected using the copper-specific BCA release assay (Brenner and Harris, 1995), with 
or without a second treatment of ascorbic acid following copper binding and overnight dialysis 
(Figure 4.19b). The data indicated that both MBP-PfCtr211NtTD and MBP-PfCtr369NtTD bound 
copper  in vitro with an apparent preference for Cu+  (Figure 4.21a). The exclusion of ascorbic 
acid from the initial CuCl2  incubation step resulted in relatively low levels of bound copper for 
both recombinant proteins (Figure 4.21a, –). On the other hand, the inclusion of ascorbic acid to 
the  CuCl2  incubation  step  resulted  in  an  ~80% increase  of  copper  levels  bound  to  MBP-
PfCtr211NtTD and ~70% increase for MBP-PfCtr369NtTD. Both these increases were found to be 
statistically  significant,  as  determined  by  Student's  t-test  (p-value  <0.05). The  omission  of 
ascorbic acid from the BCA release assay also supports a preference for Cu+, since this still 

















































Ascorbate – + – + – + CuCl2 – + – + – +
Figure 4.21 Copper binding to MBP-PfCtr211NtTD and MBP-PfCtr369NtTD in vitro and in vivo
A 10 µM of affinity-purified MBP-PfCtr211NtTD, MBP-PfCtr369NtTD or MBP was incubated with CuCl2 in the presence 
(+) or absence (–) of ascorbic acid in vitro. The BCA release assay was used to detect copper with (solid bars) or 
without (open bars) the addition of ascorbic acid. The BCA-Cu+ complex was detected at 354 nm. The concentration 
of the copper standard (CuCl2 only) was equimolar to the amount of protein used. B 0.5 mM CuCl2 was added to the 
cell  growth medium after  the induction of  recombinant  protein  expression.  Following affinity  purification,  copper 
bound in vivo was detected by the BCA release assay with (solid bars) or without (open bars) the addition of ascorbic 
acid.  As before the BCA-Cu+ complex  was detected at  354 nm.  ** (for  MBP-PfCtr211NtTD) and  ▲▲ (for  MBP-
PfCtr369NtTD) denote statistical significance, as determined by Student's t-test (p-value <0.05). Results are means ± 
S.E. of triplicate measurements from each duplicate dialysis bag.
Following  E.  coli growth  and  protein  expression,  in  the  presence  of  0.5  mM CuCl2, MBP-
PfCtr211NtTD and MBP-PfCtr369NtTD were subsequently amylose purified and analysed for the 
presence  of  copper.  Both  recombinant  proteins  were  found  to  bind  copper  in  vivo,  with 
detectable copper levels dependent on the addition of extracellular copper (Figure 4.21b). The 
increase in the amount of copper bound to MBP-PfCtr211NtTD and MBP-PfCtr369NtTD in vivo 
when extracellular copper was added, was found to be statistically significant (p-value <0.05). 
As  with  the  in  vitro analysis,  the  oxidation  state  of  the  bound  copper  was  determined  by 
including (Figure 4.21b, grey bars) or omitting (Figure 4.21b, open bars) ascorbic acid from the 
BCA release assay. For both MBP-PfCtr211NtTD and MBP-PfCtr369NtTD Cu+  appeared to be 
bound  in vivo;  however, it  appeared to form a smaller proportion of the total bound copper, 
particularly for MBP-PfCtr211NtTD. This result did, however, indicate a similarity between copper 
binding in vitro and in vivo. As before, control experiments for the in vivo and in vitro conditions 











































Figure 4.22 MBP-PfCtr211NtTD and MBP-PfCtr369NtTD protein yields
E. coli host cells were grown in the absence (open bars) or presence (solid bars) of extracellular CuCl2 and the yields 
of affinity purified recombinant protein determined. The MBP carrier protein alone was included as a control. ** (for 
MBP-PfCtr211NtTD) and ▲▲ (for MBP-PfCtr369NtTD) denote statistical significance, as determined by Student's t-test 
(p-value <0.05).
Analysis of copper binding in vivo established the ability of the amino terminal domain of each 
of  the  P.  falciparum copper  transport  proteins to bind copper  in  a cellular  environment.  As 
previously mentioned, the detection of a significant concentration of bound copper appeared 
dependent  on  the presence of  extracellular  copper.  A consequence of  adding extracellular 
copper to the E. coli  growth medium was a statistically significant increase (p-value <0.05) in 
the yield of both recombinant P. falciparum proteins (Figure 4.22). A similar phenomenon was 
not  observed for  the cytoplasmically expressed P.  berghei protein (data not  shown).  Under 
standard  conditions  the  P.  falciparum  recombinant  protein  yields  were  found  to  be  poor, 
particularly for MBP-PfCtr211NtTD with an average yield of 0.74  mg per litre of culture, whilst 
MBP-PfCtr369NtTD had  a  slightly  improved  yield  of  1.53  mg per  litre  of  culture.  However, 
expression  in  the  presence  of  0.5  mM  CuCl2  significantly  improved  these  yields  with  an 
approximate 5-fold increase for MBP-PfCtr211NtTD to 3.76 mg per litre of culture and a 4-fold 
increase for MBP-PfCtr369NtTD to 5.98  mg per litre of culture(Figure 4.22). When expressed 
under the same culture conditions, a comparative analysis for MBP alone indicated minimal 
alteration to protein yield when CuCl2 was added to the growth medium (Figure 4.22).
Previously  it  has  been  demonstrated  that  peptides  representative  of  the  copper  transport 
protein's methionine motifs bind Cu+ with methionine-only coordination (Jiang et al., 2005). In 























methionine peptides to bind Cu+. Ascorbic acid is stable to aerial oxidation in the absence of 
metal  ions,  but  the  presence  of  iron  or  copper  ions  catalyse  its  oxidative  degradation  via 
equations 1 and 2 (Figure 4.23) (Jiang et al., 2005). Oxidative degradation results in a loss of 
ascorbate's characteristic, pH-dependent absorption band between 245 and 265 nm (Buettner, 
1988). This is therefore a convenient spectroscopic signal for the presence of catalytic metal 
ions in solution. The pH-dependent oxidation rate of the reaction is first-order, with respect to 
both the ascorbate monoanion (HAsc—)  and the metal  ion.  The oxidation rate is,  however, 
known to decrease in the presence of metal chelators with slower oxidation rates indicative of 
more stable chelates (Khan and Martell, 1967). Chelators that favour Cu2+ slow reaction rates 
by making equation 1 rate-limiting, whilst chelators that stabilise Cu+ shift the rate-limiting step 
to equation 2 (Figure 4.23). This effect was previously demonstrated for the copper-catalysed 
oxidation  of  ascorbate  in  aqueous  acetonitrile  (Mi  and  Zuberbühler,  1992).  Similarly  the 
spectroscopic signal, provided by the ascorbate UV-vis assay, was used to demonstrate the 
ability  of  methionine  peptides  to  bind  Cu+ (Jiang et  al.,  2005).  For  the  current  study,  the 
ascorbate  UV-vis  assay  was  used  to  analyse  the  ability  of  MBP-PfCtr211NtTD and  MBP-
PfCtr369NtTD to bind copper in vitro. This assay was also employed to gain further insight into 
the preferred oxidation state of bound copper.
Equation 1: HAsc— + Cu2+ → HAsc•— + Cu+
Equation 2: Cu+ → Cu2+
Figure 4.23 Equations representing the copper-catalysed oxidative degradation of ascorbic acid
The effect  the  recombinant  proteins  had  on  copper-catalysed  ascorbic  acid  oxidation  was 
examined by monitoring the loss of absorbance, at 255 nm, of a 120 μM ascorbic acid solution 
at  pH 4.5.  This  particular  pH was selected for  several  reasons.  First,  the oxidation rate of 
ascorbic  acid  increases  with  increased  concentration  of  HAsc—,  which  has  a  pKa of  4.1, 
therefore using elevated pH values can amplify unwanted errors. Second, the hydrolysis of Cu2+ 
is  minimal  at  this  lower  pH  (Jiang et  al.,  2005).  Last  and  perhaps most  important,  hCtr1-
transfected human cells show increased copper uptake at a low extracellular pH  (Lee et al., 
2002). As expected, the freshly prepared ascorbic acid control showed a constant absorbance 
at 255 nm (A255) over a period of 300 seconds, indicative of the stability of the solution (Figure 
4.24, ■). When 8 μM CuCl2 was added, the A255  signal was found to decrease highlighting the 
catalytic oxidation of ascorbic acid by copper (Figure 4.24, ▼). The oxidation of ascorbic acid 
was, however, inhibited by the addition of 5 μM purified MBP-PfCtr211NtTD (Figure 4.24, ▲) or 
MBP-PfCtr369NtTD (Figure 4.24, ►). The presence of either recombinant protein results in only 




CuCl2 was added.  This  result  indicates  that  both MBP-PfCtr211NtTD and MBP-PfCtr369NtTD 
chelate  copper in solution, thus preventing its participation in the redox cycle (Figure 4.23). 
Although this assay is not definitive of the copper species being preferentially bound by each 
protein, it is likely to be  Cu+  based on the  in vitro and  in vivo  copper-binding studies (Figure 
4.21). Thus it is highly likely that equation 2 is the rate-limiting step of the redox cycle (Figure 
4.23).
Figure 4.24 Copper-catalysed oxidative degradation of ascorbic acid in the presence of MBP-PfCtr211NtTD 
and MBP-PfCtr369NtTD
120 µM ascorbic acid (H2Asc) at pH 4.5 (■). Addition of 8 µM CuCl2 to the H2Asc solution (▼). MBP-PfCtr211Nt
TD (▲), 
MBP-PfCtr369NtTD (►) or MBP (♦) were added to the CuCl2/H2Asc solution.
4.3 Discussion
Both prokaryotes and eukaryotes require copper as an essential enzyme co-factor for survival. 
It was similarly determined that P. falciparum requires intracellular copper for transition from the 
ring to trophozoite stage of parasite development (Rasoloson et al., 2004). Characterisation of 
a  P.  falciparum P-type  ATPase  copper  efflux  protein  further  supported  the  presence  of  a 
parasite intracellular copper pool (Rasoloson et al., 2004). However, the mechanism by which 
the malaria parasite acquires and transports extracellular copper into its cytosol is unknown. 
One possible  mechanism is  via  a  dedicated  parasite  copper  transport  protein.  A BLASTp 
search of  the  Plasmodium database (PlasmoDB),  coupled with an  in  silico-based analysis, 
identified  putative  copper  transport  protein  sequences  in  eight  species  of  the  Plasmodium 
parasite (Chapter 3). Using rodent-infecting and P. falciparum parasites as model organisms, 
the presence of a parasite copper transporter coding sequence was confirmed. Additionally, a 
recombinant form of the transporter's amino terminus was shown to bind copper in vitro and in 














4.3.1 Confirmation of a Plasmodium spp. copper transport protein coding sequence
Bioinformatics tools provide a useful means by which to predict the function of a hypothetical 
protein. However,  protein function and structural  properties can only be confidently inferred 
through biochemical and cell biological experimentation (Birkholtz et al., 2008). Using rodent-
infecting parasites and P. falciparum as reference organisms, the malaria parasite was probed 
for the presence of an open reading frame (ORF) encoding a putative copper transporter. In 
this regard,  copper transporter ORF's were PCR amplified from the  P. yoelii  (PY00413),  P. 
berghei (PBANKA_130290) and P. falciparum (PF14_0211 and PF14_0369) genomes. For P. 
yoelii, an 1800bp amplicon was obtained from genomic DNA (Figure 4.1a) corresponding with a 
full-length ORF containing two introns and three exons. Amplicon identity was supported by 
nested PCR (Figure 4.1b) and BamHI restriction digestion (Figure 4.1c). Although a full-length 
P. berghei ORF was not similarly amplified from genomic DNA, a region of the ORF predicted 
to encode the transporter's amino terminus was amplified by RT-PCR (Figure 4.1d) and the 
amplicon sequenced. The sequenced product was almost identical to the published PlasmoDB 
sequence (Figure 4.2), thus supporting the presence of a putative copper transporter ORF in 
the genome of rodent-infecting malaria parasites. RT-PCR amplification also confirmed that the 
targeted ORF was transcribed by P. berghei for native protein expression. 
The P. falciparum genome is predicted to encode two putative copper transporters (Chapter 3). 
Other  Plasmodium parasite species are also predicted to encode two transporters, except  P. 
yoelii  whose second predicted transporter's amino acid sequence largely lacks characteristic 
copper transporter features. The P. yoelii genome was, however, only partially sequenced and 
hence not fully assembled, which may have contributed to errors in gene annotation (Vaughan 
et al., 2008). This seems likely since the related P. berghei genome is predicted to encode two 
putative copper transporters (PBANKA_130290 and PBANKA_102150) of which only one was 
PCR  amplified  (PBANKA_130290).  To  confirm  the  presence  of  two  P.  falciparum copper 
transporter ORF's, each was targeted for PCR amplification using sequence-specific primers. 
The two respective  full-length P. falciparum ORFs are predicted to be 423 bp for PF14_0211 
and 920 bp for  PF14_0369, with similar  sized PCR amplicons obtained from  P. falciparum 
genomic DNA (Figure 4.3). PCR amplification and sequencing of a portion of the ORF predicted 
to  encode  each  respective  protein's  amino  terminus  showed  a  close  resemblance  to  the 
sequences retrieved from the PlasmoDB (Figure 4.4).
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4.3.2 Identification of a native murine malaria parasite copper transport protein
Determining the subcellular location of a native protein can be achieved using a protein-specific 
antibody-based  approach  (Martin et  al.,  2009a).  Anti-peptide  antibodies  were  therefore 
generated (Section 4.2.2.1) and used to identify and localise the native parasite protein. In the 
first  instance  the murine malaria  parasite  model  was  used for  protein  localisation.  Copper 
transporters characterised to date have been shown to localise to the cell membrane (Dancis 
et al., 1994; Lee et al., 2002; Mackenzie et al., 2004; Riggio et al., 2002). To obtain copper the 
parasite transporters are likely to be membrane localised, as suggested by the identification of 
three predicted transmembrane domains in the parasite copper transport protein sequences 
(Figure 3.3). Analysis of fractionated P. yoelii-infected mouse red blood cell lysate on a western 
blot,  probed  with  the  specific  anti-CSD  antibody,  identified  a  32kDa  protein  band  in  the 
insoluble “membrane” fraction that was absent from the soluble fraction (Figure 4.7). Additional 
protein bands below the 32kDa band could be the result of protein degradation. The addition of 
protease inhibitors did not alter this observation.
Immunolocalisation studies, using fluorescent microscopy, indicated that the  P. yoelii copper 
transporter was associated with a parasite membrane (Figure 4.8b). Considering the anti-CSD 
antibodies can also recognise the P. berghei copper transporter, the possibility exists that the 
parasites used for this study actually represented the berghei species. Unfortunately both the 
parasite species and protein location could not be confirmed since antibodies against a specific 
membrane  marker  protein  were  not  available  for  this  study.  The  pattern  of  fluorescence 
obtained for the putative copper transport protein was, however, noticeably different from the 
pattern  obtained  for  the  cytoplasmic  control  protein,  lactate  dehydrogenase  (LDH)  (Figure 
4.8a),  suggesting different locations. Further experimental  evidence is,  however, required to 
confirm the specific location of the putative copper transport protein. This could be achieved 
through co-localisation experiments using a membrane marker protein for confocal microscopy 
or via immunogold labelling for transmission electron microscopy. An alternative to antibody-
based detection is to attach a fluorescent tag to the carboxyl terminus of the copper transporter, 
for example. Parasites would then be transfected with this construct and the localisation of the 
target protein tracked throughout the parasite's life cycle.
4.3.3 Recombinant expression of the amino terminus of a putative  P.  berghei  copper 
transport protein
The coding domain of the P. berghei copper transport protein's amino terminus was amplified 
by RT-PCR, cloned and used for recombinant protein expression. The ability of this protein to 
bind copper would suggest a role for the whole protein in copper transport. This assumption is 
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based on the finding that the amino terminus of  other copper transport  proteins studied, is 
involved in the initial acquisition and transport of the cuprous ion (De Feo et al., 2009; Larson 
et al., 2010; Nose et al., 2006). Initial attempts to express the recombinant  P. berghei amino 
terminus (PbCtrNt)  made use of  the pET23a vector.  The expressed protein  was,  however, 
found to be targeted to insoluble inclusion bodies (Table 4.1), which is undesirable given the 
inherent difficulties faced with protein refolding in vitro. Fusion of the amino terminal domain to 
a soluble carrier protein was therefore explored. Soluble fusion partners, such as glutathione S-
transferase  (GST)  and  maltose  binding  protein  (MBP),  can  improve  folding  of  inherently 
insoluble,  unstable  or  unfolded  proteins  (Kapust  and  Waugh,  1999;  Makrides,  1996; 
Nallamsetty  and  Waugh,  2007).  The  carrier  protein  is  thought  to  rapidly  adopt  a  native 
conformation thereby promoting the correct folding of downstream units (Baneyx, 1999).
As with the expression of  His6-PbCtrNt (pET23a),  expression of  GST-PbCtrNt produced an 
insoluble product (Table 4.1). On the other hand, fusion to the MBP carrier protein produced a 
soluble product targeted to the cell cytoplasm (pMal-c2), although some of the protein was still  
found  as  an  insoluble  sample  (Figure  4.10).  Additionally,  the  expressed  product  appeared 
largely degraded or truncated, as evidenced by multiple protein bands below the desired 61kDa 
product. The addition of protease inhibitors, during lysate preparation, suggested degradation 
did not occur following cell lysis (data not shown). This indicated that product truncation and/or 
degradation may have occurred during protein synthesis in the host cell cytoplasm. A strategy 
used to avoid this problem is expression of a target protein in a host strain bearing mutations to 
native protease genes (Baneyx, 1999). E. coli BL21 cells lack the lon and ompT genes, which 
encode  proteases  catalysing  the  endoproteolytic  cleavage  of  damaged  and  recombinant 
proteins  (GST handbook).  Expression  using  this  strain  made  no  observable  improvement 
(Figure 4.11).  The presence of high molecular weight multimers in all  purified samples was 
another concern. These protein multimers are formed from MBP-PbCtrNt, as indicated by anti-
MBP  (Figure  4.11)  and  specific  antibody  blots  (data  not  shown).  Expressing  problematic 
recombinant proteins by fusion to a soluble carrier partner, such as MBP, can be accompanied 
by  large  molecular  weight  aggregates  as  a  result  of  carrier  protein-induced  solubilisation 
(Kapust and Waugh, 1999; Nominé et al., 2001a; Sachdev and Chirgwin, 1999; Zanier et al., 
2007).
In an effort to reduce MBP-PbCtrNt degradation and multimer formation various alterations to 
culture and purification conditions were examined (Table 4.2). Variations to temperature, pH 
and  cell  density  can  affect  proteolytic  activity,  protein  secretion  and  the  levels  of  protein 
production in E. coli expression systems (Makrides, 1996). Reducing the growth temperature is 
known to help limit the in vivo aggregation of recombinant proteins and improve production of 
128
soluble protein (Gräslund et al., 2008; Vasina and Baneyx, 1997). This is presumed to be due 
to slower rates of protein production, thereby allowing newly transcribed recombinant protein 
time to fold correctly (Vera et al., 2007). In addition, the composition of the cell growth medium 
should be carefully formulated and monitored, since it too can have significant metabolic effects 
on the cells and protein production  (Makrides, 1996). In this study, changes to nutrient broth 
composition  made  no  improvement  to  the  MBP-PbCtrNt  banding  pattern  (Table  4.2).  The 
recombinant expression of other malarial parasite proteins at reduced growth temperatures has 
proven beneficial (Flick et al., 2004; Jalah et al., 2005). For example, expression of soluble P. 
falciparum LDH at  15°C increased expression levels (Berwal et  al.,  2008). Growth at 15°C 
made  little  improvement  to  MBP-PbCtrNt  expression  (Table  4.2).  Recombinant  protein 
production is also affected by cell density. Induction of expression is usually initiated in mid-to-
late log phase, which can be identified by a culture having an optical density between 0.4 and 
0.6, at 600 nm. At post-log phase, recombinant protein production can be affected by a limited 
availability  of  dissolved  oxygen  and  increased  carbon  dioxide  levels  (Makrides,  1996). 
Expression of GST-PfEMP1 domains post-log phase was, however, found to improve protein 
production (Flick et al., 2004). A similar observation was not made for MBP-PbCtrNt (Table 4.2).
A critical  step  in  recombinant  protein  purification  is  the  preparation  of  the  bacterial  lysate. 
Optimal conditions maximise cell  lysis and affect  the cell  fraction to which the recombinant 
protein is extracted,  while minimizing oxidation and proteolysis (Gräslund et  al.,  2008).  The 
lysis  buffer  typically  consists  of  a  strong  buffering  species  to  overcome the effects  of  the 
bacterial lysate, high ionic strength to enhance protein solubility and stability plus a reducing 
agent to prevent protein oxidation (Gräslund et al., 2008). The conditions used for cell lysis and 
protein purification were systematically tested for their effects on the quality of purified MBP-
PbCtrNt. Different buffers, pH's and the addition of detergents, redox reagents and chaotropic 
agents  were  tested  (Table  4.2),  with  protein  aggregates  only  disrupted  under  reducing 
conditions  in  the  presence  of  8  M  urea  (Figure  4.12).  Previous  studies  with  human 
papillomavirus  (HPV)  E6  oncoprotein,  as  a  MBP-fusion  (MBP+E6),  identified  that  protein 
aggregation  most  likely  occurred  in  vivo during  protein  expression  (Nominé et  al.,  2001b). 
These aggregates were only solubilised using harsh denaturing conditions suggesting that the 
interactions  maintaining  MBP+E6  aggregates  were  probably  similar  to  those  found  in 
precipitates of misfolded proteins and bacterial inclusion bodies (Nominé et al., 2001b).
The amino acid residues likely to contribute to aggregate formation are the cysteine residues, 
of  which  PbCtrNt  has  eight  (Figure  4.13a).  This  is  likely  to  have  affected  heterologous 
expression  since  the  bacterial  cytoplasm  has  a  strong  reducing  potential  and  thus  few 
cytoplasmic  proteins  with  disulfide  bonds  (Fahey et  al.,  1977).  This  property  generally 
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translates into the misfolding of heterologous proteins whose tertiary structure depends, in part, 
on disulfide bond formation (Makrides, 1996). The problem can be overcome by exporting the 
target protein from the cytoplasm to the oxidising environment of the bacterial cell periplasm 
(Baneyx, 1999). Attempts at this approach, by fusing  PbCtrNt to MBP having a periplasmic 
malE leader  sequence,  proved  unsuccessful  (data  not  shown),  which  may  be  due  to  the 
presence of a predicted amino-terminal signal sequence in the inserted gene.
Molecular exclusion chromatography (MEC) was used to fractionate the multiple MBP-PbCtrNt 
products. MBP-PbCtrNt was, however, found to elute in the void volume of Sephacryl S-100 
and  S300  resins  (Figure  4.14),  thereby  suggesting  a  significant  number  of  MBP-PbCtrNt 
monomers  aggregate  in  the  cell  cytoplasm  to  form  “soluble”  inclusion  bodies.  A similar 
observation was made for MBP-E6 expression (Nominé et al., 2001b; Zanier et al., 2007) and 
although the protein aggregated due to misfolding, it was still found to be able to bind zinc ions 
with a similar stoichiomery to that of the native protein. This suggested the recombinant protein 
was synthesised with a native-like fold, thus enabling correct coordination of the metal centre 
(Zanier et al.,  2007). MBP-PbCtrNt was therefore assessed for copper binding in vitro and in 
vivo with  bound  copper  detected  by  the  copper-specific  BCA release  assay  (Brenner  and 
Harris, 1995). MBP-PbCtrNt bound copper under both examined conditions (Figure 4.20) with 
an apparent binding preference for the cuprous ion (Cu+). However, considering the misfolded 
nature of MBP-PbCtrNt, these results were cautiously interpreted since other structural studies 
were not carried out.
4.3.4  Recombinant  expression  of  the  amino  termini  of  two  P.  falciparum  copper 
transport proteins
Plasmodium parasite gene sequence features that affect recombinant expression include signal 
peptides, transmembrane domains, rare codons, the presence of introns and the AT-richness of 
the genome (Mehlin et al., 2006; Sørensen and Mortensen, 2005a; Vedadi et al., 2007). The 
predicted amino terminal signal peptide was not removed from  PbCtrNt, which could explain 
the problems experienced with His6-PbCtrNt expression (Table 4.1)  and with the ineffective 
targeting of MBP-PbCtrNt to the cell periplasm. The two P. falciparum copper transporter amino 
terminal domains were therefore cloned and expressed with the exclusion of a predicted signal 
peptide. However, when expressed as pMal-c2 constructs, both MBP-PfCtr211NtTD and MBP-
PfCtr369NtTD produced a similar result  to that obtained for cytoplasmically expressed MBP-
PbCtrNt (Figure 4.15). This suggested it was a sequence feature of the partner protein that was 
responsible for protein aggregation. For  PbCtrNt, this sequence feature was suggested to be 
the  presence  of  multiple  cysteine  residues.  PfCtr211NtTD has  two  such  cysteine  residues 
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(Figure 4.13b) whilst  PfCtr369NtTD has five (Figure 4.13c), with a higher number of cysteine 
residues seeming to correlate with an increase in high molecular weight protein aggregates. 
Most bacterial proteins that require stable disulfide bonds are in fact exported (Thornton, 1981) 
since the oxidising environment of  the cell  periplasm facilitates the correct  folding of  these 
proteins (Makrides, 1996). Targeted expression of MBP-PfCtr211NtTD and MBP-PfCtr369NtTD to 
the  periplasm  was  therefore  examined  and  was  found  to  significantly  reduce aggregate 
formation and protein proteolysis, although some product truncation was still evident (Figure 
4.17).
4.3.5 Copper binding to MBP-PbCtrNt, MBP-PfCtr211NtTD and MBP-PfCtr369NtTD
Similar  to  MBP-PbCtrNt,  copper  binding  studies  using  MBP-PfCtr211NtTD and  MBP-
PfCtr369NtTD indicated that both proteins bound copper in vitro and in vivo (Figure 4.21) with an 
apparent preference for the cuprous ion. Copper is presumed to be coordinated to methionine 
motifs (MxM or MxxM) present in each of these Plasmodium proteins. These motifs have been 
demonstrated to be essential for the function of the yeast and human copper transporters when 
extracellular copper is limited (Eisses and Kaplan, 2005; Guo et al., 2004; Puig et al., 2002a). 
The amino terminus of the yeast copper transporter contains eight such methionine motifs, but 
only the last methionine of the eighth motif is essential for function  (Puig et al., 2002a). This 
particular  methionine  has  been  found  to  be  conserved  in  other  characterised  copper 
transporters and is located 20 amino acids from the first transmembrane domain. Analysis of 
the two  P. falciparum copper transporters identified one MxxM motif in  PfCtr211NtTD  and one 
MxM  motif  in  PfCtr369NtTD  (Figure  4.13).  Based  on  hydropathy  plots  (Figure  3.3)  it  was 
established that the last methionine of each of these motifs was located 20 amino acids from 
the first predicted transmembrane domain. This suggests that this motif may be involved in 
copper coordination. However, the involvement of other residues in copper coordination cannot 
be excluded. This is of particular importance since a number of cysteine and histidine residues 
are also present in the amino-terminal sequences of the Plasmodium copper transporters. Both 
cysteine and histidine residues have been implicated in metal ion coordination in other proteins 
(Davis and O'Halloran, 2008; Eisses and Kaplan, 2005).
In contrast to the  P. falciparum proteins, the amino terminal domain of the  P. berghei  copper 
transporter contains two MxM motifs. The second of these two motifs contains a methionine 
residue 20 amino acids from the first predicted transmembrane domain, therefore implicating 
this motif in copper coordination. However, copper coordination to the other methionine motif, 
or to histidine and cysteine residues, cannot be excluded. Preliminary electron spin resonance 
data, from MBP-PbCtrNt copper binding studies, suggested that copper was coordinated by 
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two histidines, a cysteine and methionine residue (data not shown). Identification of the specific 
residues involved in copper coordination to the Plasmodium proteins requires the use of more 
sophisticated techniques such as protein crystallisation or nuclear magnetic resonance (NMR) 
spectroscopy.  These  techniques  could  also  be  used  to  confirm  the  folded  state  of  each 
recombinant protein, which would help determine the importance of correct protein folding to 
copper coordination.
When expressed in the presence of  copper,  the final  yield of  MBP-PfCtr211NtTD and MBP-
PfCtr369NtTD was significantly increased (Figure 4.22). A similar phenomenon was, however, 
not observed when MBP-PbCtrNt was expressed in the presence of copper. This observation 
could perhaps be accounted for by the fact that MBP-PbCtrNt appears to aggregate in the E. 
coli host cell. However, the fact that MBP-PbCtrNt was still capable of binding copper  in vivo 
(Figure 4.20b),  despite its aggregation,  suggests other factors influenced these differences. 
One likelihood is the differing copper requirements of the cellular compartments to which the 
respective proteins were targeted, namely the cytoplasm and periplasm. Almost all  bacterial 
copper proteins, such as multi-copper oxidases, amine oxidases and lysine oxidases are found 
in the bacterial periplasm or excreted extracellularly  (Rensing and Grass, 2003). It has even 
been proposed that  E.  coli cells  do not  require  copper  for  cytoplasmic  enzymes and only 
require  copper  for  periplasmic  or  inner  membrane  enzymes,  such  as  Cu,Zn-superoxide 
dismutase  or  cytochrome-c  oxidase  (Bagai et  al.,  2008).  Since  copper  is  required  in  the 
periplasm,  efficient  regulatory  mechanisms  are  essential  (Macomber et  al.,  2007).  This  is 
perhaps best highlighted by studies of two periplasmic proteins thought to be involved in copper 
homoeostasis,  namely  PcoA and  PcoC.  Mutation  of  either  protein  interferes  with  copper 
resistance (Brown et al., 1995) whilst gene deletion causes copper hypersensitivity (Huffman et  
al., 2002).
Due to the oxidising environment of the bacterial periplasm, tight control of copper ensures this 
metal ion cannot freely enter redox chemistry to produce harmful reactive oxygen species (Puig 
et al., 2002b). Under standard laboratory growth conditions, this implies there would be limited 
copper available in the periplasm for copper binding proteins that are not required for  E. coli 
metabolic  function.  Consequently,  MBP-PfCtr211NtTD and  MBP-PfCtr369NtTD expression  is 
perhaps limited to ensure native E. coli copper-dependent proteins can function normally under 
these  growth  conditions.  However,  if  excess  extracellular  copper  is  added  to  the  growth 
medium, MBP-PfCtr211NtTD and MBP-PfCtr369NtTD protein yield is improved (Figure 4.22) by 
alleviating the copper-related metabolic stress from the E. coli cells. The lack of an increase in 
protein yield for cytoplasmically expressed MBP-PbCtrNt, could perhaps be related to the fact 
that few cytoplasmic E. coli proteins require copper as an essential cofactor (Macomber et al., 
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2007). Thus the cytoplasmic expression of MBP-PbCtrNt would place less stress on  E. coli 
cellular metabolism under standard growth conditions, resulting in similar yields in the presence 
or absence of extracellular copper.
In mammalian and yeast cells the favoured redox state of copper for transfer and transport, is 
the reduced cuprous ion (Cu+) (Hassett and Kosman, 1995; Puig et al., 2002a). This is thought 
to be due to the fact that Cu+ is more exchange labile than Cu2+ thereby facilitating its transfer 
between two binding sites (Jiang et al.,  2005; Rees and Thiele, 2007). Considering the highly 
reactive nature of Cu+ in an oxidising environment, the challenge is to safely sequester these 
ions prior to transport across the lipid bilayer. The methionine motifs present in the extracellular 
amino terminus of the copper transporter family are thought to provide this desired coordination 
environment  (Jiang et al.,  2005; Puig et al.,  2002a). Methionine only coordination of Cu+ has 
been  established  through  a  unique  study  using  a  synthesized  methionine  motif  peptide 
(MTGMKGMS).  Inhibition  of  copper-catalysed  ascorbic  acid  oxidation,  by  this  peptide, 
suggested it  chelated Cu+ thereby preventing it  from participating in the redox cycle (Figure 
4.23). This data, combined with similar experiments using peptide variants lacking methionines 
as well as electrospray mass spectra, strongly supported methionine-specific coordination of 
Cu+ (Jiang et al., 2005). The affinity with which these motifs bound copper (~2.5 µM) was also 
found to be compatible with biological copper uptake, which is between 1 and 5 µM in a variety 
of organisms (Puig and Thiele, 2002). These methionine motifs were therefore suggested to be 
required by copper transport proteins for extracellular copper acquisition and transport across 
the membrane.
The two P. falciparum copper transporter amino termini are each predicted to contain a single 
methionine motif (Figure 4.13). This motif is presumed to be involved in copper binding, as 
suggested from the  in vitro  and  in vivo  studies. The ability of the recombinant  P. falciparum 
amino termini to inhibit copper-catalysed ascorbic acid oxidation was examined and indicated 
that both MBP-PfCtr211NtTD and MBP-PfCtr369NtTD inhibited ascorbic acid oxidation (Figure 
4.24). Considering the dynamics of the redox cycle (Figure 4.23), this result suggested that 
each protein coordinated the Cu+ ion. Therefore, the ability of these recombinant proteins to 
readily  bind  copper  combined  with  protein  localisation  studies  (Figure  4.8)  supports  a 
physiological role for the  Plasmodium copper transporters (Chapter 3).  Nevertheless, cation 
uptake and/or functional complementation studies will be necessary to confirm the directional 
transport of copper by these parasite proteins.
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CHAPTER 5
The Plasmodium spp. putative Cox17 copper metallochaperone: Recombinant protein 
copper binding studies 
5.1 Introduction
The redox activity of copper has been harnessed for catalysis by a broad range of enzymes. 
These enzymes are critical  to a number of  cellular  biochemical and regulatory functions in 
microbes, plants and animals (Kim et al., 2008; Lutsenko, 2010). However, it is this same redox 
property that allows copper to generate free radicals if left unregulated within a cell. This has 
therefore resulted in the development of sophisticated cellular mechanisms for the acquisition, 
distribution and regulation of copper (Dameron and Harrison, 1998; Kim et al., 2008; Leary et  
al.,  2009). These mechanisms involve copper transporters, metallochaperones and molecules 
that chelate copper in biologically inert complexes. Excess cytosolic copper is exported from 
cells  via copper efflux proteins belonging to the P-type ATPase family  of  transporters.  The 
importance  of  these  cellular  pathways  is  best  highlighted  by  human  diseases  and 
pathophysiologies resulting from defects in copper homoeostasis (Bertinato and L'Abbe, 2004; 
Kim et al.,  2008). These diseases include Menkes and Wilson's disease, caused by genetic 
defects  (Camakaris et  al.,  1999;  Shim and Harris,  2003),  and Alzheimer's  and Parkinson's 
disease,  resulting  from  alterations  in  copper  balance  (Hung et  al.,  2010) Considering  the 
biochemical role of copper, it is expected that humans and human pathogens share a similar 
cellular requirement of copper for growth, proliferation and development (Kim et al., 2008).
Following copper entry into the cytosol of eukaryotic cells, it is delivered to target proteins via 
soluble Cu+-binding proteins known as copper chaperones  (Rosenzweig, 2002). It is unclear 
how chaperones obtain their cargo, but appears to involve direct interaction with the copper 
transport  protein  (Xiao et  al.,  2004).  It  is  currently  understood that  there are  three cellular 
pathways  that  require  copper  chaperones.  These  pathways  involve  copper  shuttling  to: 
cytosolic Cu,Zn-superoxide dismutase, metal  transporting P-type ATPases and mitochondria 
(Boal and Rosenzweig, 2009). Of these three pathways, the mitochondrial pathway appears to 
be the most complex (Lutsenko, 2010). Copper delivery to the mitochondrion is essential, since 
the copper-requiring protein cytochrome-c oxidase is localised there. Copper is essential for 
cytochrome-c oxidase function and is aided in its assembly by the copper metallochaperone 
Cox17  (Glerum et  al.,  1996;  Punter  and  Glerum,  2003).  Cox17  was  also  suggested  to 
contribute to copper delivery to the mitochondrion (Beers et al., 1997).
The suggestion that Cox17 was involved with copper shuttling was based on its localisation to 
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both the cytosol and mitochondrial intermembrane space (Beers et al., 1997) coupled with its 
copper  binding  properties  (Heaton et  al.,  2001;  Srinivasan et  al.,  1998).  This  idea  was, 
however, disputed by the finding that cytochrome-c oxidase deficiency, in cox17Δ yeast cells, 
could  be  functionally  complemented  by  restricting  Cox17  location  to  the  mitochondrial 
intermembrane space  (Maxfield et  al.,  2004).  In addition,  cox17Δ cells still  maintain similar 
mitochondrial copper levels to those observed in wild-type cells. This therefore suggested that 
Cox17 was not an obligate mitochondrial copper transporting metallochaperone. Searches for 
additional metallochaperones led to the observation that the bulk of mitochondrial copper is 
localised within the matrix in a soluble, low molecular weight complex termed CuL (Cobine et  
al.,  2004).  Subsequent  studies  identified  that  CuL was  also  abundant  in  the  cytosol  as  a 
copper-free ligand (Cobine et al., 2006b). It was therefore proposed that Cu+ binding to apo-
CuL in  the cytosol  triggers translocation  of  the  anionic  CuL complex to the mitochondrion, 
thereby delivering copper  (Leary et al., 2009). Although this model is distinct from the other 
metallochaperone systems in the cytosol,  it  does not exclude the importance of the copper 
metallochaperones identified as essential for cytochrome-c oxidase assembly, namely Cox17, 
Cox11 and Sco1 (Lutsenko, 2010).
Catalytically active cytochrome-c oxidase is assembled via numerous steps, requiring over 30 
accessory proteins  (Cobine et al., 2006a). Of particular importance to cytochrome-c oxidase 
activity is Cox17-mediated copper delivery to Sco1 and Cox11 for subsequent insertion into the 
cytochrome-c  oxidase  CuA and  CuB  sites,  respectively  (Cobine et  al.,  2006a).  The 
indispensability of  Cox17 function is  highlighted by embryonic  lethality  in  COX17 null  mice 
(Takahashi et al., 2002). The highly conserved and essential nature of Cox17 and its cellular 
role suggests novel Cox17 candidate proteins would be similarly essential to their host cells. A 
Cox17 homologue was identified in the proteome of the Plasmodium parasite, with its metabolic 
role supported by the identification of putative proteins required for the assembly of a parasite 
cytochrome-c  oxidase  complex  (Table  3.1).  The  aim  of  this  study  was  to  clone  and 
recombinantly  express  the  P.  yoelii  and  P.  falciparum Cox17  proteins  to  measure  copper 
binding in vitro and in vivo.
5.2 Results
5.2.1 Confirmation of a native Plasmodium Cox17 coding domain
The initial identification of a putative parasite Cox17 coding domain made use of the rodent-
infecting malaria parasite model.  P. falciparum was subsequently used to corroborate these 
results. P. yoelii Cox17 is predicted to be encoded by an open reading frame of 201bp, whilst 
the  P.  falciparum Cox17  open  reading  frame  is  predicted  to  be  204bp.  However,  due  to 
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constraints in the designing of the reverse primer, the expected sizes of the  P. yoelii  and  P. 
falciparum PCR amplicons was 192bp and 195bp,  respectively.  For  both  parasites  a  PCR 
amplicon of  approximately  200 bp was amplified from genomic DNA (Figure 5.1).  The 3bp 
difference between these two amplicons would not be discernible by agarose gel analysis. The 
LDH control was amplified as an 835bp product from the genomic DNA of both parasite species 
(Figure 5.1). Additional controls included DNA isolated from uninfected BALB/c mouse blood 
(Figure 5.1a) or no DNA template (Figure 5.1b). Both reactions returned negative results.
Figure 5.1 PCR amplification of the P. yoelii and P. falciparum Cox17 coding domains
The P. yoelii (A) and P. falciparum (B) Cox17 coding domains were PCR amplified from genomic DNA and analysed 
on a 1% agarose gel. Lane 1, Cox17; lane 2, LDH control; lane 3, negative control. Molecular mass markers (M) are 
on the left of each gel (see materials and methods for details).
To confirm the identity of the amplicons, the Cox17 PCR products were ligated into the pGEM®-
T vector and sequenced. Alignment of the sequencing data with the corresponding PlasmoDB 
sequences  indicated  a  100%  sequence  identity  for  both  PCR  products  (Figure  5.2).  As 
expected, translation of these sequenced products yielded amino acid sequences with 100% 
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PyCox17_vect      ATGGGATTAGGTTTAACTAAGCCATTAAATACAACTGAGGAAAGTAAAACGTGTGCAAAA 60
PyCox17_plas      ATGGGATTAGGTTTAACTAAGCCATTAAATACAACTGAGGAAAGTAAAACGTGTGCAAAA 60
                  ************************************************************
PyCox17_vect      AAAAAGAAAATATGTTGTGTATGCTTAGATACAAAAAAATTAAGAGATGAATGTATTGTT 120
PyCox17_plas      AAAAAGAAAATATGTTGTGTATGCTTAGATACAAAAAAATTAAGAGATGAATGTATTGTT 120
                  ************************************************************
PyCox17_vect      AATTTAGGAGAAGAACAATGTAAGAAATATATTAATGATCATAATCAGTGCCTAAGAAAT 180
PyCox17_plas      AATTTAGGAGAAGAACAATGTAAGAAATATATTAATGATCATAATCAGTGCCTAAGAAAT 180
                  ************************************************************
PyCox17_vect      GAAGGGTTTGAT 192
PyCox17_plas      GAAGGGTTTGAT 192
                  ************
PfCox17_vect      ATGGGTATGAGCTTGAACAAACCAATAAATAACACGAATGAAGCAAATAAAGGAGAAGTT 60
PfCox17_plas      ATGGGTATGAGCTTGAACAAACCAATAAATAACACGAATGAAGCAAATAAAGGAGAAGTT 60
                  ************************************************************
PfCox17_vect      AAAAAAAAAAAAATTTGTTGTGTTTGTTTAGAAACCAAAAAGTTAAGAGATGAATGTATT 120
PfCox17_plas      AAAAAAAAAAAAATTTGTTGTGTTTGTTTAGAAACCAAAAAGTTAAGAGATGAATGTATT 120
                  ************************************************************
PfCox17_vect      GTTAAATTGGGGGAAGAGCAGTGTAAGAAATTTATCGATGATCATAATAAATGTTTAAGG 180
PfCox17_plas      GTTAAATTGGGGGAAGAGCAGTGTAAGAAATTTATCGATGATCATAATAAATGTTTAAGG 180
                  ************************************************************
PfCox17_vect      AGTGAAGGTTTTGAT 195
PfCox17_plas      AGTGAAGGTTTTGAT 195
                  ***************
Figure  5.2  Alignment  of  the  sequenced  P.  yoelii and  P.  falciparum Cox17 amplicons  with  PlasmoDB 
sequences
P. yoelii (PyCox17_vect)  (A) and P. falciparum (PfCox17_vect) (B) Cox17 amplicons were aligned with sequences 




5.2.2 Anti-peptide antibody production for parasite Cox17 protein detection
Figure  5.3 Anti-peptide  antibody  responses  against  peptides  selected  from  the  P.  yoelii  (KTC)  and  P. 
falciparum (NKG) Cox17 metallochaperones  
Anti-peptide antibody production against the KTC (A) and NKG (B) peptides was monitored by ELISA over a 12 
week period. In all panels peptide-specific antibody production is shown for chicken 1 (▬) and chicken 2 (▬). Also 
shown is the antibody production against the rabbit albumin carrier for chicken 1 (▬) and chicken 2 (▬).
For  the  detection  of  either  native  or  recombinant  P.  yoelii and  P.  falciparum Cox17 
metallochaperones, antibodies were generated against peptides from each protein. Details of 
peptide selection are described in Section 3.2.8 (KTC for P. yoelii and NKG for P. falciparum). 
Antibody titres against each peptide were monitored by ELISA over a 12-week period, with 
responses to both the KTC (Figure 5.3a) and NKG (Figure 5.3b) peptides showing some minor 
differences between chickens.  For  these two peptides,  antibody production  was detectable 
from week three  with  a  peak  after  week  four.  Antibody  production  then  either  plateaus  or 
decreases to the end of  week twelve.  Anti-peptide antibody titres showed similar  trends to 
antibodies generated against  the anti-rabbit  albumin carrier  protein  (Figure  5.3).  Antibodies 
were isolated from egg yolks, pooled and affinity purified on a peptide-specific matrix. Bound 
antibodies were eluted from the matrix (Figure 5.4) and pooled for each peptide. The final yield 
for  the  Cox17  antibodies  was  5.7  mg  for  anti-KTC  and  9.0  mg  for  anti-NKG  antibodies. 
Attempts to detect the native  P. yoelii and P. falciparum Cox17 metallochaperones, using the 
respective antibodies, were unsuccessful in both blotting and immunoprecipitation experiments 
(data not shown).
































Figure 5.4 Affinity purification profiles for anti-P. yoelii (KTC) and -P. falciparum (NKG) Cox17 antibodies 
Representative purification profiles  of  antibodies raised against  the KTC (A)  and NKG (B)  peptides are shown 
above. Shown in all panels are the purification profiles for antibodies purified from eggs collected 4 to 8 weeks post-
inoculation of chicken 1 (▬) and chicken 2 (▬).
5.2.3 Recombinant expression of P. yoelii and P. falciparum Cox17
Using recombinant  P. yoelii and  P. falciparum Cox17, the  in vitro and  in vivo  copper binding 
ability of each protein was to be examined. The BCA release assay was again used to detect 
bound  copper  (Brenner  and  Harris,  1995). Preparation  of  the  parasite  Cox17  expression 
constructs followed the strategy outlined for expression of the amino terminal domain of the 
parasite copper transport proteins (Figure 4.9). Following PCR amplification of the P. yoelii and 
P. falciparum Cox17 coding domains (Figure 5.1),  the PCR products were gel purified and 
ligated into a pGEM®-T cloning vector. These constructs were transformed into E. coli JM109 
cells,  positive  colonies  identified  and  the plasmid  isolated.  The  P.  yoelii Cox17  insert  was 
excised by EcoRI and NotI digestion, whilst the P. falciparum insert was excised by BamHI and 
NotI digestion. Each insert was gel purified and ligated into a pET expression vector digested 
with the corresponding restriction enzymes. Initial attempts at recombinant expression of His6-
PyCox17 and His6-PfCox17 made use of the pET23a and pET28a vectors transformed into E. 
coli BL21(DE3) cells.





























Figure 5.5 Pilot expression and small-scale purification of recombinant His6-PyCox17
His6-PyCox17 expressed from the pET23a (A) and pET28a (B) vectors. All samples were analysed by 10% Tricine-
SDS-PAGE. In A and B: lane 1, total cell protein; lane 2, soluble fraction; lane 3, unbound protein fraction; lane 4,  
resin wash eluate and lane 5, Ni-NTA bound protein. Molecular mass markers (M) are on the left of each gel (see 
materials and methods for details). 
In initial screening, His6-PyCox17 was expressed as a soluble protein by both the pET23a and 
pET28a  vectors  (Figure  5.5),  whilst  His6-PfCox17  expression  was  not  detected  (data  not 
shown). Small-scale experiments with the pT-PyCox17 constructs suggested higher expression 
levels for the pET28a construct (Figure 5.5b). This difference was not apparent in larger scale 
preparations,  hence  the  pET23a  construct  was  selected  for  further  studies.  The  pET23a-
expressed product was approximately 11.6kDa in size (Figure 5.5a), which is larger than its 
predicted size but is a similar finding to that reported for purified yeast Cox17  (Beers et al., 
1997). 
Table 5.1 Confirmation of PfCox17 amplicon ligation into expression vectors




pET23a a a a
pET28a a a a
pGex-4T-1 a a a
Reasons  for  the  apparent  lack  of  His6-PfCox17  expression  by  the  pET vectors  were  not 
understood. Ligation of the PfCox17 coding domain into the two pET vectors was confirmed by 
BamHI digestion, PCR using pET- and PfCox17-specific primers (Table 5.1), and sequencing 
the amplicon (Figure 5.2b).  Altering the fermentation conditions made no difference to His6-
PfCox17 expression (data  not  shown).  A new  PfCox17 expression construct  was therefore 
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Figure 5.6 Pilot expression and small-scale purification of recombinant GST-PfCox17
12.5% SDS-PAGE analysis of GST-PfCox17 expression. Lane 1, total cell protein; lane 2 soluble fraction; lane 3, 
unbound protein fraction; lanes 4 and 5, resin wash eluate; lane 6, glutathione agarose-bound protein.  Molecular 
mass markers are on the left of each gel (see materials and methods for details).
GST-PfCox17 expression  required  that  the  PfCox17 coding sequence  was excised  from a 
pGEM®-T cloning vector by BamHI and NotI digestion, gel purified and ligated into a BamHI-
NotI digested pGex-4T-1 expression vector. The construct was then transformed into  E. coli 
BL21 host cells and screened for the expression of the GST-PfCox17 fusion protein. Successful 
ligation was confirmed by  BamHI digestion and PCR amplification (Table 5.1). GST-PfCox17 
was expressed as a soluble protein and purified by small-scale glutathione-agarose affinity 
chromatography  (Figure  5.6).  The  two  prominent  expression  products  were  approximately 
33.5kDa and 30.3kDa in size, respectively, where the larger of the two corresponded to the 
predicted size for GST-PfCox17. The smaller protein may be a truncated product. The BL21 
host cells used are protease deficient suggesting the smaller proteins are unlikely to be the 
result of proteolysis (Figure 5.6).
Figure 5.7 Recombinant expression and affinity purification of His6-PyCox17
10% Tricine-SDS-PAGE analysis of affinity purified His6-PyCox17 (A), detected with an anti-His6 antibody (B) and 
anti-KTC anti-peptide antibody (C) following blotting to nitrocellulose. Lane 1, soluble cell lysate; lane 2, unbound 
protein fraction; lanes 3 – 5, protein eluate from Ni-NTA affinity matrix. Molecular mass markers (M) are on the left of 







































For the expression of His6-PyCox17 it was found that induction with 0.4 mM IPTG, for 4 hours, 
at 37°C was optimal, whilst for GST-PfCox17 induction with 0.5 mM IPTG, for 4 hours, at 37°C 
was optimal (data not shown). Each construct was then prepared for large-scale expression 
and purification of the recombinant protein. Following cell lysis, each recombinant protein was 
affinity purified using the Ni-NTA matrix for His6-PyCox17 (Figure 5.7) and glutathione-agarose 
for GST-PfCox17 (Figure 5.8). His6-PyCox17 yields were 3.95 mg and GST-PfCox17 6.87 mg 
protein  per  500  ml  of  culture.  The identity  of  each recombinant  protein  was  confirmed by 
western  blot.  Purified  His6-PyCox17 was  detected by  both  an  anti-His6 and  anti-KTC anti-
peptide antibody (Figure 5.7) and GST-PfCox17 was detected by an anti-GST and anti-NKG 
anti-peptide antibody (Figure 5.8). The His6-PyCox17 bands of a higher molecular weight than 
the monomeric species are likely to represent multimers. Although less evident, GST-PfCox17 
also produced multimeric species (Figure 5.8). 
Figure 5.8 Recombinant expression and affinity purification of GST-PfCox17
12.5% SDS-PAGE analysis of affinity purified GST-PfCox17 (A), detected by an anti-GST antibody (B) and anti-NKG 
(C) anti-peptide antibody following blotting to nitrocelulose. Lane 1,  soluble cell  lysate;  lane 2, unbound protein 
fraction; lanes 3 – 5, protein eluate from glutathione-agarose affinity matrix. Molecular mass markers (M) are on the 
left of each gel (see materials and methods for details).
5.2.4 Copper binding studies with His6-PyCox17 and GST-PfCox17
Recombinant  S. cerevisiae and H. sapiens Cox17 have been reported to bind copper  in vivo 
(Heaton et al., 2001; Srinivasan et al., 1998; Takahashi et al., 2002; Voronova et al., 2007a). 
Similar experiments have been undertaken for His6-PyCox17 and GST-PfCox17. Briefly, for the 
in vitro study of copper binding, 10 µM purified recombinant protein was incubated with a 20-
fold molar excess of  copper in  the presence of  DTT and ascorbic acid,  which acts as the 
reducing agent. Ascorbic acid was included to ensure that copper is reduced and maintained in 



























      M.      1.          2.        3.          4.         5.
A. B. C.
142
(Banci et al., 2008b). These conditions were used to emulate the reducing environment of the 
cell cytosol. Following overnight dialysis, protein-bound copper was detected using the copper-
specific BCA release assay (Brenner and Harris, 1995). The BCA release assay was conducted 
on duplicate samples with or without the inclusion of ascorbic acid (Figure 5.9, solid and open 
bars, respectively) to identify the oxidative state of the bound copper. Similar to the previous 
results (Chapter 4), both His6-PyCox17 and GST-PfCox17 could be reconstituted with Cu+  in 
vitro as seen following protein incubation with CuCl2 in the presence of DTT and ascorbic acid 
(Figure 5.9a,  +). The binding of the Cu+ ion, to both recombinant proteins, was supported by 
omitting  ascorbic  acid  from  the  BCA release  assay,  which  resulted  in  the  formation  of  a 













Ascorbate + + + CuCl2 – + – + – +
Figure 5.9 Copper binding to His6-PyCox17 and GST-PfCox17 in vitro and in vivo
Copper binding was analysed A in vitro and B in vivo. (A) 10 µM affinity purified protein was incubated with CuCl2 in 
the presence (+) of ascorbic acid. The standard BCA release assay was altered to test for bound copper in the 
presence (solid bars) or absence (open bars) of ascorbic acid. The BCA-Cu+ complex was detected at 354 nm. The 
concentration of the copper standard (CuCl2  only) was equimolar to the amount of protein used. (B) 0.5 mM CuCl2 
was added to the cell growth medium after induction of recombinant protein expression. Following affinity purification 
bound copper was detected by the BCA release assay with (solid bars) or without (open bars)  the addition of  
ascorbic acid and the BCA-Cu+ complex detected at 354 nm. ** (for His6-PyCox17) and ▲▲ (GST-PfCox17) denote 
statistical  significance as determined by Student's  t-test  (p-value  <0.05).  Results are means  ± S.E. of  triplicate 
measurements from each duplicate dialysis bag.
Copper  binding to  His6-PyCox17 and GST-PfCox17 was also  evaluated  in  vivo.  As before 
(Chapter 4), copper binding in vivo was determined by expressing the two recombinant proteins 
in the presence or absence of  0.5 mM CuCl2.  Bound copper was detected using the BCA 




























shown to bind copper in vivo (Figure 5.9b), with the addition of extracellular copper producing a 
statistically significant increase in the amount of copper detected (p-value <0.05). The oxidation 
state of the bound copper was determined by including (Figure 5.9b, solid bars) or omitting 
(Figure 5.9b, open bars) ascorbic acid from the BCA release assay. His6-PyCox17 and GST-
PfCox17 bound Cu+  in vivo (Figure 5.9b). Interestingly, when the in vitro and in vivo data are 
compared, a similar amount of copper was found to be bound to these two proteins under the 
two conditions tested (Figure 5.9). Copper did not bind to the GST carrier protein (Figure 5.9) 
thereby indicating that copper binding was specific to the PfCox17 partner protein.
Figure 5.10 Copper-catalysed oxidation of ascorbic acid is inhibited by His6-PyCox17 and GST-PfCox17
A 120 µM solution of ascorbic acid (H2Asc) at pH 4.5 (■). Addition of 8  µM CuCl2 to the H2Asc solution (♦).  His6-
PyCox17 (▼), GST-PfCox17 (▲) and GST carrier protein (►) added to the H2Asc-copper solution.
As before,  the effect  that  the recombinant  proteins  had on copper-catalysed ascorbic  acid 
oxidation was examined by monitoring the loss of absorbance, at 255 nm, of a 120 μM ascorbic 
acid solution at pH 4.5. This pH was selected for reasons previously described (Section 4.2.4). 
As expected, the control  reaction,  with freshly prepared ascorbic acid,  showed a persistent 
absorbance at 255 nm (A255) over a period of 300 seconds, indicative of the stability of the 
solution to aerial oxidation (Figure 5.10, ■). Upon the addition of 8 μM CuCl2, the A255 signal was 
found to decrease thereby highlighting the catalytic oxidation of ascorbic acid by copper (Figure 
5.10,  ♦).  The  copper-catalysed  oxidation  of  ascorbic  acid  was,  however,  inhibited  by  the 
addition of 5 μM of purified His6-PyCox17 (Figure 5.10,  ▼) or GST-PfCox17 (Figure 5.10, ▲). 
The presence of either recombinant protein results in only a slight decrease in ascorbic acid 
stability  over  time,  compared  to  the  dramatic  decrease  seen  when  CuCl2 is  added.  This 
indicates that both His6-PyCox17 and GST-PfCox17 chelate copper in solution, thus preventing 
its participation in the redox cycle.  Taken together with the previous copper binding results 













(Figure  5.9),  it  is  presumed that  both  proteins  chelate  the cuprous ion  in  solution  thereby 
shifting the rate-limiting step to equation 2 of this redox cycle (Figure 4.23). Interestingly, for the 
ascorbate  oxidation  assay,  His6-PyCox17  and  GST-PfCox17  produce  a  very  similar  result 
(Figure 5.10).  This  was in  contrast  to  the differences observed for  the  in  vitro and  in  vivo 
copper-binding assays (Figure 5.9). Overall these studies suggest that both proteins bind Cu+ in 
solution. This is in agreement with findings for other Cox17 metallochaperones, such as  S. 
cerevisiae Cox17 (Abajian et al., 2004; Beers et al., 1997; Palumaa et al., 2004; Voronova et  
al., 2007b).
5.3 Discussion
The  copper  metallochaperone  Cox17  was  first  identified  in  S.  cerevisiae as  an  essential 
component  for  cytochrome-c  oxidase  assembly  (Glerum et  al.,  1996).  Cox17  is  a  small, 
cysteine-rich protein that has been reported to bind between one and four Cu+ ions (Abajian et  
al., 2004; Arnesano et al., 2005; Voronova et al., 2007a). Based on its localisation, Cox17 was 
initially implicated in shuttling copper from the cytosol to the mitochondrion (Beers et al., 1997). 
However, this idea was revisited when it was found that Cox17 was still effective in copper 
delivery to cytochrome-c oxidase when tethered to the mitochondrial  intermembrane space 
(Maxfield et al., 2004). Although the precise mechanism of copper delivery to the mitochondrion 
is not fully understood, the importance of Cox17 function to yeast and mammalian cell survival 
is well documented (Glerum et al., 1996; Takahashi et al., 2002). The identification of a putative 
Plasmodium spp.  Cox17  metallochaperone  sequence  (Table  3.1)  suggested  that  malaria 
parasites might use similar pathways for cytochrome-c oxidase assembly. This was supported 
by  the  presence  of  both  Sco1  and  Cox11  parasite  orthologs  (Table  3.1).  In  this  study 
recombinant P. yoelii and P. falciparum Cox17 proteins were shown to bind copper.
5.3.1  Confirmation of a putative  Plasmodium  Cox17 copper metallochaperone coding 
sequence 
A putative Cox17 protein sequence was identified in eight species of the Plasmodium parasite 
following a BLASTp screen of PlasmoDB with the A. thaliana Cox17 sequence (Section 3.2.4). 
The  presence  of  essential  amino  acid  residues,  in  each  retrieved  sequence,  suggested  a 
copper binding role (Figure 3.6). The P. yoelii and P. falciparum Cox17 coding domains were 
PCR  amplified  and  sequenced,  with  each  sequence  showing  100%  identity  to  the 
corresponding PlasmoDB sequences (Figure 5.2). Sequencing of the PCR products confirmed 
the presence of an open reading frame for parasite Cox17. To detect native malarial parasite 
Cox17,  the  anti-peptide  antibodies  generated  in  this  study  (Section  5.2.2)  were  used  in 
immunoprecipitation and blotting experiments. For both P. yoelii and P. falciparum the detection 
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of  native  Cox17 was,  however,  unsuccessful.  Reasons for  this  remain  unknown,  but  were 
thought to either pertain to the relative expression levels of parasite Cox17 or to target protein 
degradation.
Analysis of the putative P. falciparum Cox17 metallochaperone gene (PF10_0252) transcription 
levels show consistent levels throughout the parasite's life cycle (Figure 3.8c). In comparison to 
the reference protein, lactate dehydrogenase, Cox17 transcription is approximately 5-fold less. 
The low expression levels may reflect a tight homoeostatic regulation of cellular copper, similar 
to that observed in other systems (Lutsenko, 2010). However, a consequence of this decreased 
protein expression is  an associated difficulty in  detecting the native protein.  As mentioned, 
attempts were made to detect P. yoelii and P. falciparum Cox17 by immunoprecipitation, similar 
to  the  approach  previously  used  for  the  characterisation  of  P.  falciparum  protein  kinases 
(Merckx et  al.,  2003).  However,  no  signal  was  detected  on  a  western  blot  of  the 
immunoprecipitate.  Although  native  Cox17  immunoprecipitation  was  unsuccessful,  parasite 
LDH has been precipitated using this same method in the laboratory as has recombinant His6-
PyCox17 and GST-PfCox17 (data not shown). For parasite lysate preparation care was also 
taken with reducing agents, excessive detergent concentrations or extremes in pH that can 
interfere  with  antibody-antigen  interactions  (Immunoprecipitation  troubleshooting  guide, 
Stressgen Biotechnologies Corp.).
Protease inhibitors were included in the lysis buffer to reduce proteolysis, which can interfere 
with target protein detection. The solution structure of S. cerevisiae Cox17 established that the 
protein has a structural  organisation  with an  α-helical  hairpin  preceded by an unstructured 
amino terminal segment of approximately 20 amino acids  (Abajian et al., 2004). Considering 
the  conservation  of  essential  amino  acids  within  the  Plasmodium spp.  Cox17  sequences 
(Figure 3.5), it is presumed these proteins would have a similar structure and fold to yeast and 
human Cox17 as suggested by the homology model of PfCox17 (Figure 3.6). This makes the 
amino terminal segment of these proteins particularly prone to degradation, which may then 
contribute to the lack of parasite Cox17 detection due to a loss of the targeted epitope.
5.3.2  Recombinant  expression  of  the  putative  P.  yoelii and  P.  falciparum Cox17 
metallochaperones
The function of a hypothetical Plasmodium protein is determined using a thorough biochemical 
analysis  (Birkholtz et  al.,  2008). Isolating sufficient quantities of native protein from malaria 
parasites, for functional studies, is difficult.  The heterologous expression of  P. yoelii and  P. 
falciparum Cox17 was therefore pursued using  E. coli as the expression host. Interestingly, 
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despite the sequence similarity of PyCox17 and PfCox17, expression of these proteins as His-
tagged proteins yielded different results. His6-PyCox17 was successfully expressed from two 
pET vectors (Figure 5.3), whereas the expression of His6-PfCox17 from the same two vectors 
was unsuccessful. This result perhaps highlights the 'power of orthologues' as described by 
Vedadi  et al. (2007). In this study seven Apicomplexan genomes were regarded as a 'super 
genome'. Heterologous expression of proteins from multiple Apicomplexan genomes yielded at 
least twice the percentage of purified proteins, crystals and structures than that obtained from 
P.  falciparum alone  (Vedadi et  al.,  2007).  This  therefore  suggests  that  the  problem  with 
PfCox17 expression could be related to certain properties of its coding sequence, such as the 
presence of rare codons or an A+T bias in the coding sequence (Birkholtz et al., 2008). Recent 
studies have, however, suggested that the A+T bias in Plasmodium sequences has less of an 
impact on heterologous expression than originally thought  (Mehlin et al., 2006; Vedadi et al., 
2007).
Rare codons are known to affect heterologous protein expression due to differences in codon 
usage between the E. coli  host and heterologous target gene. These differences can impede 
translation due to the demand for one or more tRNAs that may be rare or lacking in the E. coli 
population  (Makrides, 1996). In this regard the presence of AGA and AGG codons, encoding 
arginine, have proven most problematic (Kurland and Gallant, 1996). Analysis of the PyCox17 
and PfCox17 coding sequences identified an equal number of these particular codons in each 
sequence.  In  addition,  these  arginine  codons  were  located  at  similar  positions  in  each 
sequence. Interestingly, when other rare codons were taken into account it was found that the 
PyCox17 coding sequence contained a higher percentage of these codons. One significant 
difference between the two coding domains though, is the presence of a doublet of rare codons 
within  the first  10  amino acids of  the  PfCox17 sequence and not  the  PyCox17 sequence. 
Clusters of rare codons, such as doublets or triplets,  can create translational errors. These 
errors  include  mistranslational  amino  acid  substitutions,  frameshifting  events  or  premature 
translational termination  (Sørensen and Mortensen, 2005a). Dramatic translational errors are 
generally expressed as a failure to produce a complete canonical copy of  a target  protein, 
resulting in the production of truncated products (Kurland and Gallant, 1996). Following GST-
PfCox17 expression,  truncation  of  the  full-length fusion protein  was observed (Figure  5.8). 
Considering  the  same  coding  sequence  was  used  for  His6-PfCox17  and  GST-PfCox17 
expression,  the  truncation  of  GST-PfCox17  suggests  the  rare  codon  doublet  may  have 
contributed to the inability to detect His6-PfCox17 expression.
Fusion to soluble carrier proteins, such as glutathione S-transferase (GST) and maltose binding 
protein (MBP), can improve the folding of inherently insoluble, unstable or unfolded proteins 
147
(Kapust and Waugh, 1999; Makrides, 1996; Nallamsetty and Waugh, 2007). In this instance, a 
GST carrier protein was selected since yeast and mammalian Cox17 have been successfully 
expressed as GST-fusions (Srinivasan et al., 1998; Takahashi et al., 2002). Fusion of PfCox17 
to GST was found to assist protein expression (Figure 5.8). This supports the suggestion that 
the elevated expression of  an amino-terminal fusion partner can be transferred to a poorly 
expressing passenger protein as a result  of  mRNA stabilisation  (Sørensen and Mortensen, 
2005b).  Successful  GST-PfCox17  expression  suggests  that  the  presence  of  a  rare  codon 
doublet had little influence on expression since this was still present in the fusion construct. 
Analysis of affinity purified His6-PyCox17 (Figure 5.7) and GST-PfCox17 (Figure 5.8) samples 
identified the presence of multimeric species. Similar results have been observed for human 
and  yeast  Cox17,  which  exist  in  a  dimeric  and  tetrameric  state  that  inter-convert  in  a 
concentration-dependent manner (Heaton et al., 2001; Voronova et al., 2007a).
5.3.3 Copper binding to His6-PyCox17 and GST-PfCox17
Mammalian Cox17, which contains six conserved cysteine residues, can in principle exist in 
three different oxidation states; the fully oxidised protein with three disulfide bonds (Cox173S-S), 
a partially oxidised form with two disulfide bonds (Cox172S-S) or a fully reduced state where no 
disulfide bonds (Cox170S-S) are present (Palumaa et al., 2004; Voronova et al., 2007a). These 
various forms of Cox17 have been found to differ in their copper binding ability. The partially 
oxidised state binds a single Cu+ ion,  whereas the fully  oxidised state cannot  bind copper 
(Palumaa et al., 2004). On the other hand, the fully reduced form of Cox17 contains six free 
cysteine residues that cooperatively bind four Cu+ ions to form a tetracopper-thiolate cluster 
(Arnesano et al., 2005; Palumaa et al., 2004; Voronova et al., 2007b). Recombinant bacterial 
expression of human Cox17, in an unaltered cellular redox environment, was found to yield 
three almost equally populated redox states corresponding to Cox172S-S, Cox171S-S and Cox170S-S 
(Voronova et al., 2007b). Based on copper transfer studies, the preferred cellular redox state of 
Cox17 appears to be the partially oxidised state, Cox172S-S  (Banci et al., 2008a). This state can 
been attained,  in vitro, by treating purified Cox17 with millimolar concentrations of DTT since 
Cox17 contains two stable disulfide bonds and one labile bond that is susceptible to reducing 
agents  (Arnesano et  al.,  2005;  Banci et  al.,  2008b;  Voronova et  al.,  2007a).  Purified His6-
PyCox17  and  GST-PfCox17  were  therefore  treated  similarly  to  promote  this  redox  state 
(Cox172S-S) for in vitro copper binding studies.
Analysis of  in vitro copper binding to His6-PyCox17 and GST-PfCox17 revealed both proteins 
could bind copper following protein purification (Figure 5.9a). The differences in copper binding 
between the His6-tagged and GST-fusion proteins has also been reported for  yeast  Cox17 
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(Heaton et  al.,  2001;  Srinivasan et  al.,  1998).  GST-tagged  yeast  Cox17  bound  two molar 
equivalents  of  Cu+ (Srinivasan et  al.,  1998) whilst  untagged  Cox17  bound  three  molar 
equivalents  (Heaton et al., 2001). This was suggested to be a result of the obligate dimeric 
state of GST  (Heaton et al.,  2001). An important difference between the present study, and 
those  with  yeast  Cox17,  is  that  copper  binding  was  examined  in  vivo  for  yeast  Cox17. 
Therefore another explanation for the differences (Figure 5.9a) is that a mixed distribution of 
protein  redox  states  was  created,  following  DTT treatment,  thereby  causing  differences  in 
copper binding. Alternatively, DTT itself may have leached bound copper from the recombinant 
protein, similar to what was observed for Cu4Cox17 when DTT was used at supramillimolar 
concentrations  (Palumaa et al., 2004). A further possibility is that these differences relate to 
truncated GST-PfCox17 accounting for  part  of  the 10  µM protein solution.  This  could have 
reduced the amount of protein able to bind copper in solution.
His6-PyCox17 and GST-PfCox17 were also  found to bind copper  in  a cellular  environment 
(Figure 5.9b). A comparison of the in vivo data with the in vitro reconstitution of each protein 
indicated a similar difference between proteins with regard to the amount of copper bound. 
GST dimerisation may have contributed to these differences,  as reported for  yeast  Cox17, 
since it can result in a non-native conformer of Cox17 being induced by Cu+ binding (Heaton et  
al., 2001). It is also possible that copper ions bound  in vivo were lost during purification and 
dialysis, as reported for native yeast Cox17 purification  (Beers et al., 1997). Through a slight 
modification of the BCA assay it was shown that both recombinant proteins bound the cuprous 
ion under the two conditions examined. This finding is in agreement with the preferred redox 
state of  copper  bound to mammalian and yeast  Cox17 (Abajian et  al.,  2004;  Banci et  al., 
2008b; Beers et al., 1997; Palumaa et al., 2004).
The ascorbic acid oxidation assay has previously been used to demonstrate the copper binding 
ability of a methionine peptide (Jiang et al., 2005) and was used to demonstrate copper binding 
to the amino terminal domains of the P. berghei and P. falciparum copper transporters (Section 
4.2.4). Ascorbic acid is stable to aerial oxidation, but the presence of metal ions, such as iron or 
copper, catalyse its oxidative degradation  (Jiang et al., 2005). The oxidation rate of ascorbic 
acid can be monitored between 245 and 265 nm (Buettner, 1988). Conveniently the oxidation 
rate of ascorbate is known to decrease in the presence of metal chelators with slower oxidation 
rates  indicative  of  more  stable  chelates  (Khan  and  Martell,  1967).  Metal  chelation  by  the 
Plasmodium copper transporters was thought to be via methionine motifs present in the protein 
sequence, but this was not confirmed. Plasmodium Cox17 recombinant proteins are predicted 
to coordinate copper via a similar cysteine motif to that found in yeast Cox17 (Abajian et al., 
2004). 
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The  ability  of  His6-PyCox17  and  GST-PfCox17  to  inhibit  copper-catalysed  ascorbic  acid 
oxidation was tested  in  vitro (Figure 5.10).  Both  proteins inhibited ascorbate oxidation  and 
showed a near identical  decrease in the oxidation rate. The reduction in the oxidation rate 
suggests stable chelation of what is presumed to be the cuprous ion. Although the ascorbate 
UV-vis assay alone does not prove the preferred copper oxidation state for these Plasmodium 
proteins, when analysed in conjunction with the previously described in vivo assay it suggests 
the cuprous ion is the preferred substrate. Given the reducing potential of both the prokaryotic 
and eukaryotic cell cytoplasm (Schafer and Buettner, 2001) it is predicted that the Cu+ ion is the 
likely oxidation state in which copper would be found within the cell  (Davis and O'Halloran, 
2008).  A similar  reducing cytoplasmic  environment  has been identified  for  the  Plasmodium 
parasite  (Krnajski et  al.,  2001).  If  copper  is  present  in  a reduced state within the parasite 
cytoplasm, it is the likely substrate for cytoplasmic copper-requiring proteins. Parasite Cox17 is 
presumed to be located in the cytoplasm based on previous findings (Beers et al., 1997).
In the  present  study  P.  yoelii and  P.  falciparum Cox17 were recombinantly  expressed and 
shown to bind copper, but further protein characterisation is necessary. Firstly, native parasite 
Cox17 requires localisation using an antibody-mediated approach. This can be achieved using 
confocal and/or transmission electron microscopy.  Alternatively,  Cox17 localisation could be 
determined  by  attaching  it  to  a  fluorescent  GFP-tag.  Secondly,  to  assist  with  establishing 
protein  function,  Plasmodium Cox17  could  be used  in  a  yeast  functional  complementation 
system using  cox17Δ cells.  Thirdly,  site-directed  mutatgenesis  could  be  employed  to  help 
identify the amino acid residues important for Cox17 structure and function. A final possibility 
would be to attempt producing protein crystals of Plasmodium Cox17, with and without bound 





Malaria  is  a  devastating  disease  caused  by  single-celled  parasites  belonging  to  the 
Plasmodium genus.  P. falciparum is responsible for the most severe form of the disease. Not 
only is malaria a major cause of child mortality in the developing world, but it is also a large 
contributor to economic hardship in endemic countries, particularly those within sub-Saharan 
Africa. The complexity of the parasite's life cycle has hindered the development of an effective 
malaria vaccine, with no commercial vaccine currently available (Crompton et al., 2010). Apart 
from vaccination with radiation-attenuated P. falciparum sporozoites (Hoffman et al., 2002), the 
most promising vaccine candidate has been the RTS,S vaccine (Casares et al., 2010; Stoute et  
al., 1997; Sun et al., 2003). With regard to disease control, an additional problem being faced is 
the emergence of drug-resistant parasite strains. This has led to searches for new antimalarial 
drug  targets,  which  has  been  enhanced  by  the  complete  sequencing  of  a  number  of 
Plasmodium spp. genomes (Carlton et al., 2002; Carlton et al., 2008; Gardner et al., 2002; Pain 
et al., 2008). Presently, the front-line approach for the treatment of malaria is artemisinin-based 
combination therapy (World malaria report, 2010).
To prevent malaria transmission, the World Health Organisation (WHO) recommends the use of 
insecticide-treated  bed  nets  and  indoor  residual  spraying  using  WHO-approved  chemicals 
including  DDT.  In  endemic  countries,  indoor  residual  spraying  remains  one  of  the  main 
interventions for reducing and interrupting malaria transmission through vector control (World 
malaria  report  2010).  In  areas  of  high  disease  transmission  it  is  also  recommended  that 
intermittent preventative treatment regimes be implemented, particularly for pregnant women. 
Confirmed cases of uncomplicated P. falciparum malaria should be immediately treated with an 
artemisinin-based  drug  combination,  whilst  P.  vivax infections  should  be  treated  with 
chloroquine where it still remains effective (World malaria report, 2010). For P. vivax infections it 
is also recommended that treatment is combined with a 14-day course of primaquine to prevent 
relapse. Due to the potential emergence of parasite resistance to artemisinins (Dondorp et al., 
2009;  Noedl  et  al.,  2008),  artemisinin-based  monotherapies  are  being  withdrawn from the 
market to be replaced by combination therapies (World malaria report 2010). Monitoring the 
efficacy  of  currently  employed  antimalarials  is  important  for  reducing  the  spread  of  drug 
resistance, however, there is still a pressing need for novel drug and drug target identification. 
In  this  regard,  a  class  of  parasite  proteins  gaining  increased  attention  are  the membrane 
transport proteins (Kirk and Saliba, 2007; Martin et al., 2009a; Staines et al., 2010).
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In a related protozoan parasite,  Theileria parva, a membrane-bound protein (the polymorphic 
immunodominant  molecule)  has been established as a potential  diagnostic  and therapeutic 
target  (Toye et  al.,  1996). In  the current  study,  a  Plasmodium ortholog to this  protein was 
identified and found to possess features suggestive of a role as a copper transport protein 
(Chapter 3). In yeast and mammalian cells the copper transport protein functions to acquire 
extracellular  copper  and  transport  it  into  the  cell  (Kim et  al.,  2008;  Lutsenko,  2010).  This 
transporter  plays  an important  role  since copper  is  an essential  micronutrient  for  all  living 
organisms.  Considering  the  importance  of  copper  transport,  it  would  stand  to  reason  that 
inhibiting a putative Plasmodium parasite copper transporter could prove effective for targeted 
drug  inhibition.  Supporting  this  idea  was  the  finding  that  the  intracellular  copper  chelator, 
neocuproine, inhibits  P. falciparum  growth  in vitro  (Rasoloson et al., 2004). However, limited 
information is currently available regarding  Plasmodium parasite proteins involved in copper 
homeostasis. The identification of a parasite mechanism for copper excretion (Rasoloson et al., 
2004), suggested an opposing mechanism for copper acquisition is likely to exist. A mechanism 
not  yet  considered for  this  process,  is  copper  acquisition  via a dedicated copper  transport 
protein.  Therefore the primary aim of  the present  study was to identify and characterise a 
Plasmodium parasite copper transport protein and in addition, it was endeavoured to identify 
and characterise an associated copper metallochaperone.
6.2 Identification of Plasmodium parasite copper-requiring protein orthologs
Sequencing the  P.  falciparum  genome  (Gardner  et  al.,  2002) has enabled a great  deal  of 
research  that  was  previously  not  possible.  One  such  example  is  the  establishment  of  a 
protozoan  parasite  structural  genomics  project  (www.sgpp.org).  The  availability  of  the  P. 
falciparum genome sequence has the potential to reveal novel drug targets as well as genes 
important  for  parasite  biology  and pathogenesis.  Of  the  approximately  5,300  P.  falciparum 
genes identified, comparatively few have been confirmed to code for protein  (Mehlin et  al., 
2006;  Singh et  al.,  2010;  Tuteja,  2007).  However,  only  a couple  of  these protein-encoding 
genes are suggested to encode proteins that interact with copper (Kita et al., 1998; Rasoloson 
et al., 2004). In the study by Rasoloson and colleagues (2004), a BLASTp search of PlasmoDB 
Version  4.0  identified  candidate  copper  metallochaperone  orthologs  for  P.  falciparum 
cytochrome-c oxidase and CuP-ATPase.  In the present study,  a similar  BLASTp search, of 
PlasmoDB Version  7.1, identified  the  same Cox17  metallochaperone  candidate  as  well  as 
additional  co-metallochaperones  required  for  the  assembly  of  mitochondrial  cytochrome-c 
oxidase (Table 3.1)  (Cobine et  al.,  2006a; Horng et  al.,  2004). In addition, orthologs of the 
copper-dependent  enzyme  S-adenosyl-homocysteine  hydrolase  as  well  as  cytochrome-c 
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oxidase subunits I, III, Vb and VIb were identified (Table 3.1). Identification of these copper-
dependent  protein  orthologs  support  the  likelihood  that  the  Plasmodium parasite  requires 
intracellular copper for its metabolism. However, how the parasite acquires extracellular copper 
remains uncharacterised.
A  BLASTp  search  of  PlasmoDB,  with  the  sequence  of  the  T.  parva polymorphic 
immunodominant  molecule,  identified a candidate copper transport  protein sequence in  the 
genomes  of  eight  Plasmodium parasite  species.  An  in  silico analysis  of  these  sequences 
(Section 3.2.2) identified features characteristic of known copper transporters (Figures 3.1 and 
3.2),  thereby  supporting  the  possibility  that  these  proteins  play  a  role  in  parasite  copper 
acquisition.  Within  yeast  cells  it  was  initially  assumed  that,  following  copper  acquisition, 
intracellular  copper  ions  were  shuttled  from  the  copper  transport  protein  to  mitochondrial 
cytochrome-c oxidase via Cox17 (Beers et al., 1997; Glerum et al., 1996). Although this simple 
mechanism has since been disputed (Cobine et al., 2006a; Leary et al., 2009; Lutsenko, 2010), 
the importance of Cox17 to cytochrome-c oxidase assembly remains well documented (Glerum 
et al., 1996; Takahashi et al., 2002). Identification of a putative  Plasmodium parasite Cox17 
metallochaperone  sequence,  as  well  as  its  associated  co-metallochaperones,  suggests  a 
similar  parasite  mechanism  for  copper  loading  into  cytochrome-c  oxidase.  To  support  this 
possibility the Cox17 sequences were subject to an in silico analysis (Section 3.2.4). From this 
study, characteristic Cox17 sequence features were identified in each retrieved  Plasmodium 
sequence  (Figure  3.5),  thereby  supporting  the  likelihood  that  this  protein  functions  as  a 
metallochaperone required for cytochrome-c oxidase assembly. In an effort to confirm native 
expression  of  the  parasite  copper  transporter  and  Cox17  metallochaperone,  anti-peptide 
antibodies were raised for use in immunofluorescence and western blotting studies.
6.3 Production of anti-peptide antibodies used for the detection of a Plasmodium copper 
transporter and Cox17 metallochaperone
The availability of the published amino acid sequences for  P. falciparum and murine malaria 
parasites  enabled  the  selection  of  immunogenic  peptides  from the copper  transporter  and 
Cox17  metallochaperone.  Peptides  were  selected  using  an  epitope  prediction  algorithm 
(Cármenes et al., 1989) and anti-peptide antibodies were produced in chickens (Figure 4.5 and 
Figure 5.3). The use of synthetic peptides for antibody production is a useful approach when 
the native protein cannot  be easily isolated and/or purified to homogeneity  (Saravanan and 
Kumar,  2009).  Studies  carried  out  in  our  laboratory  have  shown  that  synthetic  peptides, 
coupled to a carrier protein, induce an immunogenic response in chickens producing up to 30 
mg of affinity purified anti-peptide antibodies. Chicken antibodies have also been successfully 
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used for the characterisation of several P. falciparum protein kinases (Dorin et al., 2005; Merckx 
et al., 2003) and lactate dehydrogenase (Hurdayal et al., 2010). The antibodies raised in this 
study, detected a murine malaria parasite copper transporter in parasite lysates as well as by 
immunofluorescence  microscopy.  Detection  of  the  metallochaperone  was,  however, 
unsuccessful. Similarly, detection of the P. falciparum copper transporter and metallochaperone 
was unsuccessful in both western blotting and fluorescent microscopy formats. Detection of a 
murine malaria parasite copper transporter confirms native parasite expression of this protein 
and  supports  the  possibility  of  there  being  a  dedicated  parasite  mechanism  for  copper 
acquisition. Localisation of this protein, to what appears to be a parasite membrane, was in 
agreement with the prediction that the identified protein is an integral membrane protein. This 
does,  however,  require  confirmation  using  either  co-localisation  experiments,  transmission 
electron microscopy or perhaps via transfection studies with a fluorescently tagged protein.
6.4 Recombinant expression of the amino terminal domain of the putative Plasmodium 
spp. copper transporter and full-length Cox17 metallochaperone
An  in  silico analysis  of  the  putative  Plasmodium  parasite  copper  transporter  and  Cox17 
metallochaperone sequences identified conserved features important for copper binding. For 
the  copper  transporter  sequences  these  included  important  methionine  motifs  within  the 
extracellular  amino  terminal  domain,  whilst  the  Cox17  proteins  were  found  to  contain  a 
conserved  CysCysXaaCys  copper-binding  motif  (Figure  3.6).  Previous  studies,  with  similar 
proteins or selected domains thereof, have established the possibility of reconstituting a purified 
recombinant protein with copper  in vitro or testing its ability to bind copper  in vivo by adding 
copper to the cell growth medium  (Heaton et al.,  2001; Jensen et al.,  1999; Lutsenko et al., 
1997; Palumaa et al., 2004; Srinivasan et al., 1998). The successful recombinant expression of 
the P. falciparum CuP-ATPase amino terminal domain, in E. coli cells, coupled with the ability of 
this protein to bind copper in vitro and in vivo (Rasoloson et al., 2004), supported the use of a 
similar  approach  to  examine  the copper  binding  ability  of  the  recombinant  amino  terminal 
domain  of  a  putative  Plasmodium sp.  copper  transporter  and  full-length  putative  Cox17 
metallochaperone.
Initial  attempts at  expressing the amino terminal  domain of  the putative  P.  berghei copper 
transport protein yielded an insoluble product (Table 4.1). This was overcome by fusing the 
amino terminal domain to the maltose binding protein (MBP), however, the expressed product 
appeared  to  aggregate  within  the  E.  coli  cell  cytoplasm.  This  was  likely  to  be a  result  of 
PbCtrNt's  high  cysteine  residue  content  (Figure  4.13a).  This  problem was  predicted to  be 
overcome by targeting protein expression to the oxidising environment of the cell periplasm, but 
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this was unsuccessful. This was thought to be due to the presence of a signal sequence in 
PbCtrNt, which has been reported to interfere with the recombinant expression of Plasmodium 
parasite proteins  (Mehlin et  al.,  2006;  Vedadi et  al.,  2007).  These  problems  were  largely 
overcome when expressing truncated amino terminal domains of two putative  P. falciparum 
copper transporters, which specifically lacked the predicted signal peptide. For these proteins, 
the removal of the predicted signal peptide appeared to assist with targeted protein expression 
to the E. coli cell periplasm (Figure 4.16). Expression within the E. coli periplasm appeared to 
assist the folding of both  P. falciparum  proteins since an absence of high molecular weight 
aggregates  was  noted  (Figure  4.17).  A  similar  phenomenon,  where  recombinant  protein 
expression  has been  assisted,  was  observed for  other  cysteine-rich  P.  falciparum proteins 
when fused to MBP and expressed in the cell periplasm (Outchkourov et al., 2008; Planson et  
al., 2003). 
As with the amino terminal  domain of  the copper  transport  protein,  both a  murine malaria 
parasite  and  P.  falciparum putative  Cox17  metallochaperone  orthologs  were  recombinantly 
expressed.  Interestingly,  the  expression  of  a  His6-tagged  P.  yoelii Cox17  ortholog  was 
successful whilst the expression of a similarly tagged  P. falciparum Cox17 ortholog was not 
detectable. Reasons for this were not clear, but the result appeared to support the notion of 
utilising the “power of orthologs” for the successful recombinant expression of Apicomplexan 
parasite proteins (Vedadi et al., 2007). Fusion of P. falciparum Cox17 to a GST carrier protein 
did, however, result in successful recombinant protein expression. Considering no alterations 
were made to the  P. falciparum Cox17 coding sequence, the successful expression of GST-
PfCox17 was unexpected since His6-tagged PfCox17 did not express. This result did, however, 
support  the  idea  that  fusion  to  a  soluble  carrier  protein,  such  as  GST,  can  improve  the 
expression  and  folding  of  inherently  insoluble,  unstable  or  unfolded  proteins  (Kapust  and 
Waugh,  1999;  Makrides,  1996;  Nallamsetty  and Waugh,  2007).  An alternative  approach to 
improve  recombinant  PfCox17  expression  could  be  to  utilise  a  codon  optimised  coding 
sequence. The use of synthetic, codon-optimised Plasmodium genes has so far improved the 
quality  and  quantity  of  other  heterologously  expressed  recombinant  Plasmodium proteins 
(Chowdhury et al., 2009; Flick et al., 2004; Mehlin et al., 2006; Vedadi et al., 2007), suggesting 
a similar result might be achievable for PfCox17. Alternatively, recent studies suggest that co-
expression with P. falciparum heat shock protein 70 (PfHsp70) can improve the heterologous 
production of malarial parasite proteins (Stephens et al., 2011).
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6.5 Copper binding to a recombinant amino terminal domain of the putative Plasmodium 
spp. copper transporter and Cox17 copper metallochaperone
The copper binding capacity of each recombinant protein being studied, was tested in vitro and 
in vivo. Protein-bound copper was detected using the copper-specific bicinchoninic acid assay 
(Brenner and Harris, 1995). Each of the purified recombinant proteins was capable of binding 
copper  in vitro. These studies also suggested that the amino terminal domain of the putative 
Plasmodium parasite copper transporters had a binding preference for the cuprous ion (Figure 
4.20a and Figure 4.21a), which was similarly observed for the metal binding domain of PfCuP-
ATPase  (Rasoloson et al., 2004). Furthermore, a similar preference for the cuprous ion has 
been observed for  yeast  and mammalian copper transporters  (Hassett  and Kosman, 1995; 
Puig et al., 2002a). The recombinant amino terminal domains MBP-PbCtrNt, MBP-PfCtr211NtTD 
and MBP-PfCtr369NtTD were also observed to bind the cuprous ion in vivo (Figure 4.20b and 
Figure 4.21b). Since Cox17 is predicted to be intracellular  (Beers et al., 1997), the reducing 
environment of the cytosol suggests copper would naturally be present in the reduced, cuprous 
state. Copper binding studies with the recombinant  Plasmodium  Cox17 proteins established 
that they too were capable of binding copper both in vitro and in vivo. For recombinant fusion 
proteins,  control  copper  binding studies  with the respective  carrier  proteins  (MBP or  GST) 
confirmed  that  copper  binding  was  specific  for  the  fused  parasite  proteins.  These  results 
therefore support the presence of a dedicated Plasmodium spp. copper transport protein and 
elaborate on the uncharacterised pathways for intracellular copper distribution in the parasite.
6.6 Proposed mechanism for Plasmodium parasite copper acquisition
The  presence  of  important  functional  copper  transport  protein  motifs  in  the  putative 
Plasmodium copper  transporters (Figure 3.1 and Figure 3.2)  suggests they are membrane 
bound and play a similar role to yeast and mammalian copper transporters. Association of a 
putative  murine  malaria  parasite  copper  transporter  with  what  appears  to  be  a  parasite 
membrane  (Figure  4.8)  supports  this  possibility.  Furthermore,  it  was  established  that  a 
recombinant  form  of  the  amino  terminal  domain  of  the  Plasmodium parasite's  copper 
transporter could bind copper (Figure 4.20 and Figure 4.21), which has similarly been observed 
for the human copper transporter ortholog (De Feo et al., 2009; Jiang et al., 2005; Larson et al., 
2010). However, it is still necessary to confirm the location, orientation and direction of transport 
for the Plasmodium copper transporter. Establishing protein location, in particular, will assist in 
elucidating protein function since it  is  predicted that  each of the two putative  P. falciparum 
copper transporters are targeted to different organelles (Figure 6.1). Considering the similarities 
identified between the Plasmodium transporters and other characterised copper transporters, 
two potential mechanisms for parasite copper acquisition are proposed (Figure 6.1).
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Figure 6.1 Proposed mechanism for P. falciparum copper acquisition
Following invasion of the red blood cell (RBC), the Plasmodium parasite is encapsulated within the parasitophorous 
vacuole  membrane  (PVM).  Two putative  copper  transporters  are  predicted  to  be  transcribed  by  P.  falciparum, 
PF14_0211 and PF14_0369. PF14_0211 is  predicted  to  be  in  a  parasite  membrane (A),  whilst  PF14_0369 is 
predicted to be in  an apicoplast  membrane (B).  The Cox17 metallochaperone is predicted to  load copper into 
cytochrome-c oxidase, which is thought to be associated with the mitochondrion (van Dooren et al., 2006). Unknown 
transport or transfer steps are marked with a question mark (?).
A number of Plasmodium parasite transport proteins are targeted to the surface of the parasite, 
whilst  others  are  localised  to  the  membranes  of  the  parasite  apicoplast,  mitochondrion, 
digestive vacuole and organelles of the secretory pathway. The likely cellular destination(s) of a 
given transporter can be inferred by signals present in its protein sequence and/or by its close 
similarity to a transport protein of known cellular location  (Martin et  al.,  2005; Martin et  al., 
2009a). Analysis of the two putative P. falciparum copper transporters identified a signal peptide 
in both proteins, whilst  an apicoplast transit  peptide was also identified in PF14_0369. This 
suggests PF14_0211 is targeted to the parasite plasma membrane, whereas PF14_0369 is 
targeted  to  the  apicoplast  (Figure  6.1).  Although  targeting  of  PF14_0211  to  the  parasite 
membrane seems most likely, it cannot be excluded that PF14_0211 might also be targeted to 
the parasitophorous vacuole membrane. This is a possibility since the signal/s for targeting 
membrane proteins to the parasitophorous vacuole membrane remain unknown (Martin et al., 
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2009a).  Should  PF14_0211  be  localised  to  the  vacuolar  membrane,  it  would  presumably 
transport copper from the erythrocyte cytosol into the parasitophorous vacuole for the parasite 
(Figure 6.1). However, it is currently believed that only high-capacity, low-selectivity channels 
are located in the vacuolar membrane to render it freely permeable to low-molecular-weight 
solutes (Desai et al., 1993; Martin et al., 2009a). Since these solutes could include copper, it is 
possible that PF14_0211 location in the vacuolar membrane is unnecessary, suggesting this 
transporter could be exclusively in the parasite plasma membrane.
The  P. falciparum apicoplast is a plastid bound by four membranes that is homologous and 
conceptually  similar  to  the  plant  chloroplast,  which  was  derived  from  a  modified 
cyanobacterium in a eukaryotic host cell  (Lim and McFadden, 2010; Ralph et al., 2004). The 
apicoplast is essential for parasite survival  (Goodman et al., 2007; Vaughan et al., 2009) and 
contains several plastid-derived biochemical pathways  (Lim and McFadden, 2010). A striking 
feature of the apicoplast is its close association with the parasite mitochondrion (Bannister et  
al., 2000; van Dooren et al., 2006). This association is thought to be conducive to substrate 
exchange (Ralph et al., 2004), but the majority of the membrane-bound transporters required 
for such processes remain to be identified (Lim and McFadden, 2010; van Dooren et al., 2006). 
In  the  present  study  it  was  proposed  that  one  of  the  P.  falciparum copper  transporters 
(PF14_0369) is located in an apicoplast membrane (Figure 6.1). Reasons for this association 
remain elusive, particularly since the membrane orientation and direction of transport remain 
unknown. However, the possibility exists that the parasite apicoplast acts as a site for copper 
storage,  similar  to  the  Chlamydomonas chloroplast  (Merchant et  al.,  2006).  This  therefore 
implies  that,  depending  on  its  orientation,  the  PF14_0369  copper  transporter  could  either 
function to redistribute stored copper for intracellular use or alternatively acquire surplus cellular 
copper for  storage.  However,  it  is  perhaps more likely that  PF14_0369 functions in  copper 
redistribution since in the Chlamydomonas chloroplast, for example, copper is acquired through 
the  action  of  two  independent  P-type  ATPases  whilst  copper  transporter-type  proteins  are 
thought  to  mobilise  stored  copper  (Merchant et  al.,  2006;  Shcolnick  and  Keren,  2006). 
Considering the close association between the apicoplast and mitochondrion it is plausible that, 
if copper were stored in the apicoplast, PF14_0369 could provide a more direct route of copper 
delivery to Cox17 for subsequent insertion into cytochrome-c oxidase.
Regardless  of  their  specific  loctions,  it  is  presumed that  both  PF14_0211  and  PF14_0369 
would  transport  copper  across  the  membrane  via  a  passive  mechanism,  similar  to  that 
suggested for the human copper transporter (Lee et al., 2002). Another similarity likely to exist 
between the human and putative Plasmodium copper transporters, is that copper is transported 
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across the membrane in its reduced, cuprous form. This probability was based on the data 
obtained from copper binding studies with MBP-PfCtr211NtTD and MBP-PfCtr369NtTD  (Figure 
4.21).  Once  copper  is  transported  across  the  relevant  parasite  membrane(s)  and  into  the 
cytosol,  it  is  presumably  distributed  to  target  proteins  by  intracellular  metallochaperones. 
Although the majority of these target proteins and metallochaperones remain to be identified, a 
putative  Plasmodium parasite Cox17 metallochaperone ortholog was identified in the present 
study  and  shown  to  bind  copper  (Figure  5.9).  Supporting  a  parasite  requirement  for  this 
metallochaperone was the  in  silico  identification of  parasite cytochrome-c oxidase complex 
orthologs. In yeast and mammalian cells, Cox17 is required for copper delivery to cytochrome-c 
oxidase for its activation in the mitochondrion (Kim et al., 2008; Lutsenko, 2010). However, in 
yeast and mammalian cells, the mechanism by which copper is delivered to the mitochondrion 
still requires further elucidation (Lutsenko, 2010). This therefore limits the similarities that can 
be drawn between the mammalian and corresponding parasite mechanisms, apart from the fact 
that Cox17 is likely to be required for copper delivery to the cytochrome-c oxidase complex 
(Figure 6.1).
6.7 Conclusions and future direction
The pressing need for new antimalarial chemotherapeutics has resulted in an expanded search 
for  novel  targets.  However,  the  demand  for  new  drugs  continues  to  outstrip  efforts  in 
development (Mehlin et al., 2006). In the present study, it was suggested that targeted inhibition 
of  Plasmodium  parasite  proteins  required  for  copper  homeostasis  could  prove  effective  in 
arresting parasite growth. Drug-targeted inhibition of proteins involved in copper homoeostasis 
would  likely  disrupt  copper-dependent  metabolic  pathways  within  the  parasite,  thereby 
inhibiting growth.  Such an effect  has been observed following treatment  of  a  P.  falciparum 
culture with the intracellular copper chelator neocuproine  (Rasoloson et al., 2004). However, 
considering  the  general  importance  of  copper  to  all  living  organisms,  as  well  as  the 
conservation of copper binding motifs in proteins from eukaryotes to prokaryotes (Andreini et  
al., 2008), it seems likely that developing a specific inhibitor of  Plasmodium parasite copper-
dependent  proteins  would  be  difficult.  However,  it  may  be possible  to  utilise  the  transport 
mechanism of the copper transporter for the delivery of a drug compound. This suggestion is 
based on the finding that the uptake of platinum containing anti-cancer drugs, such as cisplatin 
and oxaliplatin, is mediated by the copper transport protein in human cells (Holzer et al., 2006; 
Howell et al., 2010; Larson et al., 2009). By utilising a similar approach, it could perhaps be 
possible to target the malaria parasite, but considering the sequence similarity between the 
parasite and human copper transporters this too could prove difficult.
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Results from the present study provide an insight into the existence of additional pathways for 
copper  homoeostasis  in  the  malaria  parasite.  However,  the  directional  transport  of  each 
putative copper transporter and its specific location in the parasite remains to be determined. It 
is also necessary to determine the kinetics of these transporters if they are to be considered as 
either viable drug transporters or targets in their own right. Similarly, the binding kinetics and 
cellular location of the putative parasite Cox17 copper metallochaperone requires confirmation 
and  further  characterisation.  In  both  instances,  protein  location  could  be  determined  by 
immunolocalisation  and  electron  microscopy  (Agarwal et  al.,  2011;  Martin et  al.,  2009a; 
Rasoloson et al., 2004), whilst protein function could be inferred through a mutational analysis 
or  by implementing a yeast  complementation assay  (Lee et  al.,  2000;  Zhou and Gitschier, 
1997). Copper transport kinetics could also be established by using transfected Xenopus laevis 
oocytes (Martin et al., 2005; Staines et al., 2010). The potential importance of each protein to 
the parasite could be inferred from gene knock-out studies using transgenic parasites, as has 
been done for parasite cysteine repeat modular proteins 3 and 4 (Douradinha et al., 2011) and 
lipoic acid protein ligase A1 (Günther et al., 2009). Interpreting results from these studies does, 
however,  warrant  a note of  caution considering that  a large proportion of  the  Mycoplasma 
genitalium genome  is  dispensable  for  survival  (Hutchison et  al.,  1999).  Resolving  these 
features would provide further insight  into the transport  and shuttling mechanisms of  these 
proteins and suggest whether or not they are similar to those identified in yeast and mammalian 
systems. Although the results of this study established the copper binding ability of parasite 
proteins involved in copper homoeostasis, further work is clearly required to determine their 
potential as novel drug targets.
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